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ABSTRACT
Although monoclonal antibody (mAb) therapy has improved the outcome of low- 
grade B-cell non-Hodgkin lymphomas (B-NHL), they remain incurable diseases. The 
intimate relationship between immune cells and lymphomas for its maintenance and 
progression suggests that immunotherapy may represent a valuable strategy towards the 
control and eradication of these malignancies. Despite initial successes of anti-idiotype 
vaccination, its clinical benefits have not been definitely proven. New insights into the 
mechanisms whereby (i) tumour escape immunity, (ii) certain anticancer treatments exert 
immunogenic functions, (in] microenvironment influences lymphoma growth should open 
new ways for immunotherapeutic intervention.
Towards this goal, dendritic cells (DCs) loaded with autologous killed tumour cells 
were used to immunize indolent B-NHL patients against a wide spectrum of tumour 
antigens, thereby enhancing the possibility of a clinical success. A significant correlation 
was observed between clinical responses and both regulatory T cell frequency decrease 
and natural killer cell activation. These effects were positively associated with calreticulin 
and heat shock protein (HSP)90 surface expression in dying tumour cells used in the 
vaccine formulations. Therapeutic improvements might thus be accomplished by 
stimulating tumour release of "eat-me” signals.
T-cell maturation and anti-lymphoma activation were also associated with a 
positive clinical outcome. A novel artificial expansion system was developed to boost these 
effects through the ex-vivo generation of functional, long-lasting polyclonal T cells and 
adoptive cell therapy.
Finally, the investigation of tumour-restricted humoral immunity in clinical 
responders permitted the serological identification of HSP105 as a novel potential NHL 
immunodominant antigen. HSP105 expression correlated with B-NHL proliferation and 
aggressiveness. A specific neutralizing Ab significantly reduced lymphoma burden in 
xenotransplanted mice, thus laying the basis for a novel passive immunotherapy for B-NHL.
Collectively, these results provide important information on mechanisms 
underlying anti-lymphoma immunity and open up the possibility of improving active and 
passive immunotherapy to the treatment of indolent B-NHLs.
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1 INTRODUCTION
1.1 Indolent B-cell NHL
1.1.1 Clinical and biologic characteristics
Non-Hodgkin lymphomas (NHLs) are a group of malignancies that arise from 
mature T- or B-lymphocytes in the lymphoid tissue, which includes the lymph nodes, 
spleen, and other organs of the immune system. NHLs are the seventh most common 
cancer in males and females in the United States. In the Western world, about 45 new cases 
of lymphoma are diagnosed per 100,000 people per year (Fisher and Fisher 2004), with an 
even higher incidence in elderly people. The age-adjusted incidence of NHLs rose by more 
than 79% from 1975 to 2005, representing an average annual percentage increase of about
2.6 percent, one of the highest registered. The reasons for this increase are not certain, and 
there are probably multiple causes, including human immunodeficiency virus (HIV) 
infection or acquired immune deficiency syndrome (AIDS) and the massive introduction of 
herbicides and pesticides containing organochlorine, organophosphate and phenoxyacid, 
all compounds that are linked to lymphoma. Exposure to certain viruses and bacteria, such 
as Ebstein-Barr Virus (EBV) and Helicobacter Pylori, is associated with NHL. Furthermore, 
inherited syndromes, such as Sjogren and Klinefelter syndromes, can predispose 
individuals to the later development of NHLs. The concept of predisposition genes is under 
study to determine if they play a role in the sporadic occurrence of NHL in otherwise 
healthy individuals.
About 85% of NHLs are of B-cell origin (B-NHLs), the rest are T-cell or natural killer 
(NK) cell malignancies. Exciting progress has been made in the past 20 years to elucidate 
the cellular origin of human B-cell lymphomas and the identification of key transforming 
events, in particular the role of chromosomal translocations in lymphoma pathogenesis. B- 
cell development takes place in distinct differentiation steps that are characterized by the 
specific structure of the B-cell receptor (BCR). BCR development occurs via an error-prone 
process involving the combinatorial rearrangement of the V, D, and J gene segments in the 
heavy (H) chain locus and the V and J gene segments in the light (L) chain loci (Brack, 
Hirama et al. 1978) (Figure 1.1).
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Figure 1.1 Molecular processes that remodel immunoglobulin genes.
Immunoglobulins (Igs) are expressed exclusively by B cells, after rearrangement of variable (V) regions, 
which interact with antigen, and constant (C) regions, which mediate their effector functions. (A) "V(D)J 
recombination” happen in the V regions of both heavy- (H) and light-chain (not shown) genes. About 50 
functional VH gene segments, 27 DH segments and 6 JH segments are available in the germline, allowing the 
generation of a diverse repertoire of VH gene rearrangements. The diversity is further increased by the 
addition or removal of nucleotides at the joining sites of the gene segments. The process of somatic hyper­
mutation is activated when B cells reach the germinal center (GC, shown in more details in Figure 5.2) and 
leads to the introduction of point mutations, deletions or duplications in the rearranged V-region of Ig genes 
( “X” in the Figure). Class switching leads to the replacement of the IgM (C n (mu)) and IgD (C 8 (delta)) C- 
region gene segments with the IgG (C y (gamma) 1) ones by recombination at the switch regions (S ix (mu) 
and Sy (gamma)l) and gives rise to an Ig with different effector functions but the same antigen-binding 
domain.
Mature (naive) B cells carry a BCR composed of two identical heavy chain and two 
identical light-chain immunoglobulin (Ig) polypeptides that are covalently linked by 
disulphide bridges (Rajewsky 1996). Antigen recognition by naive B cells favours their 
recruitment into secondary lymphoid follicles where they undergo somatic hypermutation 
of VH genes and class switch recombination at the IgH locus, and are selected for increased 
BCR-antigenic epitope affinity through affinity maturation. These processes form the 
germinal centre (GC) reaction that leads to the preferential expansion of the most suitable 
B cell clone(s) able to specifically clear pathogens and thus protect the host tissues (LeBien 
and Tedder 2008). Finally, GC B cells differentiate into memory B cells or plasma cells and 
leave the GC microenvironment (Figure 1.2).
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Figure 1.2 B-cell development.
Naive antigen-activated B cells that receive "helper" signals are driven into B-cell follicles in secondary 
lymphoid organs, such as lymph nodes, where they establish germinal centers (GC). Proliferating GC B cells 
displaced the naive IgM+IgD+ B cells to the outside of the follicle, where they form a mantle zone (dotted). 
Within GC, a dark zone, with proliferating GC B cells (dark gray), and a light zone, containing resting GC B 
cells (light gray), can be distinguished (left and right sides, respectively). Proliferating GC B cells undergo 
somatic hypermutation in Ig V regions and, when they acquire an increased affinity for the antigen, they are 
positively selected through the interaction with CD4+ T cells (Th) and follicular dendritic cells (FDC) in the 
light zone. A fraction of these GC B cells undergo class-switch recombination, and, finally differentiate into 
memory B cells or plasma cells and leave the GC microenvironment.
Malignant B cells seem to be 'frozen' at a particular differentiation stage, which 
reflects their origin. Thus, human B-cell lymphomas are assigned to their proposed normal 
B-cell counterpart on the basis of the particular structure of BCR, the expression patterns 
of differentiation markers, and their specific tissue localization (Epstein, Kiippers et al. 
1999; Shaffer, Rosenwald et al. 2002; Kiippers 2005) (Figure 1.3).
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Figure 1.3 Cellular origin of human B-cell lymphomas.
Human B-cell lymphomas are assigned to their proposed normal B-cell counterpart. Most lymphomas are 
derived from germinal-center (GC) B cells or from B cells that have passed through the GC, indicating its role 
in the pathogenesis of B-cell lymphoma. FL: follicular lymphoma; BL: Burkitt's lymphoma; DLBCL: diffuse 
large B-cell lymphoma; GCB: germinal center B-cell like; ABC: activated B-cell like; CLL: chronic lymphocytic 
leukemia; MCL: mantle cell lymphoma; MZL: marginal zone lymphoma; LPL: lymphoplasmacytoid lymphoma; 
MM: multiple myeloma; MALT: mucose-associated lymphoid tissue lymphoma; HL: Hodgkin's lymphoma.
According to these features, the W orld Health Organization classification (WHO) has 
identified 12 subtypes of B-NHL, which are listed in Table 1.1 (Jaffe 2009). Follicular 
lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the two most prevalent 
NHL subtypes and together account for about 50 percent of cases. Reciprocal chromosomal 
translocations involving one of the Ig loci and a proto-oncogene constitute the hallmark, 
and thus a diagnostic marker, of many types of B-cell lymphoma (W illis and Dyer 2000; 
Kiippers and Dalla-Favera 2001) (Table 1.1). As a consequence of the t(14;18), the BCL-2 
oncogene comes under the control of the active Ig locus, causing a deregulated, constitutive 
expression of the oncogene.
Translocations may happen during three major steps throughout the life of a B cell: i. 
as mistakes occurring during Ig V(D)J gene segment recombination in early B-cell 
development in the bone m arrow (BM) (Jager, Bdcskor et al. 2000), ii. as by-products of the 
somatic hypermutation process (Bross, Fukita et al. 2000), and iii. during class-switch 
recombination in the GC. The last two processes are typical features of B-cell development 
that occur exclusively in the GC (Esser and Radbruch 1990), partly explaining w hy B cells 
are more prone to undergo malignant transform ation than T cells and why most B-cell 
lymphomas derive from GC B cells or the ir descendents. Besides chromosome 
translocations, many other transform ing events have also been implicated in the 
pathogenesis of B-cell lymphomas, such as mutations in tumour-suppressor genes (such as
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TP53 and the gene encoding IkBoc], genomic amplifications (such as REL) and 
translocations not involving Ig loci (API2- MALT1) (Table 1.1). Finally, viruses might also 
be involved in the transformation of B cells. The most relevant example is EBV, which is 
found in nearly all endemic Burkitt's lymphomas (BL), in many post-transplant and 
primary effusion lymphomas (Thorley-Lawson and Gross 2004; Young and Rickinson
2004).
The survival and/or proliferation advantages provided by the constitutive 
expression of an oncogene and the deletion/inactivation of a tumour suppressor gene 
represent the driving force for the uncontrolled expansion of a B-cell clone. Carrying the 
same BCR on the surface, B-NHLs are distinguished by the unique antigenic determinants 
of BCR hypervariable regions, termed idiotype (Id), which represent a one amongst few 
tumour-specific antigens identified until now.
Table 1.1 B-cell lymphoma classification.
Lymphoma
Frequency
among
lymphoma
(% )
Proposed
cellular
origin
Chromosome
translocation
(frequency)
Tumour-
suppressor
gene
mutation
(frequency)
Viruses
(frequency)
Other
alterations
(frequency)
B-CLL 7
CD5+ small 
memory, 
naive, or 
marginal- 
zone B cells
-
ATM (30), 
TP53 (15) -
Deletion on 13q14 
(60)
MCL 5
CD5+ 
mantle-zone 
B cells
CCND1-lgH (95) ATM (40) -
Deletion on 13q14 
(50-70)
FL 20 GC B cells BCL2-lgH (90) - - -
MALT 7 Marginal- zone B cells
API2-MALT1 (30), 
BCL10 IgH (5), 
MALT1-lgH (15-20), 
FOXP1-lgH (10)
CD95 (5-80)
Indirect role of 
Helicobacter 
Pylori in gastric 
MALT 
lymphomas
-
MZL 2
Marginal- 
zone or 
monocytoid B 
cells
- - - -
Splenic MZL 1
Small lgD+ 
naive 
marginal- 
zone B cells
- -
Deletion on 7q22- 
36 (40)
BL 2 GC B celsl MYC-IgH or MYC- IgL (100)
TP53 (40), RB 
(20-80)
EBV (endemic, 
95; sporadic, 30) -
DLBCL 30-40 post-GC B cells
BCL6-various (35) 
BCL2-lgH (15-30) 
MYC-IgH or MYC- 
igL (15)
CD95 (10-20), 
ATM (15), 
TP53 (25)
-
Aberrant 
hypermutation of 
multiple proto- 
oncogenes (50)
Primary 
mediastinal B- 
cell lymphoma
2 Thymic B cells - SOCS1 (40) -
Aberrant 
hypermutation of 
multiple proto­
oncogenes (40)
Post­
transplant
lymphoma
<1 GC B cells - - EBV (90) -
Primary
effusion
lymphoma
<0.5 (Post) GC B cells - -
HHV8 (95), EBV 
(70) -
LPL;
Waldenstrom’s
disease
1 (Post) GC B cells PAX5-lgH (50) - - -
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B-CLL, B-cell chronic lymphocytic leukemia; MCL, mantle-cell lymphoma; FL, follicular lymphoma; MALT, 
mucosa associated lymphatic tissue lymphoma; MZL, marginal zone lymphoma; BL, Burkitt's lymphoma; 
DLBCL, diffuse large B-cell lymphoma; LPL, lymphoplasmacytic lymphoma; GC, germinal center.
Clinically, NHLs are classified according to the Cotswolds modification of the Ann 
Arbor staging system (Olweny 1990) into four stages based on anatomic sites of 
involvement and the presence of disease above or below the diaphragm (Figure 1.4). For 
each stage, lymphomas are further divided in two subsets according to the presence (A) or 
not (B) of systemic symptoms (night sweats, weight loss of >10% or fevers) (Figure 1.4).
STAGE I STAGE II STAGE III STAGE IV
Figure 1.4 Ann Arbor staging system.
Schematic examples of stage I-IV disease is shown. Stage I: single lymph node or single extralymphatic site; 
stage II: two or more tumour sites in the same side with respect to the diaphragm or contiguous 
extralymphatic site; stage III: involvement of both site of the diaphragm or spleen, or contiguous 
extralymphatic sites or both; stage IV: diffuse or disseminated involvement of one or more extralymphatic 
sites and/or lymph nodes. Dotted line indicated the diaphragm; black filled circles represent involved tumour 
sites.
Commonly, NHLs are further characterized as either “aggressive” or “indolent" 
(http://www.nih.gov/), even though the WHO lymphoma classification (Jaffe 2009) does 
not include this terminology. Rapidly progressing high-grade or aggressive NHLs account 
about 60% of cases in the United States, with DLBCL being the most common subtype. 
Slow-growing indolent NHLs encompass the low-grade and some categories of 
intermediate-grade subtypes, with FL being the most frequent (Table 1.2). Both 
intermediate/aggressive and indolent diseases are diagnosed at stage III or IV in more than 
50% and 80% of cases, respectively. In contrast with other types of cancer, stage IV NHL 
may be still highly curable, depending on the patient's specific subtype of disease. Since the 
subtype and stage of NHL and whether it is the indolent or aggressive form determines 
appropriate treatment, an accurate diagnosis is required to optimize the management of 
NHL patients.
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Table 1.2 Frequencies of indolent lymphoma according to the WHO classification system.
Frequency, %
Follicular Lymphoma . 22 |
Small lymphocytic lymphoma 6
[ Marginal zone B-cell lymphoma, mucosa-associated lymphoid tissue type
i
5 j
Marginal zone B-cell Lymphoma, nodal type 1
| Lymphoplasmacytic lymphoma ■■ I
(Adapted from Gribben 2007)
FL represents not only the most common indolent NHL, but also the second most 
frequent subtype of lymphoma worldwide, accounting for approximately 20% of malignant 
lymphomas in adults, but 40% of all lymphomas diagnosed in the United States and in 
Western Europe (Armitage and Weisenburger 1998). FL is derived from GC B cells and 
maintains the gene expression profile of this stage of differentiation (Dave, Wright et al.
2004). Morphologically, the disease is composed of a mixture of centrocytes and 
centroblasts and is graded from 1 to 3, depending on the proportion of large cells per high- 
power field. Grades 1 and 2 are indolent disease. The rare subtype grade 3b is more 
aggressive and should be discriminated from lower-grade cases.
FL cells express a surface Ig (more frequently IgM+/-IgD > IgG > IgA), B-cell- 
associated antigens (CD19, CD20, CD22, CD79a and CD79b), and 60% express CD10. They 
are CD5-, CD23-/+, CD43-, and C Dllc-. CD5 and CD43 negativity is useful in 
differentiating FL from chronic lymphocytic leukemia (CLL) and MCL, whilst CD 10 
reactivity is useful in distinguishing MZL (Vitolo, Ferreri et al. 2008). The hallmark of FL is 
the chromosomal translocation t(14;18), present in 70-95% of the cases, which results in 
the constitutive expression of the antiapoptotic protein BCL2, and thus allows to 
distinguish reactive from neoplastic follicles (Ngan, Chen-Levy et al. 1988; Pezzella, Tse et 
al. 1990).
FL can involve every anatomic district, but the most common presentation is 
multiple lymphoadenopathy. Advanced disease is found in 80-85%, 70-75% and 65-70%  
of grade 1, 2 and 3 cases respectively. As other indolent lymphomas, FL is characterized by 
extreme and often unpredictable clinical variability, with a continuous pattern of relapse 
that sometimes leads to a rapid unexpected clinical worsening, and remains incurable with 
the available therapies (Hiddemann, Buske et al. 2005). As an example, 15-60% FL undergo 
transformation in a largely unpredictable way into the more aggressive histologic 
malignancy DLBCL, following molecular mechanisms that are not entirely known (Horning 
and Rosenberg 1984; Lossos 2005; Rosenberg 2008). Transformed lymphomas are usually 
quite aggressive and poorly responsive to chemotherapy (O'Brien, Easterbrook et al. 1991), 
with a median survival from transformation of about 18 months (Rohatiner and Lister 
2005; Montoto, Davies et al. 2007). Thus, the accurate biomolecular characterization of 
tumour features associated with progression or response after therapy is essential to 
identify predictive and prognostic biomarkers and molecular targets for new drug 
development, thereby enabling the improvement of the clinical management for indolent 
NHL patients.
Multiple lines of evidence also point to a crucial dependence of indolent lymphomas 
on infiltrating immune cells for its maintenance and progression (Herreros, Sanchez- 
Aguilera et al. 2008). An important example is the demonstration that removing bacteria or 
viruses, such as Helicobacter pylori and hepatitis C virus and EBV, from the lymphoma
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microenvironment may efficiently arrest tumour growth [Wotherspoon, Doglioni et al. 
1993; Hermine, Lefrere et al. 2002; Sagaert, De Wolf-Peeters et al. 2007]. Tumour- 
infiltrating immune cells, including T lymphocytes, macrophages and dendritic cells [DCs], 
can provide contact-dependent or independent signals for lymphoma cell survival [de Jong 
2005; Dave 2008]. Proliferation of B-CLL cells is largely restricted to proliferation centres 
in lymph nodes and BM, where neoplastic cells are in intimate contact with nurse-like cells 
[NLCs], CD4+ T cells and DCs that prevent apoptosis and/or trigger survival of tumour B 
cells [Figure 1.5A] [Schmid and Isaacson 1994; Ghia, Circosta et al. 2005; Nishio, Endo et al.
2005]. Several findings indicate the participation of immune cells also in the biology and 
pathogenesis of FL [Alvaro, Lejeune et al. 2006a; Glas, Knoops et al. 2007]. FL cell growth 
depends on stromal cells and, in particular, upon follicular DC CD40 stimulation that can 
prevent caspase activation and the spontaneous apoptosis of indolent lymphoma cells 
[Figure 1.5B] [Eray, Postila et al. 2003; Goval, Thielen et al. 2008]. Noteworthy, the gene 
and immunohistochemical signature of non-tumour cells in the neoplastic tissue currently 
represents the best predictor for FL patient survival [Figure 1.5B] [Dave, Wright et al. 
2004; Farinha, Masoudi et al. 2005; Lee, Clear et al. 2006; Glas, Knoops et al. 2007].
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Figure 1.5 Lymphoma microenvironment.
(AJ Chronic lymphocytic leukaemia cells proliferate in transformation centres responding to environment 
signals. NLCs, nurse-like cells. [B] Survival of tumour cells in FL depends on their interaction with multiple 
subpopulations of specialized T cells, macrophages and dendritic cells. GC, germinal centre; Treg, regulatory 
T cells; TFH, follicular B-helper T cells; LAMs, lymphoma associated macrophages. [Adapted from Herreros 
2008]
The dysfunctional immune profiles in FL microenvironment can also reprogram other 
immune cells such as T regulatory cells [Tregs] and lymphoma-associated macrophages 
[LAM]. FL cells can attract or locally convert FOXP3+ Tregs that in turn suppress anti- 
tumour immunity directly by impairing T cell activation [Yang, Novak et al. 2006; Yang, 
Novak et al. 2007; Ai, Hou et al. 2009] and through the induction of M2 polarization of LAM, 
amplifying the tumour immune evasion [Farinha, Masoudi et al. 2005; Alvaro, Lejeune et al. 
2006b; Tiemessen, Jagger et al. 2007]. However, published data on the prognostic 
significance of the presence of Tregs within FL microenvironment are highly conflicting 
[Gribben 2010] [Table 1.3].
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Table 1.3 Immune microenvironment in FL.
Study
FOXP3
few
FOXP3
many
FOXP3
Intra-
follicular
CD68
many
CD4
few
CD4
many
CD4
Inter-
follicular
CD8
few
CD21/23
disrupted
Farinha P, 
Blood 2010 good poor poor poor - ND ND - ND
Carreras J, 
Blood 2006 poor good good - - ND ND ND ND
Lee AM, J Clin 
Oncol 2006 poor good good - poor good good - ND
Alvaro T, J
Clin Oncol poor good good good poor good - poor ND
2006
Glas AM, J
Clin Oncol - - - - - - good - poor
2007
(Adapted from Gribben 2010)
The highly heterogeneous treatments used in these studies may partly explain the 
observed discrepancies since they have shown to d ifferentia lly impact the immune cells 
w ith in  FL m icroenvironment (de Jong, Koster et al. 2009). A very recent study conducted in 
a series of uniform ly treated patients has evidenced that, more than Treg amount, their 
architectural d istribution w ith in  FL lymphoma m icroenvironment plays a key role in 
predicting not only survival but also the risk of transformation (Farinha, Al-Tourah et al. 
2010). Therefore, the concomitant study of the in trinsic tumour features, the functional 
composition of the non-malignant m icroenvironment, and constitutive patient-related 
properties may be very useful to improve the management of indolent NHL patients and 
develop alternative therapies aimed at interfering w ith  the pro-survival interaction 
between tum our and inflamm atory cells.
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1.1.2 Standard therapeutic approaches
Due to the indolent course of low-grade lymphoma, a major clinical question is how 
to identify the patients that may benefit from early therapy (Gribben 2007}. The institution 
of therapy for indolent NHLs currently depends on patients' prognostic/risk factors, 
measured according to the FL International Prognostic Index (FLIPI) score that takes into 
account patients’ age (>60 years), stage of the disease, number and size (>6 cm) of involved 
nodal sites, BM involvement, haemoglobin (<120 g/d l), LDH and [32-microglobulin levels 
(Solal-Celigny, Roy et al. 2004; Buske, Hoster et al. 2006; Federico, Bellei et al. 2009). Using 
these parameters, 3 risk groups have been identified, w ith  91, 69, and 51% progression 
free survival (PFS) and 99, 96, and 84% survival rate at 3 years for patients at low, 
intermediate, and high risk, respectively. Although FLIPI score helps to risk-stratify 
patients, there is a need for robust biomarkers of disease outcome.
The identification of a gene expression prognostic signature related to tum our 
in filtra ting  immune cells can provide additional im portant inform ation to predict survival. 
However, at present these factors cannot yet be considered, since they need to be further 
corroborated before entering the clinical practice (Dave, W right et al. 2004; Farinha, 
Masoudi et al. 2005; Carreras, Lopez-Guillermo et al. 2006; Lee, Clear et al. 2006). 
Expectant management ("watch and w a it” approach) is usually considered for 
asymptomatic patients w ith  low-bulk disease until clear indications for treatm ent in itia tion 
(Figure 1.6) (Vitolo, Ferreri et al. 2008). Indeed, no survival advantage has been 
demonstrated when patients in these condition have been immediately treated (Hoppe, 
Kushlan et al. 1981).Once treatment is indicated, many therapeutic approaches are 
available (Table 1.4).
Table 1.4 Treatment strategies for indolent lymphomas._______________________
Advanced stage disease
Watchful waiting
Alkylating agents 
Purine analogs
Combination chemotherapy
Monoclonal antibodies
• Unconjugated
• Conjugated: radioimmunoconjugates, immunotoxins
Chemotherapy + monoclonal antibodies (chemoimmunotherapy)
High-dose chemotherapy + autologous/allogeneic stem cell transplantation
Reduced intensity conditioning allogeneic stem cell transplantation 
Palliative radiotherapy 
Localized disease
Radiotherapy
Watchful waiting
(Adapted from Gribben 2007)
Combination chemotherapy regimens including alkylating agents, such as 
chlorambucil and cyclophophamide (CVP: cyclophosphamide, vincristine, and prednisone;
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or CHOP: cyclophosphamide, doxorubicin /  hydroxydoxorubicin, vincristine and 
prednisone], have been the standard of therapy for indolent lymphomas for decades 
(Lister, Cullen et al. 1978; Dana, Dahlberg et al. 1993; Peterson, Petroni et al. 2003). Purine 
analogues (i.e. Fludarabine) have been also extensively studied, and their combination with 
cyclophosphamide (Hochster, Oken et al. 2000; Eichhorst, Busch et al. 2006) and 
mitoxantrone (Velasquez, Lew et al. 2003) have provided higher response rates compared 
to either agents alone. However, since the introduction of monoclonal antibodies (mAbs) 
for the treatment of lymphoma, the standard of choice as first-line therapy has been their 
combination with chemotherapy, namely chemoimmunotherapy (Keating, O'Brien et al.
2005).
The most widely used mAb is rituximab, a chimeric unconjugated Ab against the 
CD20 antigen licensed by the Food and Drug Administration (FDA) (Food and Drug 
Administration. Draft labeling text for Rituxan (rituximab). http://www.fda.gov/cder/ 
foi/label/2006/103705s5230-s52311bl.pdf. Accessed February 2, 2007) and the European 
Agency for the Evaluation of Medicinal Products (European Medicine Agency. European 
Public Assessment Report for Mabthera. http://www.emea. 
eu.int/humandocs/Humans/EPAR/mabthera/ mabthera.htm. Accessed February 2, 2007) 
to treat DLBCL as well as relapsed or refractory, low-grade CD20+ B-NHLs as a single 
agent; non-progressing (including stable disease), low-grade, CD20+ B-NHLs, as a single 
agent, after first-line CVP chemotherapy; previously untreated indolent, CD20+ B-NHLs in 
combination with CVP chemotherapy (Leget and Czuczman 1998). Multiple randomized 
clinical trials have demonstrated a significant survival benefit with the addition of 
rituximab to first-line chemotherapy in patients with FL and DLBCL (Press, Leonard et al. 
2001; Vose, Link et al. 2001; Hiddemann, Kneba et al. 2005; Marcus, Imrie et al. 2005; 
Herold, Haas et al. 2007; Schulz, Bohlius et al. 2007; Tan and Horning 2008). Rituximab has 
also been evaluated as first-line monotherapy treatment of low-grade NHLs, showing 
encouraging results (Hainsworth 2000; Hainsworth, Burris et al. 2000; Colombat, Salles et 
al. 2001; Solal-Celigny 2001).
More aggressive front-line therapies are usually considered for patients with a 
rapidly progressing disease, which represents an indicator of poor prognosis (Brice, 
Bastion et al. 1997).
According to performance status, previous therapy, response, and duration of 
response, it is possible to define treatment at relapse (palliative versus potentially 
curative). Therefore, relapsed indolent NHLs are again managed expectantly or are treated 
with rituximab as single agent (McLaughlin, Grillo-Lopez et al. 1998; McLaughlin, 
Hagemeister et al. 1999) or in combination with chemotherapy; alternatively, relapsed 
patients can enter clinical trials for the study of new biotherapies (Figure 1.6). Autologous 
haematopoietic stem cell transplantation (HSCT) is applicable in only a minority of patients, 
due to extensive prior therapy and frequent marrow involvement. However, encouraging 
results have been obtained when autologous HSCT has been instituted for young patients 
with chemo-sensitive disease. (Freedman, Ritz et al. 1991; Freedman, Neuberg et al. 1999; 
Apostolidis, Gupta et al. 2000; Rohatiner, Nadler et al. 2007) (Figure 1.6). Even though 
allogeneic HSCT is associated with a higher transplant related mortality, it is increasingly 
used as salvage therapy for relapsed or refractory indolent lymphomas, due to the lower 
risk of relapse, and the long-term progression free survival (PFS) observed after allogeneic 
compared to autologous HSCT (Toze, Barnett et al. 2004) (Figure 1.6). Donor lymphocyte 
infusion (DLI) has demonstrated a significant therapeutic activity in case of relapse after 
allogeneic HSCT, thus pointing to the efficacy of a graft-versus-lymphoma (GVL) effect in 
indolent lymphomas (Morris, Thomson et al. 2004; Gribben, Zahrieh et al. 2005). To better 
exploit the GVL activity of alloreactive donor T cells, nonmyeloablative or reduced- 
intensity conditioning regimens prior to allogeneic HSCT have been recently introduced in 
the clinical practice. This strategy has decreased the acute mortality from conditioning
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toxicity and can be used for the treatment of elderly patients and patients with significant 
co-morbidities (Khouri, McLaughlin et al. 2008; Rezvani, Storer et al. 2008). However, the 
risk of both acute and chronic graft versus host disease (GVHD) or late non-relapse deaths 
due to immunosuppression from GVHD treatment continue to exist, and the optimal 
scheduling of such a life-threatening but potentially curative therapy remains challenging. 
In sharp contrast, when newly diagnosed indolent NHL is limited (stage I or II), immediate 
involved-field radiation therapy (IFRT) is usually recommended since it has the potential 
to eradicate the disease (Vaughan Hudson, Vaughan Hudson et al. 1994; Wilder, Jones et al. 
2001) (Figure 1.6).
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Loca
(Stag
lized 
e l-ll)
Locoregional
RT
Disseminated 
(Stage lll-IV)
No/Few symptoms
Watch-and-Wait
approach
Follow-up Relapse
Symptomatic
Rituximab+ 
polychemotherapy 
Locoregional RT
PR/PD
^ Symptomatic
Watch-and-Wait
approach
Salvage therapy 
with rituximab-based 
chemoimmunotherapy 
HDT+ Auto HSCT/Allo HSCT 
New drugs or biotherapies
No/Few symptoms
Watch-and-Wait
approach
Figure 1.6 Therapeutic algorithm for the treatment of indolent NHLs.
RT: radiotherapy; HDT: high-dose therapy; Auto HSCT: autologous hematopoietic stem cell transplantation; 
Alio HSCT: allogeneic hematopoietic stem cell transplantation; CR: complete remission; PR: partial remission; 
PD: progressive disease
More extensive nodal radiation as well as the addition of chemotherapy to radiation 
therapy does not seem to improve overall survival (Matasar and Zelenetz 2008). An 
excellent therapeutic alternative for any lines of treatment of indolent NHLs is the 
enrolment of the patients in randomized clinical trials due to the slow-progressing nature 
of the disease and the possibility to keep it in check.
Several lines of evidence have pointed to a high susceptibility of lymphoma to 
immunotherapeutic approaches such as passive immunotherapy with different mAbs, 
radioimmunotherapy, vaccine-based treatments, HSCT and adoptive cellular therapy. FL B- 
NHL has long been regarded as particularly immune responsive based on reports of 
spontaneous regressions (Horning and Rosenberg 1984) and high response rates to mAbs 
(McLaughlin, Grillo-Lopez et al. 1998; Forstpointner, Unterhalt et al. 2006). Accordingly, 
over the past 30 years only the introduction of chemoimmunotherapy with rituximab has 
recently demonstrated to improve the overall survival (OS) of FL patients, indicating that 
the natural history of this disease is potentially changing (Fisher, LeBlanc et al. 2005; 
Friedberg 2008). However, resistance to rituximab remains a problem (Hainsworth, Litchy 
et al. 2005) and regimens that improve remission duration are needed. Novel treatments,
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w ithout the use of chemotherapy, such as immunotherapeutic strategies, may provide 
opportunities for the cure of relapsed/refractory indolent NHLs.
1.2 Anticancer immunotherapy
The term immunotherapy describes m ultiple approaches aiming at conferring either 
passive or active immunity. Passive im m unity supplies the immune response through the 
infusion of Abs or cytotoxic T cells, w ith  the major lim ita tion that it  is short-lived. By 
contrast, active im m unity is though to stimulate an endogenous immune response, where 
the immune system is primed to recognize the tum our as foreign, and, thus, represents the 
ideal form of immunotherapy. It is now generally agreed that the future of cancer therapy 
lies in the combination of therapies w ith  different mechanisms of action. Immunotherapy is 
increasingly used in combination w ith  trad itional treatments in comprehensive 
immunotherapeutic programmes w ith  the aim to attack cancer cells on m ultiple sides and 
promote the onset of specific im m unity to avoid recurrence (Andersen, Junker et al. 2010].
The rationale to use immunotherapy for the treatment of cancer relies on the concept 
of cancer immunosourveillance (Sahin, T iireci et al. 1995; Stockert, Jager et al. 1998], in 
which the host immune system acts as an extrinsic tum our suppressor. In cancer patients, 
however, this mechanism is gradually subverted through the process of immunoediting by 
which tum our cells reduce the ir immunogenicity. Malignant cells that can escape immune 
recognition are thus positively selected and promote the outgrowth o f the tum our (Figure 
1.7] (Dunn, Old et al. 2004]. There may be m ultiple evasive mechanisms adopted by the 
malignant cells to impede proper immune activation. Examples include the down- 
regulation of tum our antigens and major histocom patibility complex (MHC] molecules, the 
establishment of a tolerogenic environment by secreting immunosuppressive molecules 
that affect antigen presenting cells (APCs] maturation, differentiation, and activ ity and by 
enhancing Treg activity (Zou 2005].
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Figure 1.7 Dynamic model of tumour immunosourveillance.
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Following cellular transformation mechanisms that lead to the development of a neoplastic clone, its ultimate 
fate depends on immunosuorveillance: it may be eliminated (Elimination phase), maintained in a 
dormant/equilibrium state (Equilibrium phase) or escape the host protective actions of immunity by either 
becoming non-immunogenic or through the elaboration of immunosuppressive molecules and cells (Escape 
phase). (Adapted from Dunn 2004).
Immunotherapy has thus the aim to re-establish or supply for the host immune 
functions that allow the patients to recognize tumours as dangerous, mount a full-fledged 
attack, and eradicate the cancerous cells with less toxic effects than using conventional 
radiotherapy, chemotherapy and surgery.
Thus far, melanoma has been the target for the majority of studies for the potential 
efficacy of immunotherapy due to its intrinsic high immunogenicity and sensitivity to a 
specific immune attack. Indolent lymphomas, however, remain one of the most suitable 
diseases that may benefit from this kind of intervention for two main reasons. First, more 
than other malignancies, they grow thanks to the alteration of the balance between 
immunity and tolerance in the tumour microenvironment; second, their indolent course 
leaves optimal therapeutic windows for the study of potentially useful immunotherapeutic 
interventions with minimal side effects. In the past 15 years a number of immunologically 
based treatment options have been developed for patients with indolent lymphoma. To 
date, targeting CD20 on the surface of malignant B cells with mAbs, in particular rituximab, 
has been the most clinically effective strategy (Coiffier 2007). Patient-specific vaccines 
targeting the clonally derived Ig-Id protein have also been largely exploited to induce an 
endogenous adaptive anti-lymphoma response able to clear cancer cells and establish an 
anti-tumour immunological memory (Park and Neelapu 2008). Lastly, adoptive transfer of 
anti-tumour cytotoxic T lymphocytes (CTLs) has been used for indolent lymphoma patients 
on the basis of the high sensitivity of FL to GVL following allogeneic SCT and the clinical 
benefit associated to donor lymphocytes infusion (DLI) even in highly chemotherapy- 
refractory lymphomas (Khouri, McLaughlin et al. 2008; Rezvani, Storer et al. 2008). At 
present the major obstacle to the biological and clinical efficacy of anti-cancer 
immunotherapy remains immune tolerance that protects neoplastic cells from immune 
system attack. The molecular obstacles to the successful reversal of tolerance and 
induction of effective immunity are becoming clear and novel immunotherapeutic 
strategies should therefore consider multiple elements to overcome them, whilst providing 
a durable anti-tumour immune response that could be ideally maintained throughout 
patient's lifespan.
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1.2.1 Passive Immunotherapy
Passive immunotherapy does not stimulate the patient's immune system to “actively" 
respond to a disease in the way a vaccine does. It rather consists of the administration of 
mAbs produced by hybridoma or recombinant protein technology to react against specific 
antigens on cancer cells, such as a receptor, a specific enzyme or a protein. Binding of the 
Ab may then activate effector cells in the host immune system (Hjelm, Carlsson et al. 2006).
MAbs are thus a form of targeted therapy that, following reaction with the specific 
antigen, can exert protective functions in three principal ways. They can activate the 
complement system that, forming a membrane attack complex on the target cells, causes 
their lysis and death (complement dependent cytotoxicity (CDC) (Reff, Carner et al. 1994), 
or favours their opsonization and phagocytosis by neutrophils and macrophages. In 
addition phagocytes can be directly recruited to the Ab Fc via the specific receptor and eat 
the bound cell (Ab-dependent cell mediated cytotoxicity (ADCC)) (Clynes, Towers et al. 
2000). ADCC has the advantage of catalyzing T cell activation, as the digested foreign cell 
proteins are presented on the MHC molecules of APCs as peptides. Finally, depending on 
the targeted antigens, Abs have also been shown to kill cancer cells by blocking growth 
mechanisms or directly inducing apoptosis as a conventional targeted therapy does.
With the advent of mAb technology (Kohler and Milstein 1975; Stashenko, Nadler et 
al. 1980) more than ten cell-surface molecules have been identified on B cells, with 
different expression levels at various stages of their development. However, most of these 
antigens are found also on the malignant B-cell counterpart, and have been thus exploited 
as molecular targets for mAb therapy (Figure 1.8).
B-cell receptor
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Figure 1.8 B-cell antigen targets.
B-cell surface-associated antigens that have been exploited as immunotherapeutic targets for the treatment 
of B-cell malignancies. (Adapted from Tay 2010)
To date, CD20 has been the most commonly targeted antigen by mAb therapy for B- 
cell malignancies because of its advantageous characteristics of being expressed at high 
levels on the surface of most malignant B cells, where it is tightly bound with little 
modulation and no secretion or rapidly shedding in circulation. Furthermore CD20
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expression is absent on the early B-cell precursors allowing repopulation of the B-cell 
compartment after treatment (Cragg, Walshe et al. 2005]. In addition, CD20 seems to have 
an important role in the physiology of B-cell activation and cell-cycle regulation (Jazirehi 
and Bonavida 2005]. Thus, apart from its binding to normal B cells, CD20 represents an 
ideal target for B cell lymphoma.
The chimeric human-mouse IgGl kappa anti-CD20 mAb rituximab was the first 
mAb to be approved by the Food and Drug Administration in 1997 for treatment of 
relapsed or refractory CD20-positive indolent B-NHLs (Food and Drug Administration, 
http://www.fda.gov/cder/ foi/label/2006/103705s5230-s52311bl.pdf) (Leget and 
Czuczman 1998]. On binding to CD20, rituximab induces ADCC, CDC, apoptosis of 
neoplastic B cells by promoting calcium influx and caspase activation (Golay, Zaffaroni et al. 
2000; Pedersen, Buhl et al. 2002] and sensitizes malignant B cells to chemotherapy (Alas, 
Emmanouilides et al. 2001]. Rituximab has been the most valuable addition to the 
treatment for B-NHLs since 20 years and is now considered the cornerstone of therapy in 
both indolent and aggressive B-cell lymphomas. Nevertheless, about 30% and 50% of FL 
patients do not respond to rituximab in first-line or more advanced treatment settings 
respectively (McLaughlin, Grillo-Lopez et al. 1998], and approximately 60% of initial 
responders no longer benefit from retreatment (Davis, Grillo-Lopez et al. 2000]. The 
success of rituximab, but also its recognized limitations, has stimulated investigational 
efforts to develop newer-generation anti-CD20 mAbs as well as mAbs targeting different 
surface antigens expressed on malignant B cells (Table 1.5 and 1.6, Figure 1.9]. Several 
approaches are under evaluation, including humanization of the molecules to decrease 
infusion reactions and immunogenicity, while improving side-effect profile, and 
enhancement of binding affinity. Modification of the Fc portion is also being performed to 
optimize effector functions, particularly ADCC.
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Table 1.5 Anti-CD20 mAb in clinical development.
mAb Format Indication ADCC CDC Directeffects
Ag
Binding Dev. Phase
Rituximab Chimeri c lgG1 NHL/RA + + + + + +
Approved
1997
90Y-lbritumomab
tiuxetan
Murine
(90Y) NHL +/- + + + + +
Approved
2002
131 l-Tositumomab Murine
(131l)
NHL +/- + + + + + Approved2003
Ofatumomab
(HuMax-CD20)
Human
lgG1 NHL/RA + + + + + + + + +
Phase III 
trials
Ocrelizumab
Humani
zed
lgG1
NHL/RA + + + +/- + Phase III trials
TRU-015 SMIP RA + + + + + / - Phase I/ll trials
Veltuzumab
Humani
zed
lgG1
NHL/ITP + + + + + = Phase I/ll trials
AME-133V
Humani
zed
IgGi
Relapsed
NHL + + + + + + + + + +
Phase I/ll 
trials
PR013192 
(rhumAb v114)
Humani
zed
lgG1
CLL/NHL + + + + + + + + = + + Phase I/ll trials
GA101
Humani
zed
lgG1
CLL/NHL + + + + + - + + + + = Phase I/ll trials
ITP: Immune thrombocytopenic purpura; SMIP: Small Modular Immunopharmaceuticals; RA: Rheumatoid 
Arthritis
Second-generation anti-CD20 mAb include ofatumomab, veltuzumab, ocrelizumab 
that are humanized or fully human IgGl, with an unmodified Fc region (Table 1.5,1.6 and 
Figure 1.9}.
Given the finding that the V158F polymorfism on Fc receptor FcyRIII can impair 
rituximab-mediated ADCC (Cartron, Dacheux et al. 2002; Weng and Levy 2003], third- 
generation mAbs have been developed with an Fc region designed to bind with equal 
affinity mutated FcyRIII on NK cells, thus enhancing their effector functions and their 
therapeutic activity. Three such engineered anti-CD20 Abs - AME-133v (Bowles, Wang et al.
2006], PR0131921 (rhuMAb v ll4 ]  (A Trial of the Safety of Escalating Doses of PR0131921 
in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. 2009. 
(Accessed 20 May 2009, at http://clinicaltrials.gov/ct2/show/NCT00452 
127?term=PR0131921&rank=2.], and GA-101 (Salles 2009] - are currently in early phases 
of clinical development. All of them have demonstrated an increased capability to mediate 
ADCC as compared with rituximab, and GA-101 have also shown to better induce direct 
apoptosis in malignant B cells (Table 1.5].
Novel anti-CD20 mAbs have demonstrated the same favourable toxicity profiles as 
rituximab. In general, pharmacodynamic parameters do not correlate with response, and
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no clear dose-effect relationships have been detected. They are associated with significant 
efficacy, although response rates in rituximab-refractoiy patients are modest.
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Figure 1.9 History of anti-CD20 mAb in clinical translation.
Chronological introduction of anti-CD20 mAb in clinical trials, as well as the corresponding technologic 
progress for their development (generation I reagents: murine or human/mouse chimeric mAbs; generation 
II reagents: humanized or fully human mAbs; generation III reagents: Abs with modified structures, such as 
mutation or a-fucosylation of the Fc domain for enhanced FcR binding profiles) (Adapted from Lim 2010).
MAbs therapies for B-NHLs targeting neoplastic B-cell antigens distinct from CD20 
are developing exponentially in number with the aim of identifying more active and 
specific treatments. CD22, CD23, CD40, CD80, CD70, CD74 are amongst the most widely 
exploited biotargets for novel anti-lymphoma passive immunotherapy (Figure 1.8). 
However, being involved in the normal B-cell functions, these antigens are not tumour 
specific. Nevertheless, the humanized anti-CD22 monoclonal IgG epratuzumab (Leonard, 
Coleman et al. 2003), the primate-human chimeric anti-CD23 and anti-CD80 monoclonal 
IgGl lumiliximab (IDEC-152) (Pathan, Chu et al. 2008) and galiximab (Czuczman, Thall et al.
2005) have shown promising clinical results and a good safety profile in phase I / I I  trials 
for relapsed/refractory indolent NHLs (Table 1.6). Moreover, the combinations of 
epratuzumab or galiximab with rituximab demonstrated significant clinical activity with 
limited toxicity (Leonard, Coleman et al. 2005) (Czuczman 2008), with the latter showing 
even better outcomes than either agent alone (Friedberg 2008). Epratuzumab or 
lumiliximab with chemoimmunotherapy or standard chemotherapy proved feasible and 
safe approaches for NHL patients, which compared also favourably with historical controls 
receiving the same treatment without these novel agents (Micallef 2009; Byrd 2006). Such 
encouraging results have prompted the initiation of randomized phase III trials comparing 
rituximab with or without galiximab and (fludarabine, cyclophosphamide, rituximab) FCR 
regimen with and without lumiliximab.
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Due to the crucial role of CD40 engagement on the surface of lymphoma B cells for 
their proliferation and survival [Grdisa 2003; Kater, Evers et al. 2004), CD40 has been 
largely studied as a potential biotarget for these diseases. HCD122 [formerly CHIR-12.12) 
and dacetuzumab [SGN-40) are respectively a fully-human and a humanized anti-CD40 
monoclonal IgGl that, blocking CD40/CD40L-mediated signalling, activate proapoptotic 
signal transduction pathways and provide ADCC, resulting in clearance of malignant B cells 
[Law, Gordon et al. 2005; Luqman, Klabunde et al. 2008). Clinical evaluation of the 
tolerability of HCD122 is underway in phase I trials for NHLs or Hodgkin’s lymphomas, 
multiple myeloma, and relapsed CLL. Dacetuzumab has already reached phase II clinical 
trials that indicate some effects as monotherapy in patients with heavily pretreated DLBCL 
[Advani 2008) [Table 1.6). Ongoing studies are exploring its activity in combination with 
conventional therapies in multiple myeloma, DLBCL, and low-grade NHLs.
MAbs targeting CD70 and CD74 are the last ones entering preclinical and initial 
clinical development for the treatment of B-cell malignancies [Kaufman 2009). CD70 has 
the advantage of being expressed prevalently on neoplastic B cells, and rarely on normal B 
or T lymphocytes [Hintzen, Lens et al. 1994). CD70 targeting on lymphoma cells with the 
specific fully-human MDX-1411 mAb has resulted in potent ADCC induction [Israel, Gulley 
et al. 2005). CD74 is a type-II transmembrane chaperone molecule, expressed on normal 
and malignant B cells, monocytes and histiocytes. It mediates several pro-survival signals 
and favours tumour immune escape by impairing the binding of antigenic peptides to 
human leukocyte antigen system [HLA)-DR [Roche and Cresswell 1990; Starlets, Gore et al.
2006). The anti-CD74 mAb Milatuzumab [hLLl, IMMU-115) has shown to cause very 
modest ADCC or CDC, but in the presence of an appropriate cross-linking agent, it can 
inhibit cell proliferation and promote apoptosis in vitro, resulting in significant 
prolongation of survival in lymphoma mouse models [Stein, Qu et al. 2004; Stein, Mattes et 
al. 2007).
All these results have been seen with great enthusiasm, even though, as yet, none 
have demonstrated significant efficacy over that seen with rituximab. Retrospective 
analysis of failures and successes of mAb therapy has resulted in the reemphasis of three 
major caveats of this approach: [i) identity of the target antigens, [ii) the limited 
understanding of the mechanisms of action of the mAbs and [iii) resistance induction 
[Maloney 2007). Tumour specificity, essential biologic activity, the absence of mutation in 
the target epitope, and minimal shedding or extracellular secretion are the most important 
properties that an ideal mAb target should have. However, B-cell surface proteins 
identified to date do not concomitantly display all of these features. In addition, the relative 
contribution of the mechanisms responsible for the observed anti-tumour activity still 
remains largely unknown as well as the events leading to tumour resistance, which 
currently represents one of the major limitation of mAb therapy [Davis, Czerwinski et al. 
1999; Cartron, Watier et al. 2004; Zhou, Hu et al. 2008). Therefore, novel Ab-based 
immunotherapeutics continue to be under evaluation to improve the current therapies for 
B-cell malignancies.
The strategy to conjugate mAbs with toxin[s) [immunotoxin[s)) has been developed 
to more efficiently target rapidly modulating antigens and induce tumour-cell death. 
However, this approach has been limited by the induction of immune responses to the mAb 
and the toxin as well as non-specific toxicity [Messmann, Vitetta et al. 2000). This has led to 
the generation of agents with an improved safety profile. The calicheamicin-conjugated 
anti-CD22 mAb Inotuzumab ozogamicin [CMC-544) is such an example [Dijoseph, 
Armellino et al. 2004) that, having demonstrated significant single-agent activity in 
relapsed FL and DLBCL [Fayad, Patel et al. 2006), is now under clinical investigation in 
combination with rituximab [Fayad, Patel et al. 2008) [Table 1.6).
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In contrast to unmodified mAb and drug/toxin mAb conjugates, tumour-specific 
mAbs complexed to a radioisotope [1311, 90Y) do not need to bind to each tumour cell, or 
penetrate homogeneously into the neoplastic tissue to exert their effects. The ionizing 
energy emitted from therapeutic isotopes can kill cells several cell diameters away [cross 
fire effect], thus resulting in a more efficient tumour targeting. Two radiolabelled mAbs 
directed against CD20 have been tested for the treatment of relapsed/refractory NHLs 
after first-line chemotherapy: 1311-tositumomab [Bexxar) and 90Y-ibritumomab tiuxetan 
[Zevalin) [Emmanouilides 2003; Vitolo, Ferreri et al. 2008). Both have provided high 
response rate in large cohorts of patients with relapsed/refractory FL [Witzig, Flinn et al. 
2002; Witzig, White et al. 2003; Fisher, Kaminski et al. 2005; Kaminski, Radford et al. 2005). 
90Y-ibritumomab showed also greater efficacy than rituximab as single-agent in a 
randomized trial (Witzig, Gordon et al. 2002). For the majority of patients, however, the 
response duration is relatively short and, at present, it is difficult to predict the best 
candidates for this treatment.
Therefore, the need for more cost-effective immunotherapeutics has led to the 
development of novel scaffold strategies, many of which are based on the use of mAb 
fragments or single-domain Abs. The aim is to increase target multispecificity, an increased 
ability to recruit effector cells, and to bind cryptic epitopes.
Small-modular immunopharmaceuticals [SMIPs) are single-chain polypeptides with a 
target-binding domain attached to an effector domain through a flexible hinge domain, the 
latter designed to govern the engagement of receptors on immune cells for enhanced ADCC 
activity [Gill and Damle 2006). TRU-015 and TRU-016 are recently developed CD20- and 
CD37-SMIPs that have demonstrated more potent ADCC than rituximab in CLL and NHLs. 
Ongoing research is investigating the potential clinical use of these SMIPs in B-cell 
lymphomas [Burge, Bookbinder et al. 2008; Hayden-Ledbetter, Cerveny et al. 2009) [Table 
1.5).
Bispecific T-cell engager [BiTE) Abs that consist of two single-chain Abs, one specific 
for CD3, a subunit of T-cell receptor complex, and the other for a tumour-associated 
antigen, currently represent the most promising novel immunotherapeutics [Brischwein, 
Parr et al. 2007). Blinatumomab [MT103/MEDI538;bscCD3xCD19) is the first BiTE Ab 
tested clinically in patients with relapsed NHLs that has provided excellent anti-tumour 
activity in patients with FL, mantle-cell lymphoma, and CLL in a recent phase-I clinical trial 
[Bargou, Leo et al. 2008). Ongoing phase-II studies will clarify the role of this compound for 
the treatment of B-cell malignancies.
1.2.2 Active immunotherapy
The presence of a specific humoral and /o r cellular immunity against the autologous 
malignancy has been found to be associated with a significant improved survival [Zhang, 
Conejo-Garcia et al. 2003; Goodell, Salazar et al. 2006; Al-Shibli, Donnem et al. 2008; 
Hornychova, Melichar et al. 2008). Thus, many strategies have been developed to actively 
generate such immunity in cancer patients to ameliorate their prognosis. The major 
advantage of active anti-tumour immunotherapy is the potential to stimulate an 
endogenous immune response against immunogenic proteins involved in malignant 
transformations, which, through the initiation of a tumour-specific long-term immunologic 
memory, may be able to contain the disease and prevent relapse.
The possibility of reactivating the host defensive functions against cancer was firstly 
recognized by William Coley in patients with established tumours that experienced 
spontaneous regression after pathogen infections. Starting with these observations, he 
applied the first nonspecific immunostimulatoiy approaches, based on the inoculation of 
bacterial material, leading to the concept of therapeutic vaccination against cancer [Coley 
1891).
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Thanks to expanding genetic and proteomic technologies, a large number of human 
cancer antigens has now been identified, paving the way for the development of specific 
vaccines (Rosenberg 1999}. Tumour antigens have been broadly classified into two 
categories: shared self or tumour-associated antigens (TAAs) and unique or tumour- 
specific antigens (products of mutated genes, altered cell surface glycolipids and 
glycoproteins or viral antigens) (Wang and Rosenberg 1999). Shared antigens refer to 
proteins that are inappropriately expressed by tumour cells but can be found also in 
normal tissues (tyrosinase, alphafetoprotein (AFP), carcinoembryonic antigen (CEA), 
cancer-testis antigens, human epidermal growth factor receptor 2 (HER2)/neu protein). 
Unique tumour antigens result from mutations induced through physical, chemical 
carcinogens or from viral infection, and they are, therefore, expressed only by certain 
tumour types or even individual tumours (BCR-ABL, prostate-specific antigen (PSA), Ig-Id, 
EBV-EBNAs and- latent membrane proteins (LMPs), HPV-E6/E7).
Since stimulating the immune response against self-antigens has the potential to 
cause autoimmunity, the best way to attain robust protective anti-tumour immunity is 
most likely driven by breaking the tolerance to unique cancer antigenicities (Baurain, Colau 
et al. 2000; Echchakir, Mami-Chouaib et al. 2001; Karanikas, Colau et al. 2001; Schamel, 
Arechaga et al. 2005; Sensi, Nicolini et al. 2005). Thus, optimally designed cancer vaccines 
should combine the most adequate immunostimulatory agents and delivery strategies in 
order to provide the efficient in-vivo cross-presentation of the most tumour-specific 
antigens by the most potent APCs (DCs) to T cells. Such an approach is expected to enhance 
the probability of inducing a clinically successful immune response associated with a 
specific long-lasting immunological memory that can keep in check the outgrowth of 
tumour metastases, thus prevening relapses (Figure 1.10).
Cancer
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Activated 
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.cells
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Figure 1.10 Therapeutic anticancer vaccines.
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In the optimal clinical setting, therapeutic vaccines intend to boost immunity against minimal residual 
disease and prevent the outgrowth of metastases. (A) Vaccines are administered with adjuvant agents that 
favour the activation of Thl specific responses through the stimulation/recruitment of proper DCs and T cell 
subsets. Tumour antigens can be taken up by activated DCs (such as epidermis-resident Langherans cells) 
that, trafficking to the draining lymph node, present them to T cells, leading to the clonal expansion of 
tumour-specific T cells and the production tumour specific Abs. (B) Tumour-specific T cells migrate to the 
site of tumour metastases where they attempt to kill tumour cells that express antigens contained in the 
vaccine. (Adapted from Finn 2003)
Recognition of the central role of DCs has allowed the classification of anticancer 
vaccine into two categories depending on the tumour antigen delivery (Figure 1.11):
1. In-vivo DC therapy, which uses whole tumour cells, proteins, peptides, RNA, 
DNA, viral vectors antigens linked to DC maturation stimuli for in-vivo antigen uptake by 
DCs in a pro-inflammatory environment;
2. Ex-vivo DC therapy, which uses ex-vivo generated DCs loaded with whole 
tumour cells, proteins, peptides, RNA, DNA for the stimulation of CTLs upon injection into 
patients.
spo'
MHC class I•pci
Tumour antigen peptides 
Transduced tumour cells 
Viral vectors 
Plasmid DNA
MHC class II
Ex-vivo generated 
antigen-loaded DCs
Figure 1.11 In-vivo and ex-vivo DC therapy.
Left: injection of the immunogenic agents (viral vector or plasmid DNA encoding for the tumour antigen, or 
tumour cells transduced to express the antigen, or antigen peptides) for a random target of DCs in vivo. Right: 
injection of ex-vivo generated tumour antigen-loaded DCs. (Adapted from Palucka 2007)
On the basis of the successes of attenuated pathogen vaccines to treat viral diseases 
and owing to the initial lack of defined tumour antigens, whole killed tumour cells or 
tumour cell lysate represented the initial forms of anticancer vaccines (Ward, Casey et al. 
2002). Upon injection, tumour cells are destroyed as a consequence of the inflammatory 
reaction or spontaneous apoptosis induction, and antigens can be picked up by DCs and 
cross-presented to T cells for the priming of a specific adaptive immune response.
Thereafter the strategy to use whole tumour cells (Harris, Ryan et al. 2000; 
Kusumoto, Umeda et al. 2001; Jocham, Richter et al. 2004), or allogeneic cell lines for a less 
cumbersome procedure (Toes, Blom et al. 1996; Jaffee, Hruban et al. 2001; Sosman, Unger
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et al. 2002], has continued to be exploited due to the main advantage of eliciting a specific 
polyclonal immune response without the need to a priori know the tumour antigens. 
Accordingly, tumour cells have been also genetically modified to increase their 
immunogenicity and be used as a vaccine (Jaffee, Hruban et al. 2001; Kusumoto, Umeda et 
al. 20013.
The discovery of TAAs laid the basis for the design of anticancer vaccines 
specifically targeting tumour cells. In this field, peptide- or protein-based vaccines have 
been the most frequently formats used. Recently, synthetic or naturally occurring 
polypeptides encompassing a variety of immunogenic CTL and T-helper (Th) epitopes has 
provided a significant improvement in the immunogenicity of peptide-based vaccines. 
These peptides not only enable immune responses against more than one tumour antigen, 
but also favour the concurrent stimulation of CD4+ Th cells needed to induce and sustain 
the MHC class I-restricted CD8+ T-cell activation (Fayolle, Deriaud et al. 1991; Shirai, 
Pendleton et al. 1994; Hiranuma, Tamaki et al. 1999; Zeng, Li et al. 2002). Such long 
polypeptides are taken up and processed by specialized APC rather than binding directly to 
MHC class I molecules (as do peptides that are 8 to 10 amino acids long] offering an 
interesting opportunity for the induction of robust anti-tumour responses (Melief and van 
der Burg 2008). Tumour Id, the unique determinants of malignant B-cell Ig, has been the 
most widely exploited antigen as anticancer vaccines in B-cell lymphoma. Originally 
generated by hybridoma technology, anti-id protein can now be produced by recombinant 
technology cloning Ig genes into stable cell lines for its use as a vaccine. To date, several 
TAAs, for which T cells of a cancer patients and, sometimes, healthy individuals have 
shown reactivity, have been tested in clinical trials. However, as yet, no a single TAA-based 
vaccine has gained official drug approval owing to lack of proven clinical efficacy (Claesson 
2009).
As an additional option to target DC in vivo and to immunize cancer patients, viral 
vectors and plasmid DNA encoding TAAs have been exploited. This strategy requires in- 
vivo transfection and antigen production. The optimized gene sequence is delivered 
intradermally, subcutaneously (Gene Gun device), or to the muscle (intramuscular 
injection -  and electroporation), which allows, respectively, the transfection of professional 
APC (epidermal keratinocytes and Langherans DCs) or myocytes and secondary cross- 
presentation of tumour antigens by recruited DCs. Plasmid DNA vaccines are highly flexible, 
since they can encode several immunological components to direct and amplify immunity 
with low cytotoxicity, are relatively stable and potentially cost-effective for manufacture 
and storage. Viral-mediated gene transfer is more disadvantageous because of the 
immunogenicity of the viral packaging proteins, their high expense, toxic side effects, limits 
on transgene size, and potential for insertional mutagenesis (Hacein-Bey-Abina, Von Kalle 
et al. 2003). Initial clinical trials in lymphoma (Hawkins, Zhu et al. 1994; Timmerman, 
Singh et al. 2002) melanoma (Tagawa, Lee et al. 2003; Weber, Boswell et al. 2008), prostate 
(Low, Mander et al. 2009; McNeel, Dunphy et al. 2009), and cervical (Kim, Gambhira et al. 
2008) carcinomas have demonstrated the safety and immunological efficacy of DNA-based 
vaccines, with no relevant levels of integration into host cellular DNA, or the development 
of anti-nuclear auto-Abs. However, one note of caution is the possibility that vaccine 
antigen uptake and presentation may take place in the improper DC subset without the 
adequate stimuli, thus resulting in tolerance or an unwanted type of immunity rather than 
in the priming of an anti-tumour adaptive immune response (Palucka, Ueno et al. 2007).
By contrast, when generated ex-vivo, DCs are properly matured starting from CD34+ 
hematopoietic progenitors or more commonly from peripheral blood (PB)-derived 
monocytes (Banchereau and Palucka 2005; Nestle, Farkas et al. 2005). Following 
incubation with a cocktail of maturation cytokines (Sallusto and Lanzavecchia 1994), they 
are loaded with tumour antigens as to recapitulate ex vivo the early phase of DC activation.
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However, variables associated with employing DC vaccines are numerous and require 
precise consideration for their therapeutic efficacy. They include the source or DC lineage 
to use, the antigen engulfing strategy, the DC maturation and/or activation levels to achieve 
ex-vivo and the route of vaccine administration. Physiological activation of DCs occurs in 
two phases, maturation and licensing, both of which are essential steps enabling antigen- 
loaded DCs to migrate to the draining lymph nodes (LNs] where they can activate T cells 
against the antigens they are presenting. DC licensing should be avoided during their ex- 
vivo generation for vaccine purpose, since ex-vivo DC full activation may lead to the 
impairment of their immunogenic function in vivo. The goal, therefore, is to differentiate 
antigen-loaded DCs only to the point that they have acquired LN migratory capacity and 
become responsive to licensing stimuli in vivo when they reach the LN and encounter 
cognate T cells (Gilboa 2007].
The form of antigens used to load DCs is a crucial aspect to consider when designing 
anticancer vaccination strategies, since it affects the major histocompatibility complex 
[MHC] antigen presentation pathways and thereby the induction of cytotoxic CD8+ and/or 
helper CD4+ T cell responses (Nestle, Farkas et al. 2005]. The feasibility of using MHC class 
I or II peptides has been a field of intense interest. However, although the peptides can be 
easily chemically synthesized under Good Manufacturing Practice (GMP] requirements, 
these logistical advantages are offset by the paucity of known tumour-specific peptides 
(especially MHC class II restricted peptides], the limited stability of exogenous peptide- 
MHC complexes and patient-specific MHC haplotype restriction. Use of protein-based 
polyepitopic antigens to load DCs, which allows peptides to be channelled into both the 
MHC class I and MHC class II presentation pathways, is limited by access to clinical grade 
reagents. Generating clinical-grade libraries of overlapping peptides is more feasible than 
generating clinical-grade proteins but is expensive, and regulatory organizations might 
prevent the use of this approach if each peptide component has to be validated separately. 
Therefore loading DCs with total antigens, such as recombinant proteins, dying tumour 
cells, and exosomes, or transducing DCs with viral vectors and mRNA (Jenne, Schuler et al. 
2001; Gilboa and Vieweg 2004] seems to be the most promising strategy, since it allows the 
natural processing and epitope selection improving the efficacy of antigen presentation. 
Transfection of DCs with tumour transcriptome has turned out to be a more efficient 
method to load DCs (Gilboa and Vieweg 2004] compared to the use of tumour cell-derived 
cDNA (Van Tendeloo, Ponsaerts et al. 2001]. Unfortunately, DC transfection has the 
disadvantage of channelling tumour-specific antigens primarily into the MHC class I 
presentation pathway, thus limiting the generation of effective CD4+ T cell responses 
(Yewdell, Norbuiy et al. 1999]. By contrast, DCs have been shown to efficiently process 
phagocytosed dead tumour cells generating peptides for both CD8+ and CD4+ T cell- 
specific recognition (Fujii, Fujimoto et al. 1999; Palucka, Ueno et al. 2006]. The use of 
whole-tumour antigens therefore has the advantage to simultaneously deliver many TAAs 
(known and unknown, including unique TAA that are expressed by individual tumour] and 
generate CTL responses across all MHC classes, eliminating the need to predetermine the 
most suitable antigens that in a vaccine to mediate tumour rejection. In particular, these 
vaccine approaches have shown to activate CTLs against specific TAAs, as 
carcinoembryonic antigen (CEA] (Nair, Boczkowski et al. 1998], prostate-specific antigen 
(PSA] (Heiser, Dahm et al. 2000], telomerase reverse transcriptase (TERT] (Nair, Heiser et 
al. 2000], and Id (Di Nicola, Zappasodi et al. 2009]. In addition, under certain conditions, 
dying tumour cells may provide intrinsic maturation signals for DCs through the release of 
heat-shock proteins (HSP]90, and HSP70 and other molecular chaperones, such as gp96, 
calreticulin (CRT] (Basu, Binder et al. 2000]. It is worth to consider, however, that the 
advantages of whole tumour cell-based vaccines of widening the spectra of TAAs against 
which eliciting an immune response is counterbalanced by the potential risk of 
autoimmune reactions to non-tumour self-antigens (Finn 2003].
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Finally, the administration route of antigen-loaded DCs has been also recognized to 
be a critical factor for the induction of a specific cellular immune response. Although 
intranodal injection has shown to be the most efficient way to provide DC accumulation in 
secondary lymphoid organs [Lambert, Gibson et al. 2001), it is still unknown whether 
overloading this tissue with large amount of injected DCs really improve the occurrence of 
immunological and clinical responses in humans [Lesimple, Neidhard et al. 2006). 
Therefore, subcutaneously or intradermally injected DCs, which showed to reach the 
regional LNs and favour the onset of a protective immunological memory in contrast to 
those delivered intravenously, have been the most widely used (Fong, Brockstedt et al. 
2001; Mullins, Sheasley et al. 2003).
The recognition of the low immunogenicity of cancer antigens and the resultant low 
avidity of specific T cells, together with the immunosuppressive network established by 
tumour cells, has spurred the development of combination strategies to overcome these 
limitations and improve the efficacy of cancer vaccines. Matzinger's “Danger Model” 
pioneered the idea that tumour antigens presented in the context of bacterial signals may 
be viewed by the immune system as 'dangerous' leading to tumour elimination by the 
immune system (Matzinger 2002). Modifiers of the innate immunity for shaping the proper 
adaptive immune response have been thus considered essential components of anticancer 
vaccines. Accordingly, the co-administration of adjuvant agents has been largely exploited 
in active immunotherapy protocols, with the molecules mostly used being Freund's 
adjuvant, keyhole limpet hemocyanin (KLH) (Harris and Markl 2000), QS21, ISCOMs, 
montanide, HSPs, bacilli Calmette-Guerin (BCG), granulocyte/monocyte-colony stimulating 
factor (GM-CSF) (Higano, Corman et al. 2008), toll like receptor (TLR) ligands (Imiquimod 
for TLR-7/8, CpG for TLR-9) (Goldstein, Varghese et al.; Datta, Cho et al. 2004; Li, Song et al. 
2007; Brody, Ai et al. 2010). The progressive understanding of homeostatic mechanisms 
that control strength and duration of an immune response has led to the use of reagents 
that block the down-regulation or enhance the stimulation of anti-tumour immune 
activation. Numerous studies have shown that antagonistic Abs specific for co-inhibitoiy 
receptors, such as cytotoxic T lymphocytes-associated antigen 4 (CTLA-4) (Hodi, Mihm et 
al. 2003; Peggs, Quezada et al. 2006) and PD-1 (Korman, Peggs et al. 2006; Keir, Francisco 
et al. 2007), or regulatory cytokines, such as tumour growth factor-beta (TGF-p) (Gorelik 
and Flavell 2001) and interleukin (IL)-10 (Moore, de Waal Malefyt et al. 2001), Treg 
inactivation (Ruter, Barnett et al. 2009) as well as enhancement of DC-stimulation through 
Abs targeting CD205 (DEC205), the mannose receptor, DC-SIGN, Langerin, and CD40 
(Tacken, de Vries et al. 2007) allow for sustaining the proper anti-tumour adaptive 
immunity in response to a cancer vaccine towards a clinical efficacy. An additional valuable 
mechanism that can be potentiated by these strategies is the ability of some vaccines to 
generate epitope spreading through the stimulation of the immune system against off- 
target antigens, thus avoiding selective pressure of tumour antigen loss variant and 
immunoediting, and eliciting a polyepitopic immune response associated with clinical 
benefit (Disis, Bernhard et al. 2009).
1.2.2.1 Evaluation of immune response to active immunotherapy
There is a general agreement that immune monitoring of vaccinated patients should 
guide the development of cancer vaccines (Keilholz, Martus et al. 2006), since an accurate 
measurement of immune biomarkers can allow determining whether a tumour specific 
immune response can lead to tumour regression. Robert Koch described the host's 
delayed-type hypersensitivity (DTH) reaction following the intradermal injection of 
inactivated poxvirus as the first surrogate marker for specific immunity and protection 
(Koch 1890; Hogrefe 2005). Since then, a variety of in-vitro assays have been developed to 
measure immune responses to vaccines including proliferation tests (initially 3H thymidine
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incorporation assay and more recently carboxyfluorescein diacetate succinimidyl ester 
(CFSE) dilution assay], killer cell function tests (initially 51chromium release assay and 
more recently flow cytometry-based cytotoxic assay using CFSE or PKH26 and 7-AAD co- 
staining], and the most recent tests of antigen specificity (tetramer analysis, Enzyme-linked 
immunosorbent spot [ELISPOT]] and intra-cellular cytokine flow cytometry (CFC]).
Peptide-MHC I and II tetrameric complexes (tetramers) allow the enumeration, 
concurrent phenotyping, characterization, and isolation of peptide specific CD8+ and CD4+ 
T cells. The limit of detection of tetramers binding T cells is 1 tetramer-binding cell per 
8,000 cells. The main limitation of this method stems from the rare event analysis required 
to detect cell-binding tetramers (Hogrefe 2005).
ELISPOT assay, developed in 1983, recognizes antigen-dependent T-cell release of a 
particular cytokine, such as interferon gamma (IFN-y), using plates coated with the specific 
“capture” mAb and a second enzyme-labelled Ab directed to a different epitope of the same 
cytokine. Specific cytokine release by a T cell upon antigen recognition is revealed as spots 
that are counted by a computer. In the 1990s, ELISPOT was shown to correlate with the 
standard chromium-release cell-mediated cytotoxicity assay to measure T cell effector 
function. Antigen reactive cells are typically detectable at a limit of 1: 50,000 with this 
method. The magnitude of the response that may be associated with clinical efficacy 
remains unclear (Hogrefe 2005).
Like the ELISPOT, CFC assesses cytokine responses of individual cells but using 
intracellular staining with specific Abs, with a detection level of 1 antigen-reactive cell in 
50,000. CFC is unique in its ability to define the T-cell subpopulations that responds to the 
vaccine by concurrently looking at the cell surface and intracellular markers (Hogrefe
2005).
These analyses alone, however, are not completely exhaustive, since they can reveal 
only whether T cells recognizing the antigen of interest have been stimulated. Functional 
tests that analyse whether these T cells can also destroy tumour cells are required. 
Surrogate biomarkers for the induction of a specific immunity after vaccination against 
cancer have been mostly developed measuring T-cell functions, since T-cell adaptive 
response has been always considered the conditio sine qua non for cancer regression after 
therapeutic vaccination.
Given the successes of mAbs therapies, however, humoral response to anti-tumour 
vaccination are being re-evaluated. It can be monitored in the sera of vaccinated patients 
by enzyme-linked immunosorbent assay (ELISA) (Weng, Czerwinski et al. 2004; Mander, 
Chowdhury et al. 2009), magnetic beads with immobilized antigen (Schmittling, Archer et 
al. 2008) or by flow cytometry and western blotting analyses using, as target, cells 
expressing the immunogenic proteins contained in the vaccines (Reuschenbach, {von 
Knebel Doeberitz} et al. 2009), or more recently protein arrays (Belousov, Kuprash et al. 
2010).
In addition, there is a general agreement that combinations of multiple markers 
which do not only evaluate the quantity and quality of the elicited immune responses, but 
also host and tumour microenvironmental factors that may be critical in mediating a 
clinical response, will be most likely needed to evaluate the efficacy of immune based 
interventions as well as the optimal frequency and/or duration of treatment (Dang and 
Disis 2009).
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1.2.2.2 Clinical benefit of active immunotherapy
To date, an overall objective response rate of 3.3% was observed in 1306 vaccine 
treatments of cancer patients with advanced disease (Claesson 2009]. Patient responses to 
ex-vivo DC vaccinations were higher (9.5%) than those to anti-tumour immunotherapies 
using peptides (2.7%), viral vectors (1.9%), or irradiated tumour cells (4.6%) (Banchereau 
and Palucka 2005) (Table 1.7, for representative examples).
Table 1.7 Clinical efficacy of anticancer vaccines.
Vaccine type Cancer type Vaccine Totalpatients
Patients
responding
Peptide Melanoma
Melanoma
Tyrosinase + GMCSF 
Peptides in IFA or on DC
16
26
0
3
Melanoma MART-1 + IL-12 28 2
Prostate Peptides 10 0
Melanoma Peptides on PBMC + IL-12 20 2
Breast and
prostate
Cervix
Telomerase 
HPV16 E7
7
17
0
0
Colorectal Peptides in IFA 10 0
Multiple
Multiple
Multiple
NY-ESO-1
Ras in DETOX adjuvant 
Peptides in IFA
12
15
14
0
0
0
Virus Prostate Vaccinia-PSA 33 0
Prostate Vaccinia-PSA 42 0
Colorectal Vaccinia-CEA 20 0
Colorectal Vaccinia-CEA and B7-1 18 0
Multiple
Multiple
Multiple
Avipox-CEA(IGMCSF) 
Avipox-CEA 
Vaccinia + avipox-CEA
60
15
18
0
0
0
Tumour cells Melanoma Transduced with GM- CSF 26 1
Melanoma Membranes on silicone beads 17 1
Lung Transduced with GMCSF 26 1
Lung Transduced with GMCSF 43 3
Breast Transduced with B7-1 30 0
Dendritic cells Melanoma Pulsed with peptides 17 0
Melanoma
Melanoma
Melanoma
Pulsed with peptides or lysates 
Pulsed with peptides or lysates 
Pulsed with peptides
33
16
24
3
5
1
Melanoma Pulsed with MAGE-3A1 peptide 11 0
Childhood
cancers Pulsed with lysates 15 1
Kidney Transfected with RNA 15 0
Colorectal Pulsed with CEA peptides 12 1
Kidney
Multiple
Pulsed with tumour lysates 
Pulsed with tumour lysates
35
20
3
0
Heat shock 
protein Melanoma
Multiple
grp96
grp96
28
16
2
0
Total 765 29
(Adapted from Rosenberg 2004)
Despite the limited clinical efficacy of therapeutic cancer vaccines, many such 
cancer vaccine trials have been optimistically reported because surrogate or subjective 
endpoints, such as histological evidence of tumour necrosis or lymphocyte infiltration, 
were achieved. Sensitive techniques, such as tetramer or ELISPOT assays, have been used
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to demonstrate the in-vivo generation of anti-tumour T cells in vaccinated patients, but the 
paucity of clinical responses in these patients has made it difficult to validate any of these 
assays as useful surrogate of clinical efficacy. Little and/or inconsistent correlations have 
been shown between immunological and clinical responses in immunized cancer patients, 
being concordant (Banchereau, Palucka et al. 2001; Belli, Testori et al. 2002; Mazzaferro, 
Coppa et al. 2003), discordant (Lee, Wang et al. 2001; Vonderheide, Domchek et al. 2004) 
or even mutually exclusive (Rosenberg, Sherry et al. 2005), depending upon the trial. 
Noteworthy, the results obtained from circulating T cells may not reflect what is happening 
within the tissue itself.
The fact that vaccine trials have been performed in heavily pre-treated patients with 
progressive refractory tumours may be one of the reason of the limited clinical efficacy of 
cancer vaccines, since the immunosuppressive effects of the tumour microenvironment 
greatly impair the development of an effective anti-tumour immunity (Finn 2003). 
Considering that an evolving immune response could most likely prevent rather than treat 
disease relapse, an active immunotherapeutic intervention has been regarded more 
appropriate after disease stabilization following the gold-standard treatment or as an 
adjuvant therapy. Unfortunately, several phase-III trials that aimed at definitely proving 
the clinical benefit of anticancer vaccines in a wide number of patients with limited 
malignant disease, including melanoma, lymphoma, colon, prostate and renal carcinoma, 
failed to clearly demonstrated the primary end-point of an increased disease/progression 
free survival (Harris, Ryan et al. 2000; Hersey, Coates et al. 2002; Mitchell, Abrams et al.
2007) (Morton, Mozzillo et al. 2007; G-VAX, available from: 
http://www.fiercebiotech.com/story/deaths-force-halt-cellgenesys-cancer-vaccine- 
trial/2008-08-27; OncoPhage, available from: http://www.fiercebiotech.com/press- 
releases/fda-grantspermission-export-antigenics-oncophage-russia; MyVAX, Favld).
To date, autologous DCs pulsed ex vivo with prostate acid phosphatese (PAP) has 
been the first anticancer vaccine that achieved the regulatory approval by the FDA, upon 
the demonstration of a median survival improvement of 4.1 months and a death risk 
reduction of 22.5% in vaccinated hormone-refractory prostate cancer patients compared 
to the control group (Kantoff, Higano et al. 2010). Surprisingly, the prolongation of survival 
was not found to be associated with a measurable anti-tumour effect, raising concern that 
an imbalanced study-group assignment, caused by unmeasured or unknown prognostic 
variables, might have influenced the results (Kantoff, Higano et al. 2010).
There is now a general interest towards the understanding of the failure and the few 
successes of anticancer vaccines in order to develop improved approaches and properly 
design their evaluation in clinical studies. Until now, the limited efficacy of cancer vaccines 
to induce the expansion of high levels of anti-tumour T cells able to infiltrate the tumour 
and become activated after encountering the specific antigen in vivo is one of the main 
reasons for their inability to definitely clear solid tumours (Rosenberg, Yang et al. 2004). 
Lymphoid malignancies allow an easier access to the circulation and often express 
costimulatory molecules for the activation of naive and memory cells, thus partially 
explaining their slightly increased sensitivity to DC vaccines (Timmerman 2002). Several 
studies have demonstrated that large numbers of adequately activated, tumour-specific T 
cells can mediate the rejection of large, vascularised tumours in mice and humans 
(Rosenberg, Sherry et al. 2005). Cancer vaccines most likely need to generate these levels 
of immune activation to reach clinical efficacy. To increase the chance for responsiveness 
and to limit the risk of vaccine-induced immunoediting and TAA down-modulation, the use 
of polyepitopic vaccines, including the real "tumour-regression" antigens that 
demonstrated to induce immune activation associated with clinical responses in cancer 
patients, seems theoretically the most promising approach (Claesson 2009). In addition, 
agents able to break tolerance and stimulate the proliferation of anti-tumour lymphocyte
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into patients without autoimmune toxicity will likely be required to enhance vaccine 
effects.
A leading example of the apparently inconsistent successes and failure of active 
immunotherapy for cancer patients is the experience of Id vaccines. After two decades 
spent on the validation of this approach in preclinical models [Lynch, Graff et al. 1972; 
Kaminski, Kitamura et al. 1987; Kwak, Young et al. 1996] as well as in initial clinical trials 
[Inoges, Rodriguez-Calvillo et al. 2006] in 2008 two randomized clinical trials aimed at 
confirming these proof-of-principles in a large-scale setting failed [Park and Neelapu 2008; 
Freedman, Neelapu et al. 2009], and, although a third study showed encouraging results in 
this respect, it has not lead to regulatory approval for the marketing of an Id-based vaccine 
owing to insufficient patient accrual and statistical significance [de Cerio and Inoges 2009] 
[Table 1.8].
Table 1.8 Main features and interpretation of clinical trials assessing the clinical benefit of Id vaccines 
for FL.
University of Navarra, 
Spain Genitope Favrille NCI/Biovest
Vaccine
Patients
Source of tumour 
Idiotype production
Induction therapy
Comparison 
(experimental/control) 
Patient status before 
vaccination
Vaccination
Number of patients 
(actual/expected)
Primary end point
generic 
FL, first relapse
Excisional biopsy
Heterohybridoma
technology
Six cycles of CHOP or 
CNOP
Same patients: second 
compared with first CR
Second CR
Id-KLH+GM-CFSE (sc, 23- 
30 mo of active 
vaccination)
25/25
Second CR > first CR and 
13 months
MyVax 
FL, untreated
FNA/core biopsy
Recombinant DNA 
technology
CVP (8 cycles efery 3 
wk)
2/1 randomization
First CR or PR
Id-KLH+GM-CFSE or 
KLH+GM-CSF (sc, 7 
doses)
Vaccine: 192/240; 
control: 95/120
PFS (p<0.01)
Favld
FL, untreated or 
relapsed
FNA/core biopsy
Recombinant DNA 
technology
Rituximab (weekly x 4)
1/1 randomization
First CR, PR or SD
Id-KLH+GM-CFSE or 
placebo+GM-CSF (sc, 
until PD) 
Vaccine: 174 instead 
of 171; control: 175 
instead of 171
TTP (p<0.01)
Biovaxld 
FL, untreated
Excisional biopsy
Heterohybridoma 
technology 
PACE/R-CHOP 
(6-8 cycles every 
4wk)
2/1 randomization
First CR or CRu
Id-KLH+GM-CFSE 
or KLH+GM-CSF 
(sc, 5 doses)
Vaccine: 76/250; 
control: 41/125
DFS (p<0.01)
Results
Potential caveats
Refs
20 of 20 immune 
responders achieved both 
end points; 5 of 5 immune 
non-responders did not
Small proof-of-principle 
study
Inoges et al. 2006
Median PFS, 19.1 
(experimental) vs 
23.3 (control) mo (p = 
0.297)
More patients than 
expected (at least 
one-quarter) relapsed 
or progressed within 9 
months from 
randomization
Levy et al. 2009
Median TTP, 9 
(experimental) vs 12.6 
(control) mo (p = 
0.019)
Too few CR induction 
before vaccination; 
severe B cell depletion 
by rituximab in most 
vaccinated patients
Freedman et al. 2009
Median DFS, 44.2 
(experimental) vs 
30.6 (control) mo 
(p = 0.045)
Missed target ITT 
and statistically 
significant
Schuster et al. 
2009
CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CNOP, cyclophosphamide, mitoxantrone, 
vincristine and prednisone; RTX: Rituximab; CRu, complete response unconfirmed; CVP, cyclophosphamide, 
vincristine and prednisone; DFS, disease-free survival; GM-CSF, granulocyte-macrophage colony-stimulating 
factor; ITT, intent to treat; KLH, keyhole limpet haemocyanin; n.s, not significant; PACE, prednisone, 
doxorubicin, cyclophosphamide and etoposide; PFS, progression-free survival; pts: patients; CR, complete 
response; PR, partial response; SD, stable disease; TTP, time to progression. (Adapted from Bendandi 2009]
The formal proof that KLH-conjugated Id plus GM-CSF can function as a tumour 
specific vaccine leading to immune response and rejection of the corresponding tumour 
was provided by preclinical vaccination-challenge studies using murine model of myeloma 
and lymphoma [Lynch, Graff et al. 1972; Kaminski, Kitamura et al. 1987; Kwak, Young et al. 
1996]. The immune responses were highly heterogeneous and therapeutically efficacious
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when the tumour size was limited, indicating that the best clinical setting in which to 
evaluate the clinical effects of Id vaccination was represented by patients in complete 
response after standard chemotherapy (Kaminski, Kitamura et al. 1987). The biological 
efficacy of vaccination with Id-KLH plus GM-CSF was subsequently demonstrated by most 
phase I/ I I  studies in FL patients in complete clinical response or with residual disease after 
chemotherapy (Bendandi, Gocke et al. 1999; Inoges, Rodriguez-Calvillo et al. 2006; Redfern, 
Guthrie et al. 2006; Yanez, Barrios et al. 2008). Only one Phase II study showed the 
association between the occurrence of an Id-specific immune activation and the clinical 
benefit in terms of an improvement in relapse-free survival in vaccinated FL patients 
(Table 1.8) (Inoges, Rodriguez-Calvillo et al. 2006). Therefore, 3 large-scale randomized 
phase-III clinical trials were initiated with the aim of demonstrating a clear-cut survival 
improvement in vaccinated patients. These studies used either hybridoma-derived Id 
(Biovaxld, Biovest International, Schuster et al. 2009) or recombinant Id (MyVax, Genitope, 
(Levy et al. 2008); Favld, Favrille, (Freedman, Neelapu et al. 2009)) in grade 1-3 FL patients 
experiencing at least disease stabilization (Favrille), partial (Genitope) or complete 
(Biovest) remission after standard course of rituximab, CVP or PACE (prednisone, 
doxorubicin, cyclophosphamide and etoposide) regimens, respectively (Table 1.8). 
Although these clinical trials failed to confirm the clinical benefit of Id vaccination, they 
also did not prove that the negative results were due to the failure of the vaccine rather 
than to defects in study design. The pre-vaccine treatment modality has been recognized as 
one of the major flaw of these studies: rituximab-treated patients started vaccination with 
severely depleted numbers of circulating B cells, CVP did not always produce durable 
response, and PACE regimen proved inappropriate in the rituximab era, thus explaining the 
very limited patient enrolment and randomization. In addition, given the heterogeneous (i) 
natural history of indolent NHLs, (ii) influence of these tumours on host defences 
(Bendandi 2009), (iii) responsiveness of these patients to the Id-antigen (Lynch, Graff et al. 
1972), (iv) the anti-tumour effects of an immune response induced by Id-vaccines (Inoges, 
Rodriguez-Calvillo et al. 2006), coupled with the possible emergence of target antigen 
mutation or down-regulation over the course of the disease (Meeker, Lowder et al. 1985; 
Raffeld, Neckers et al. 1985), the use of standard phase-III randomized trials does not seem 
the most appropriate to assess the clinical benefit of patient-specific Id-vaccines (Bendandi 
2006; Longo 2006). The study of Id-vaccination in lymphoma patients in first relapse 
and/or progression after chemotherapy would allow the possibility to compare the length 
of the clinical responses obtained with the subsequent treatments (standard chemotherapy 
vs. vaccination protocol). In this regard, a longer duration of the vaccine-induced second 
clinical response compared to the first in a substantial proportion of patients has been 
proposed as the major end-point for regulatory approval without facing the specific 
complications of a randomization (Longo 2006; Bendandi 2009). Randomization to either 
idiotypic vaccination or maintenance rituximab after chemotherapy has been also 
suggested with the non-inferiority of Id vaccines compared to rituximab as a second 
independent main clinical end point, possibly allowing regulatory approval (Longo 2006).
1.2.3 Adoptive Cell Transfer Immunotherapy
Due to their high cytotoxic potential, specific activity and efficient homing function, 
T cells have been considered the major immune actors in the fight against cancer 
(Mitchison 1955). Several immunotherapeutic strategies have aimed to take advantage of T 
cells using specific mAbs activating or blocking respectively co-stimulatory or co-inhibitory 
molecules, and/or, as previously described, their in-vivo targeting with anti-tumour 
vaccination. Alternatively, the infusion of tumour-reactive autologous or allogeneic T cells 
into cancer patients as adoptive cell transfer therapy (ACT) has been exploited to augment
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anti-tumour immunity above the levels provided by vaccination alone and thus increase 
the possibility to eradicate established diseases.
The direct evidence that anti-tumour T cells can induce a specific response 
associated with clinical benefit is shown by the durable complete remissions observed in 
many individuals with haematological malignancies treated with DLI upon relapse 
following allogeneic transplantation [Dazzi, Szydlo et al. 2000; Lokhorst, Schattenberg et al. 
2000]. These effects have been ascribed to a graft-versus-tumour effect of donor T cells 
that can recognize in the recipient a pattern of HLA containing TAA-derived peptides as 
non-self (Cooper, Topp et al. 2003; Porter and Antin 2006; Sprangers, Van Wijmeersch et al.
2007). The ability of allogeneic HSCT or DLI to eradicate tumour and provide long-term 
survival, even in highly chemotherapy-refractory lymphomas, demonstrated the 
susceptibility of these diseases to T cell-mediated immune responses (Khouri, McLaughlin 
et al. 2008; Rezvani, Storer et al. 2008). Although potentially curative, the treatment- 
associated non-relapse mortality and chronic GVHD limit the application of these 
therapeutic interventions. In addition, they cannot be used in many patients because of 
advanced age and co-morbidities as well as the unavailability of a suitable donor. Therefore, 
efforts have been made to generate T cells targeting tumour antigens minimally expressed 
in normal tissues for harnessing this anti-tumour effector activity avoiding the toxicity of 
allogeneic HSCT and DLI. The generation of tumour-specific T cells involves many variables, 
including the source of T cells, the strategy to achieve anti-tumour T cell specificity, the 
methods of T cell stimulation and expansion, all of which affect dramatically the success of 
ACT (Table 1.9).
Table 1.9 Variables to consider in the generation of anti-tumour T cells for adoptive transfer.
Starting cell type Method of stimulation Exogenouscytokines Timing of restimulation
Unsorted PBMC Phytohemagglutinin IL-2 Weekly
CD8+ T cells anti-CD3 Ab IL-2 + IL-15 Every 10-14 days
CD4+ T cells anti-CD3 and -CD28 Abs IL-15 By size
CD8+ and CD4+ anti-CD3/-CD28 beads IL-7 + IL-15 When target cells die
Central memory T cells Irradiated target cells IL-12
Effector memory T cells Irradiated aAPC IL-21
Naive T cells Irradiated aAPC expressing co-stimulatory ligands
Other
combinations
(Adapted from Till and Press 2009)
The finding that tumour infiltrating lymphocytes (TILs) could be expanded in the 
presence of IL-2 whilst still retaining the MHC-restricted recognition of the autologous 
tumour cells represented a leading step in the development of tumour specific ACT (Muul, 
Spiess et al. 1987). The infusion of in-vitro expanded and stimulated autologous TIL in 
metastatic melanoma patients represented the first example of ACT for the treatment of
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advanced solid cancer (Figure 1.12) (Rosenberg, Yannelli et al. 1994; Dudley, Wunderlich
et al. 2002; Dudley, Wunderlich et al. 2005).
^ ^  Dendritic cells
Artificial
antigen-
presenting
cells
Tumour-derived
lymphocytes
Antigen
loading
Stimulation and expansion 
of tumour-recognising T cells
€ >  Antigen-specific 
stimulation
Selection and expansion of 
antigen-specific T cells
Figure 1.12 Isolation and ex-vivo stimulation of antigen-specific T cells for adoptive transfer.
Autologous PB or tumour-derived T cells are expanded ex vivo in the presence or not of TAA-loaded APCs, 
such as dendritic cells or artificial APCs. Enriched tumour-specific T cells are then re-infused for treatment. 
(Adapted from Disis 2009)
However, initial attempts to treat cancer patients with ex-vivo stimulated TILs met with 
limited success, largely due to the inability to fully restore adequate effector functions in 
autologous TILs in vitro (Kolenko, Wang et al. 1997; Radoja, Saio et al. 2001). The finding 
that autologous PB-derived T cells could be more easily rescued by anergy in vitro (Ohlen, 
Kalos et al. 2001; Teague, Sather et al. 2006) led to start using this cell population for the 
generation of tumour specific T cells by repetitive ex-vivo stimulation in the presence of 
professional APC loaded with the antigen(s) of interest (Figure 1.12) (Riddell and 
Greenberg 1990). Using this approach, however, the magnitude and persistence of the 
transferred immunity have been limited, mainly because T-cell cloning needs a long culture 
period and preferentially induces the differentiation of T cells with an effector-memoiy 
phenotype (Tem  cells). In contrast to initial beliefs, fully matured and activated effector T 
cells have shown limited anti-tumour efficacy in vivo, mainly because of their inability to be 
further stimulated in vivo to lyse tumour cells and persist within the memory compartment 
(Figure 1.13) (Yee, Thompson et al. 2002; Gattinoni, Klebanoff et al. 2005; Hinrichs, 
Borman et al. 2009).
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Figure 1.13 Inverse relationship of in vitro and in vivo anti-tumour functions of adoptively 
transferred naive and effector T-cell subsets.
Chronic or repetitive antigen stimulation drives naive CD8+ T cells to a terminally differentiated effector state 
and ultimately to exhaustion. For each step that characterizes this process the phenotypic changes are 
illustrated. Together with a shortening of the telomere length, CD8+ T cells progressively lose their 
proliferative potential and become exhausted and/or undergo apoptosis. In addition, CD8+ T cells lose the 
ability to secrete IL-2 and to respond to homeostatic cytokines such as IL-7 and IL-15. Although in-vitro tests 
have revealed the progressive gain of effector functions and lytic capability with stimulation, highly in-vitro 
reactive and cytolytic tumour-specific CD8+ T-cell clones loose their ability to mediate cancer regression 
when adoptively transferred. Ag: antigen. (Adapted from Gattinoni 2006)
Studies aimed at defining T-cell characteristics that are crucial for a clinically 
efficacious ACT intervention have indeed identified their in-vivo persistence and tumour 
homing properties as the most relevant (Schwartzentruber, Horn et al. 1994; Robbins, 
Dudley et al. 2004; Zhou, Shen et al. 2005). These findings have highlighted the need for 
strategies that are able to expand more undifferentiated T cells (i.e. expressing 
CD62L/CCR7 molecules) that can be further activated in situ in the host LNs, thus 
promoting the onset of long-lasting therapeutic anti-tumour effects into patients. Although 
potentially useful to reduce the length of in-vitro antigen-specific T cell stimulation whilst 
preserving their destructive functions, the rapid in-vitro expansion of TAA-specific T cells 
generated in vivo by specific immunisation has rarely been investigated (Schultze, 
Anderson et al. 2001; Rapoport, Stadtmauer et al. 2005; Powell, Dudley et al. 2006). Since
47
multiple observations have indicated the ability of polyclonal T cells generated by ex-vivo 
short expansion from bulk peripheral blood mononuclear cell (PBMC) cultures to 
efficiently mediate tumour rejection (Yee, Thompson et al. 2002; Antony, Piccirillo et al. 
2005; Dudley, Yang et al. 2008; Muranski and Restifo 2009], it has been now realized that 
the mixture of naive, effector, Tem and central memory T cells (T cm ), of both CD4+ and CD8+ 
T cells (recognizing multiple TAAs and having long-lasting in-vivo persistence potential), 
may represent a more effective T-cell product for ACT compared to highly selected specific 
CD8+ T cell clones (Antony, Piccirillo et al. 2005). Besides classic “helper" function, CD4+ T 
cells have been reported to directly destroy tumour cells and/or recruit and activate other 
immune cells, in particular APCs (Corthay, Skovseth et al. 2005; Perez-Diez, Joncker et al. 
2007; Hunder, Wallen et al. 2008). New approaches to polyclonal T-cell expansion are 
currently attempting to replace autologous DCs by more efficient artificial APCs to shorten 
the in-vitro culture period whilst driving T-cell activation and maturation towards the most 
suitable phenotype to maximize T cell in-vivo persistence and tumour homing properties 
upon adoptive infusion (Figure 1.12) (Maus, Thomas et al. 2002; Oelke, Maus et al. 2003).
In addition, the possibility of the introduction of high affinity T-cell receptors (TCR) 
and co-stimulatory molecules into circulating human lymphocytes has more recently 
allowed redirecting T cell specificity towards TAAs present on multiple tumour types 
(Gross, Waks et al. 1989; Johnson, Heemskerk et al. 2006). TCRs, obtained from rare 
reactive human clones or from transgenic mouse cells following immunisation against 
human cancer antigens, are now available for a wide array of cancer antigens expressed by 
common solid and hematologic tumours (Heemskerk, Hoogeboom et al. 2004; Cohen, 
Zheng et al. 2005; Roszkowski, Lyons et al. 2005; Zhao, Zheng et al. 2005). ACT with 
genetically engineered T lymphocytes has demonstrated clinical efficacy against several 
malignancies (Morgan, Dudley et al. 2006).
To avoid the limitations of MHC restriction imposed by the use of exp TCRs, chimeric 
TCRs, in which the variable regions of an Ab are genetically fused to an intracellular T- or 
B-cell signalling domains (most commonly CD3£, chain), have been developed against a 
variety of targets, including HER2 (Stancovski, Schindler et al. 1993), CEA (Haynes, Trapani 
et al. 2002), MARTI, MAGE-A1 (Clay, Custer et al. 1999), prostate specific membrane 
antigen (PSMA) (Ma, Safar et al. 2004) and CD33 (Finney, Lawson et al. 1998). Chimeric 
TCRs have proven to efficiently redirect the recognition specificity of lymphocytes to cell 
surface TAAs in initial clinical studies (Park, Digiusto et al. 2007). Since the clinical effects 
of ACT with chimeric TCRs bearing T cells were very modest, second generation chimeric 
TCRs, incorporating co-stimulatory molecule signalling domains, have been developed. 
They resulted in strong antigen-dependent activation and expansion of transfected T cells, 
leading to the design of a series of new phase-I clinical trials (Bendle, Haanen et al. 2009).
As there are many variables to consider in the generation and expansion of T cells, there 
are also many potential manipulations of the recipient that can be done to maximize the in- 
vivo activity of the modified T cells. The strategy to apply conditioning regimens prior to 
ACT has been shown to create a niche for the enhancement of infused T cell homeostatic 
proliferation (Tan, Ernst et al. 2002; Gattinoni, Finkelstein et al. 2005) by depleting 
immunosuppressive cells (Antony, Piccirillo et al. 2005; Sakaguchi 2005) as well as normal 
endogenous lymphocytes that act as competitor cells for homeostatic cytokines (Figure
1.14) (Dummer, Niethammer et al. 2002). Furthermore, by killing tumour cells, systemic 
chemotherapy and total body irradiation boost TAA release and cross-presentation, thus 
facilitating the activation of transferred tumour-reactive T cells (Kedl, Rees et al. 2000) 
(Figure 1.14).
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Figure 1.14 Mechanisms underlying the impact of lymphodepletion on adoptively transferred T cells.
Systemic chemotherapy or radiation before ACT might modify the tumour-bearing host Although APCs are 
reduced in number by direct killing, the reduced competition for antigen at the APC surfaces may result in a 
net increase in lymphocyte activation. The release of (Toll like receptor) TLR agonists after mucosal damage 
favours DCs maturation and lymphocyte activation. Due to the removal of host lymphocytes, NK cells, Tregs 
and myeloid-derived suppressor cells (MDSCs), activating cytokines, such as IL-2, IL-7 and IL-15, may be 
increasingly available and the host immunosuppression activities are decreased. These modifications may 
explain the improved anti-tumour efficacy of transferred CD8+ T cells observed in lymphodepleted hosts 
(Adapted from Gattinoni 2006).
Recent adoptive transfer trials for melanoma using antigen-specific T cells following 
aggressive lymphodepletion regimens have shown considerable tumour regression 
sometimes associated with long periods of T-cell survival in patients with refractory 
metastatic disease (Dudley, Wunderlich et al. 2005; Morgan, Dudley et al. 2006; Dudley, 
Yang et al. 2008). To prolong the in-vivo survival of transferred T cells even further, 
cytokines has been co-administered with ACT as adjuvant therapy. The initial use of high- 
dose IL-2 (Yee, Thompson et al. 2002; Dudley, Wunderlich et al. 2005; Till, Jensen et al.
2008) is being gradually replaced by other cytokines, such as IL-7 and IL-15, since 
exogenously administered IL-2 has been found to also favour the expansion of Tregs 
(Melchionda, Fry et al. 2005).
The successes of ACT in melanoma have spurred the application of this strategy for 
the treatment of other malignant diseases, including B-NHLs, on the basis of their high 
susceptibility to immunotherapeutic approaches and their expression of suitable antigens 
to be targeted with specific T cells. The development of post-transplant
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lymphoproliferative diseases (PTLD), caused by the reactivation of EBV infection in B cells 
of donor or recipient origin after allogeneic HSCT or solid organ transplants, respectively, 
continue to be a significant clinical problem (Rosenberg, Restifo et al. 2008). The adoptive 
transfer of in-vitro generated EBV-specific allogeneic T-cell lines have shown to efficiently 
treat and/or prevent PTLD in allogeneic HSCT (Rooney, Smith et al. 1998) and solid organ 
transplant patients (Haque, Wilkie et al. 2002; Haque, Wilkie et al. 2007). Unlike PTLD, in 
which the immunocompromised state of the host allows the expression of 
immunodominant EBV epitopes, EBV-related nasopharyngeal carcinoma (NPC) (Comoli, 
Pedrazzoli et al. 2005) and Hodgkin lymphoma (Bollard, Aguilar et al. 2004) express only 
the weakly immunogenic proteins of latent EBV (LMP1, LMP2 and EBNA-1) (Bollard, 
Cooper et al. 2008). In these cases, ACT with LMP-1 and LMP-2 specific T cells have 
achieved increased clinical efficacy compared to polyclonal anti-EBV cell lines; however, 
the time required for their generation makes the procedure not suitable for the treatment 
of patients with active disease (Bollard, Gottschalk et al. 2007).
Antigen-specific TCR-bearing T cells have also been generated for the treatment of 
NHLs. As for mAb therapy, the most widely exploited lymphoma-associated biotargets for 
transgenic TCR have been CD20 and CD19. Anti-CD20 chimeric TCR-bearing T cells have 
shown to expand in bulk culture from transfected autologous PBMCs and their use in ACT 
has resulted safe, feasible, and a well-tolerated treatment. However, the clinical responses 
were modest, probably due to the low surface expression of the transfected TCR, and the 
low in-vivo persistence of transferred T cells due to the protracted expansion time (Jensen, 
Cooper et al. 2003; Wang, Press et al. 2004; Till, Jensen et al. 2008). T cells expressing 
chimeric anti-CD19 TCR can be generated and expanded from lymphoma patients (Cheadle, 
Gilham et al. 2005) and are now under investigation as ACT in clinical trials. Meanwhile, 
the incorporation of co-stimulatory molecule (CD28, ICOS, 4-1BB) signalling domains in 
second-generation anti-CD19 and anti-CD20 chimeric TCRs have already shown to 
enhance Thl cytokine secretion by stimulated T cells, their in-vivo persistence and anti­
tumour effects in recent pre-clinical studies (Imai, Mihara et al. 2004; Kowolik, Topp et al. 
2006; Milone, Fish et al. 2009).
Cell transfer studies have thus demonstrated that the administration of highly avid anti­
tumour T cells directed against a suitable target in a lymphodepleted host environment can 
mediate the regression of certain large, vascularised, metastatic cancers in humans. Their 
use has provided guiding principles as well as encouragement to further develop 
immunotherapy for the treatment of cancer patients. However, several limitations 
currently hamper the wide application of ACT, as listed below:
I. Not all tumour-specific T cell cultures can be sufficiently expanded to reach the
amount needed for a therapeutically efficacious ACT;
II. Not all tumour-specific T cell cultures can be optimized at killing the tumour
upon infusion into patients;
III. The in-vivo infusion of large amount of ex-vivo activated and expanded
lymphocytes entails important safety concerns, particularly when they are 
genetically modified;
IV. The patient-specific nature of anti-tumour ACT makes the procedure very costly
and cumbersome and cannot be easily transferred to the commercial-scale 
mass-production techniques necessary to reach the multitude of cancer patients 
worldwide.
Whilst new insights and innovations in the coming years may overcome many current 
limitations, optimization of the presently known variables of ACT programmes might 
improve their therapeutic application.
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1.2.4 Comprehensive immunotherapy
Comprehensive immunotherapy refers to an integrative cancer medicine that not 
only focuses on the neoplastic cells but also and with the same importance, on the 
regulatory, repair and immune mechanisms of the cancer patient as a whole. This concept 
was re-evaluated since its first proposal about fifty years ago by Dr Josef M. Issels (ISSELS J, 
1970). It is now generally accepted that the intimate interplay between cells of the immune 
system and cancer is ongoing from the initiation of oncogenesis, and thus suppressive or 
repair mechanisms represent an intrinsic phenomenon of cancer (de Visser, Eichten et al.
2006). Anticancer immunotherapy should thus address the multifactorial nature of the 
disease using combination protocols that, whilst promoting tumour shrinkage by multiple 
fronts, can enhance the persistence of anti-tumour immune responses, T cell co-stimulation, 
DC immunogenicity, and counteract tumour immune evasions mechanisms.
The few past years has seen as many improvements in the field of immunotherapy 
as in the development of novel anticancer drugs, leading to the possibility of a range of 
combinatorial therapeutic options. The mechanism of action of older and newer anticancer 
therapies has become increasingly clear, and the list of conventional and unconventional 
compounds that can modulate the host environment is rapidly growing (Zitvogel, Apetoh et 
al. 2008). Accumulating evidence about the immunoadjuvant side effects of radiotherapy 
and several chemotherapeutic compounds has recently opened new possibilities for the 
design of rationale chemo-immunotherapy combination strategies able to directly kill 
tumour cells, whilst activating the immune system to produce a more robust and 
sustainable anti-tumour response. The concept of combining immune therapy with 
sequential or even concurrent chemotherapy, previously considered counterintuitive due 
to the intrinsic immune toxicity of any kinds of chemo- and radiotherapy, is now being re­
considered. Indeed, data from several studies have revealed that combining 
immunotherapy and chemotherapy can favour the onset of clinical responses in advanced 
cancer patients (Wheeler, Das et al. 2004; Gribben, Ryan et al. 2005; Arlen, Gulley et al. 
2006; Laheru, Lutz et al. 2008; Ramakrishnan, Antonia et al. 2008). Conventional therapies 
have been found to promote the activation of the immune system against cancer cells in 
two principal ways: as on-target effects, they can confer an increased immunogenic 
potential to tumour cells, thus enhancing cancer susceptibility to a specific immune attack, 
(van der Most, Currie et al. 2008); as off-target effects, they can directly stimulate or inhibit, 
respectively, immune effector or regulatory cells (Ghiringhelli, Menard et al. 2007), or 
influence stroma cells (Dudley, Yang et al. 2008).
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Table 1.10 Immunostimulatory properties of cytotoxic drugs.
Bioactivity Mechanisms Drugs
Antigen uptake Cell-surface CRT Anthracyclines, irradiation
Antigen
processing Increased MHC class 1 expression Irradiation, DAC
Increased TAA production Irradiation, DAC
mTOR activation Irradiation
HMGB1 release Anthracyclines, oxaliplatinj, irradiation
Antigen
presentation DC activation (through TLR4 and MyD88) Paclitaxel§ (in mice), irradiation
APC activation (through TBK, IRF3 and 
IFN) Vascular-disrupting agents
HSP90 Bortezomib||
Self-peptide-MHC class I complexes Myelosuppression and HSCs
Increased antigen cross-presentation Gemcitabinelf
T-cell-dependent
anti-tumour
effects
T-cell activation Taxanes and intratumour DCs or GM-CSF-containing vaccines 
Anthracyclines, oxaliplatin, 
irradiation
IL-12 with DAC 
5-fluorouracil with vaccines
Homeostatic
proliferation Cytokine sink removal? Low doses of total body irradiation
TReg-cell inhibition? 
Microbial translocation?
High doses of alkylating agents, 
fludarabine
Homing to 
tumours
Increased ICAM1, PECAM and VCAM1 
expression
Increased RANTES and CXCL10 
production
Irradiation
Vascular-disrupting agents
Target destruction Increased CD95 expression Cisplatin, irradiation, 5-fluorouracil and dacarbazine
Increased HSP production 5-Fluorouracil
Decreased succinate dehydrogenase 
activity Cisplatin
Increased TRAIL expression Imatinib mesylate# with IL-2
Generation of 
memory T cells
Homeostatic proliferation 
Self-peptide-MHC class I complexes
Total body irradiation
Cyclophosphamide, fludarabine 
with or without vaccines or HSCs
Inhibition of Tregs Inhibition of MSCs and B cells Gemcitabine
Inhibition of TReg cells Cyclophosphamide
Inhibition of M2 macrophages Taxanes
Reduced TGFbeta production Bleomycin
NK cell triggering DC-NK-cell crosstalk Imatinib mesylate
Type I IFNs Vascular-disrupting agents
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$Eloxatin; Sanofi-Aventis; §Taxol; Bristol-Myers Squibb; ||Velcade; Millennium Pharmaceuticals; T[Gemzar; 
Eli Lilly; #Gleevec, Novartis; APC, antigen-presenting cell; CXCL10, CXC-chemokine ligand 10; DAC, 5-aza-2'- 
deoxycitidine; DC, dendritic cell; GM-CSF, granulocyte/macrophage colony-stimulating factor; HMGB1, high- 
mobility group box 1 protein; HSC, haematopoietic stem cell; HSP, heat-shock protein; ICAM1, intercellular 
adhesion molecule 1; IFN, interferon; IL, interleukin; IRF3, IFN-regulatory factor 3; MSCs, myeloid suppressor 
cells; mTOR, mammalian target of rapamycin; NK, natural killer; PECAM, platelet/endothelial cell-adhesion 
molecule; TBK, TANK-binding kinase; TGF(3, transforming growth factor-beta; TLR4, Toll-like receptor 4; Treg 
cells, CD4+CD25+ regulatory T cells; TRAIL, tumour-necrosis-factor-related apoptosis-inducing ligand; 
VCAM1, vascular cell-adhesion molecule 1. (Adapted from Zitvogel 2008)
Based on initial observations by Albert and colleagues (Albert, Sauter et al. 1998), 
the biomolecular mechanisms through which apoptosis process may stimulaye the immune 
system against dying cells have been extensively studied and certain anticancer cytotoxic 
agents have shown a peculiar property to promote antitumour immune activation. These 
observations have demonstrated the possibility to immunize against cancer through its 
killing using cytoreductive treatments (Sauter, Albert et al. 2000; Zitvogel, Casares et al. 
2004). Cytotoxic agents able to influence the immunogenicity of tumour cell death were 
identified by screening for the ability of treated tumour cells to generate protective 
immunity in immunocompetent syngeneic mice following an immunisation-challenge 
schedule (Obeid, Tesniere et al. 2007a; Obeid, Tesniere et al. 2007b). Using this strategy, 
anthracycline (doxorubicin (DXR), idarubicin, mitoxantrone), oxaliplatin and ionizing 
irradiation resulted the most potent inducers of immunogenic tumour cell death (Table 
1.10). These agents showed the distinctive property of stimulating the rapid pre-apoptotic 
cell-surface translocation of the endoplasmic-resident chaperone calreticulin (CRT), which 
can promote DC phagocytosis and cross-presentation of TAAs to T cells, and, thus, the 
priming of a specific adaptive immune response (Obeid, Tesniere et al. 2007a; Obeid, 
Tesniere et al. 2007b)(Figure 1.15). As additional "eat-me” signals for DCs, the exposure of 
HSP70 and HSP90 on the plasma membrane has shown to contribute to the 
immunogenicity of dying tumour cells (Feng 2001; Binder and Srivastava 2005; Saito, Dai 
et al. 2005) (Figure 1.15). Accordingly, the proteasome inhibitor bortezomib (Velcade; 
Millennium Pharmaceuticals) and the antimetabolite drug 5- fluorouracil (5-FU) were 
found to boost the surface-translocation of HSP90 and HSP70, respectively, on human 
myeloma and gastric carcinoma cells, favouring their uptake by DCs and a specific T cell 
activation (Table 1.10) (Galetto, Buttiglieri et al. 2003; Spisek, Charalambous et al. 2007). 
As later immunogenic signals provided by dying cancer cells, the release of high-mobility 
group box 1 (HMGB-1), a ligand of TLR2 and TLR4 that facilitates TAA processing and 
cross-presentation by DCs (Scaffidi, Misteli et al. 2002; Apetoh, Ghiringhelli et al. 2007a; 
Apetoh, Ghiringhelli et al. 2007b), and adenosine triphosphate (ATP) (Ghiringhelli, Apetoh 
et al. 2009; Aymeric, Apetoh et al. 2010), which can promote the activation of DCs through 
the induction of inflammasome and the release of IL-lp, represent crucial events for the 
priming of a specific immune response associated with clinical benefit (Figure 1.15). It has 
been also becoming appreciated that treatment outcome is strongly influenced by 
characteristics of the individual patients and their counter-response to treatment. 
Importantly, the TLR4 Asp299Gly polymorphism, which was found to reduce the binding of 
HMGB1 to human TLR4, has been recently established as an independent predictive factor 
of early disease progression in metastatic colorectal and breast cancer patients treated 
with oxaliplatin- or anthracycline-based regimens, respectively (Apetoh, Ghiringhelli et al. 
2007; Tesniere, Schlemmer et al. 2010). Similarly, the loss-of-function polymorphism 
Glu496Ala in the P2RX7 receptor, which severely delays the ATP-dependent IL-1(3 release 
(Gu, Zhang et al. 2001; Sluyter, Shemon et al. 2004), was found to exert a significant 
negative prognostic impact in breast cancer patients treated with anthracyclines 
(Ghiringhelli, Apetoh et al. 2009).
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Figure 1.15 Steps leading to immunogenic tumour cell death.
Immunogenic cell-death response includes the rapid translocation of intracellular CRT to the cell surface, 
where it acts as a mandatory eat-me signal for DCs, followed by the appearance on the cell surface of other 
molecular chaperones, such as HSP90, that contribute to tumour cell- DC interaction and DC maturation. 
Then, dying cells release the chromatin-binding protein HMGB1 that is required for optimal TLR4-dependent 
processing of the phagocytic cargo by DCs. (Adapted from Tesniere 2008).
Beyond inducing immunogenic tumour cell death, some conventional cytotoxic 
agents may also render cancer cells more susceptible to killing by CTLs. For examples, 5-FU, 
irinotecan (CPT-11), cisplatin (CDDP), paclitaxel and DXR were shown to enhance lytic 
sensitivity of cancer cells by increasing their expression of co-stimulatory molecules, such 
as LFA-3 and ICAM-1 (Bergmann-Leitner and Abrams 2001; Wu, Zeng et al. 2007), or the 
mannose-6-phosphate (M6P) receptor, which is required for Granzyme B associated killing 
(Veugelers, Motyka et al. 2006; Ramakrishnan, Assudani et al. 2010) (Table 1.10). As part 
of its ability to modify transcription regulation in tumour cells, the DNA methyltransferase 
inhibitor 5- aza- 2'-deoxycitidine was shown to restore the expression of HLA class I 
molecules, predisposing neoplastic cells to immune attack (Serrano, Tanzarella et al. 2001; 
Kozar, Kaminski et al. 2003) (Table 1.10). Ionizing irradiation was also reported to up- 
regulate the expression of HLA class I molecules via the modulation of intracellular peptide 
repertoire, the stimulation of new protein synthesis and, thus, increased expression of 
tumour-derived antigenic peptides (Reits, Hodge et al. 2006), thereby boosting CTL activity 
(Garnett, Palena et al. 2004), and finally promote T cell trafficking towards irradiated
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tumour sites (Table 1.10). "The abscopal effect", namely the reduction of distant non­
irradiated metastases, represents the macroscopic effect of the profound anti-tumour 
immune modulation provided by irradiation (Munro 2009).
As off-target effects, conventional therapies may act on normal cells at the level of 
the tumour stroma or immune system, further promoting anti-tumour immune activation. 
A direct effect on immune cells has been demonstrated for most topoisomerase inhibitors 
and anti-microtubule agents that promoted DC maturation stimulating the secretion of IL- 
1(3, IL-6 and IL-12p40 and/or inducing CD40, CD80, CD86 and MHC class II expression 
(Tanaka, Matsushima et al. 2009). For instance, taxanes were reported to enhance T- cell 
proliferation and NK- cell cytolysis in breast cancer patients (Carson, Shapiro et al. 2004). 
Another alkylating agent, dacarbazine, was shown to synergize with peptide vaccines in 
melanoma patients through the enhancement of memory CD8+ T-cell responses, 
highlighting the chemo-immunotherapeutic effects of this class of compounds (Nistico, 
Capone et al. 2009) (Table 1.10). The immunomodulatory drugs lenalidomide and 
pomalinomide have demonstrated clinical anti-tumour activity in several hematologic 
diseases, including CLL and indolent lymphoma subtypes (Witzig, Vose et al. 2007), which 
is related to their properties to inhibit pro-inflammatory cytokine production, increase NK 
cell cytotoxicity and regulate T-cell co-stimulation and activation (Ramsay, Clear et al.
2009) (Table 1.10).
The immunostimulatory properties of some chemotherapeutic compounds may also 
result from the inhibition of the immunosuppressive mechanisms promoted by the tumour. 
Gemcitabine, for example, facilitates the cross-presentation of TAAs by DCs, as a 
consequence of the direct cytotoxic effect on tumour cells, but it also showed to counteract 
the tumour-induced expansion of myeloid-derived suppressor cells (MDSCs) (Suzuki, 
Kapoor et al. 2005), favouring a clinically efficacious anti-tumour immunity when 
combined with recombinant cytokines or vaccines in patients with pancreatic (Plate, Plate 
et al. 2005), colon (Correale, Tagliaferri et al. 2008), or non small-cell lung cancer (NSCLC) 
(Levitt, Kassem et al. 2004) (Table 1.10). Correale and colleagues pioneered the field of 
chemoimmunotherapy in phase II trials for metastatic colon cancer by combining 
immunogenic chemotherapy (gemcitabine plus oxaliplatine) with GM-CSF and IL-2 
(Correale, Cusi et al. 2005; Correale, Tagliaferri et al. 2008) and showed that tumour 
antigen-specific immune responses and autoimmune side effects can be associated with a 
positive clinical outcome (Correale, Del Vecchio et al. 2008). Continued administration of 
low ("metronomic”) doses of cyclophosphamide was shown to selectively clear Tregs, 
inhibit their immunosuppressive function (Ghiringhelli, Menard et al. 2007), and stimulate 
IFN-a production (Schiavoni, Mattei et al. 2000), in agreement with previous clinical trials 
indicating the immunostimulatory function of this treatment (Berd, Maguire et al. 1986; 
Berd and Mastrangelo 1988; MacLean, Miles et al. 1996) (Table 1.10). Also taxanes, in 
particular paclitaxel and docetaxel, were found to reduce Treg frequency, either when 
administered alone (Zhang, Dermawan et al. 2008) or in combination with carboplatin (Wu, 
Feng et al. 2010) or cyclophosphamide (Tongu, Harashima et al. 2010) (Table 1.10). 
Similarly, preclinical studies have described the ability of lenalidomide and pomalinomide 
to inhibit Treg expansion and suppressor function (Galustian, Meyer et al. 2009).
Surprisingly, also targeted therapies, which most recently entered the clinical 
practice, partly exert their anti-tumour activity by immunoadjuvant side effects. For 
example, through the inhibition of c-KIT in host DCs, imatinib mesylate was shown to 
induce DC- mediated, NK cell activation, and DC-dependent anti-tumour effects in 
gastrointestinal stromal tumour (GIST) and chronic myeloid leukaemia (CML) patients 
(Borg, Terme et al. 2004) (Table 1.10). The level of IFN-y secretion by NK cells after 
treatment with imatinib mesylate has been recognize as a positive prognostic parameter in 
patients with GIST, strengthening the clinical importance of the immunostimulatory effect 
of this drug (Menard, Blay et al. 2009). The novel multi-kinase inhibitors sunitinib,
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successfully introduced in the treatment of patients with renal cell carcinoma (RCC], was 
reported to reduce the frequency of circulating Tregs and MDSCs (Ko, Zea et al. 2009], thus 
restoring T cells production of IFN-y (Ozao-Choy, Ma et al. 2009].
The many-sided demonstration of the immune adjuvant effects of conventional 
anticancer therapies thus forms the basis upon which to initiate clinical trials combining 
chemotherapy and immunotherapy in a comprehensive strategy. Such an approach, whilst 
promoting tumour shrinkage by multiple fronts, is expected to favour the onset and 
persistence of anti-tumour immunity, enhancing T cell co-stimulation, DC functions, and 
counteracting tumour immune-evasions mechanisms. Obviously, this strategy still need 
scientific support from basic research into the mechanism(s] of action related to cell death 
pathways accounting for immune activation (Haynes, van der Most et al. 2008].
However, although the ability of some conventional agents to alert the immune 
system about the presence of a tumour may be exploited to provide a multiple-sided attack 
against cancer cells, the riskrof selecting resistant tumour clones still remains. Indeed, 
genetic instability, which intrinsically characterizes cancer cells, can allow neoplastic cells 
to acquire survival and/or growth advantages, being thus positively selected. Stromal cells 
in the tumour microenvironment, being genetically stable and possessing limited 
proliferative capacity compared to cancer cells, may represent alternative valuable target 
for anticancer treatment, since the risk of their escape during therapy is exceedingly lower.
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1.3 Aims of the thesis
The impaired tumour-specific immune activation in indolent NHL patients as well as 
their sensitivity to immunotherapeutic intervention are well documented [Dave, Wright et 
al. 2004; Anichini, Mortarini et al. 2006a). As a step forward to improve active 
immunotherapy approaches for the treatment of these diseases, we developed a fully 
autologous ex-vivo DC-vaccine using as antigenic cargo whole autologous tumour cells 
killed by heat shock, y-irradiation and UV-C exposure. This strategy was expected to favour 
the expression of “danger signals" and the activation of DCs for the in-vivo priming of an 
adaptive immune response against a wide spectrum of TAAs. Eighteen patients with 
measurable indolent NHL who had relapsed after at least one chemo-radiotherapy regimen 
were enrolled in a pilot trial for the study of this vaccine. Vaccination achieved six objective 
clinical responses, including three continuous complete responses and three partial 
responses.
On the basis of these preliminary results, the aims of the thesis have been:
• To verify whether a positive clinical outcome after vaccination correlated with the 
induction of tumour-specific immune activation;
• To identify potential predictors of the clinical outcome of indolent B-NHL patients 
treated with a fully autologous DC-vaccine;
• To identify the NHL-associated/-specific antigens that evoked a humoral response 
associated with the clinical efficacy of vaccination, with the aim to exploit them as 
novel targets of passive immunotherapy;
• To study potential ways of intervention on the host immune system and/or the 
tumour microenvironment to increase the frequency of immunological and clinical 
responses to anticancer immunotherapy in indolent NHL patients.
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2 IMMUNOLOGIC AND CLINICAL RESPONSES TO DC-BASED 
VACCINATION IN INDOLENT NHL PATIENTS
2.1 Introduction
Immunotherapy trials targeting the tumour B-cell Id have documented clinical 
responses in a sizeable number of patients and the promotion of B- and T-cell activation 
against the autologous tumours in the majority of vaccinated patients (Kwak, Campbell et 
al. 1992; Hsu, Caspar et al. 1997; Bendandi, Gocke et al. 1999; Timmerman 2002; Redfern, 
Guthrie et al. 2006). However, three phase-III clinical trials of Id vaccination have indicated 
the lack of clinical benefit in terms of progression/disease free survival (Biovaxld, Biovest 
International, Schuster S. J. ASCO 2009 abs 27, S15; MyVax, Genitope, Levy et al. 2009; 
Favld, Favrille, (Freedman, Neelapu et al. 2009)).
Since the induction of a specific immunity against a single tumour antigen may be 
hampered by the emergence of escape variants (Thurner, Haendle et al. 1999), the use of 
whole tumour cell preparations as source of antigens to load DCs may circumvent these 
limitations. Furthermore, it has the advantage of widening the spectrum of TAAs that can 
be recognized and targeted by the immune system (Maier, Tun-Kyi et al. 2003; Neelapu, 
Gause et al. 2007), even though at the expense of a potential risk of autoimmunity. In 
particular, the strategy to pulse DCs with killed cells was already reported to favour the 
efficient transfer of TAA to the MHC class I processing pathway of DCs (Albert, Sauter et al. 
1998; Berard, Blanco et al. 2000; Hus, Rolinski et al. 2005), thereby enabling TAA cross­
presentation and CTL activation. In addition, exploiting the cytotoxicity of stress stimuli, 
such as heat shock and irradiation, to obtain the apoptotic and necrotic tumour cell bodies 
for DC loading, could even increase the immunogenicity of the vaccine through the 
expression and/or the release of immunogenic molecule, such as HSPs (Feng 2001; 
Zitvogel, Apetoh et al. 2008).
2.2 Aims of the Chapter
The aim of the work described in this Chapter was to deeply characterize the 
immunological responses of indolent NHL patients enrolled in a pilot trial of DC-based 
vaccination and to analyse their association with the clinical outcome, monitored at the 
Medical Oncology Unit of the Fondazione Istitu ti di Ricovero e Cura a Carattere Scientiflco 
(IRCCS') Istituto Nazionale dei Tumori di Milano, under the supervision of Dr Massimo Di 
Nicola. Changes in post- compared to pre-vaccination circulating and/or tumour-associated 
T-cell and NK cell populations as well as tumour-reacting Abs were correlated with the 
clinical changes observed in the patients.
The information obtained aimed to provide a valuable insight not only for identifying 
those patients who would benefit from such a treatment but also in the development of 
improved lymphoma vaccines. The results reported here also formed the basis for 
additional studies on the immune response to the vaccine.
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2.3 Materials and Methods
2.3.1 Patient characteristics
Eighteen patients with FL (n=12) or lymphoplasmocytoid lymphoma (n=6), who 
were relapsed after their previous treatment, were accrued to this pilot study between 
January 2003 and May 2005. The clinical characteristics of the patients are summarized in 
Table 2.1. The median number of previous treatment regimens was two (range 1-5). The 
study included 4 patients treated with high dose sequential chemotherapy (HDS) 
supported by autologous HSCT. Eligibility criteria for entry into the study were as follows: 
confirmed diagnosis of indolent B-NHL (lymphoplasmocytoid or FL grades I-IIIa), relapse 
after previous treatment, age > 1 8  years old and Eastern Cooperative Oncology Group 
performance status < 2. Patients were required to be at least 180 days from their last 
treatment, to have measurable disease and adequate haematological, renal, and hepatic 
functions. Patients were ineligible if they had more than six prior treatment regimens, 
concurrent immunosuppressive therapy, a history of central nervous system lymphoma, 
serious coexistent active medical problems, a history of a prior malignancy (excluding non­
melanoma carcinomas of the skin and in situ cervical carcinomas) unless the patient was in 
remission for >2 years, or were pregnant or breast feeding. Analysis of the disease 
response to DC vaccination was performed using Cheson criteria (Cheson, Pfistner et al.
2007). Seven out of 18 patients were evaluated for clonal rearrangement of Bcl-2/IgH 
genes to evaluate minimal residual disease (MRD). All 18 patients were assessed for a 
response based on a central radiology and/or clinical evaluation. The study protocol was 
approved by the Italian Istituto Superiore di Sanita and by the Institutional Scientific 
Review Committee. Written informed consent for vaccination procedure and for the 
investigational use of lymphocytes, serum samples and tumour specimens was obtained 
from each patient before enrolling in the study, in accordance with the Declaration of 
Helsinki.
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Table 0.1 Patients' characteristics.
Patient
group/
UPN
no.
A ge(y)/
Sex
NHL type  
and stage
P revious treatm ent, 
response/duration
Sites  o f d isease at 
vacc ination  (cm *)
C lin ical
R esponse,
TTP
Post­
vaccination
Therapy
C urrent
status,
survival
after
vaccination
C lin ically  responding patients
12 65/M LP, Stage  
IA -6  C V P  (C R /3 6  m onths)
Periaortic LN (1.8); BM 
and PB CR
No additional 
tx
CR, +67
mos
13 7 2 /F
FL grade I, 
S tag e  IIA
-6  C V P  (P R /1 6  months);
-4  R ituxim ab (C R /2 4  m onths)
M ediastinal, axillary and  
sup raclav icu lar LN (2)
C R
No additional 
tx
C R , + 6 4
m os
FL grade
-6 R -M egaC EO P
Cervical, axillary,
No additional 
tx
CR, +63  
mos
14 52/F Ilia, Stage
IVA
(P R /1 0  m onths);: mediastinal, periaortic 
and parailiac LN (2.5)
CR
-H D S  (CR/6 months)
1 4 9 /F
LP, S tag e  
IVA
-6  C V P  (C R /4 8  months);
-8 R ituxim ab (P R /7 2  m onths)
C erv ica l, axillary, 
m ediastinal, periaortic, 
periiliac LN (2 .5 ); BM
PR , 4 7  m os
No additional 
tx
PD , +81  
mos
5 52/M
FL grade 1, 
Stage IVA
-6 CVP (C R /24 months);
-4 Rituximab (P R /t  5 months)
Cervical, periaortic and 
periiliac LN (2.5); BM
PR, 12 mos HDS
autoBMT
PR, +74
mos
6 4 5 /M
FL grade  II, 
S tag e  IVA
-6 R -C E O P  (C R /1 2  m onths); 
-4  R ituxim ab (P R /8  months); 
-H D S  (C R /1 2  m onths)
Cerv ica l, axillary, 
m ediastinal, periaortic  
and inguinal LN (2 .5 )
PR , 7 m os D H A P
Died, 22  
mos
Patients w ho experienced the disease stab ilization
_ _ -6 CVP (PR /36 months) Cervical, axillary and
2 60/M
LP, Stage  
IVA -6 Rituximab (C R/48 months)
mediastinal LN (3); 
spleen; BM and PB
SD
no aauinonai o u , -*-ou 
tx mos
4 51 /M
FL grade  II, 
S tag e  IA
-4  R ituxim ab (C R /2 4  months); 
-R T  30 G y (C R /2 4  m onths)
Inguinal and periliac LN  
(2 .5 )
S D
No additional 
tx
C R , + 7 8  
mos
-8  Rituximab (PR /16 months); 
-4 CVP (PR /18 months);
-4 R -CH O P (SD/32 months)
9 63/M LP, Stage  
IVA BM (massive) and PB SD
No additional SD, +69  
tx mos
10 54 /M
FL g rade  1, 
S ta g e  IVA
-8 R -C V P  (C R /3 6  m onths)
C erv ica l, axillary, 
m ediastina l, periaortic  
and p arailiac  LN (5);
SD
No additional 
tx
S D , + 6 8  
mos
11 72/M FL grade II, 
Stage IVB
-18 mo Leukeran 
(C R /84 months)
Cervical, axillary, 
mediastinal, periaortic 
and inguinal LN (4); BM
SD, 10 mos R -CHOP
CR, +68  
mos
16 5 5 /F
FL grade  1, 
S ta g e IV A
6 C V P  (C R /2 4  m onths)
Axillary, cervical, 
m ediastina l and  
periaortic LN (3); BM
S D
No additional 
tx
C R , + 5 5  
m os
17 65/M LP, Stage  
IDA
8 C VP (C R /98 months)
Cervical, axillary, 
mediastinal and 
periaortic LN (3); speen;
SD, 10 mos HDSautoBMT
CR +52  mos
18 6 2 /F
FL grade 1, 
S ta g e  IIIA
6 R -C V P  (C R /3 6  months);
4 R ituxim ab (C R /2 6  m onths)
Axillary, periaortic and  
periiliac LN (4)
S D
No additional SD , + 5 2  
tx m os
Patients w ho experienced  the progression of the disease
3 60/M FL grade II, 
Stage IVA
-8 C H O P (PR /16 months) Axillary, mediastinal, 
periaortic, inguinal LN PD, 1 mo
FIDS
autoBM T
C R  +78  mos
-6 Rituximab (PR /8 months) (3); SDleen 1
7 50 /M
FL grade  1, 
S tag e  IVA
-6  C H O P  (P R /1 2  months); 
-4  R ituxim ab (P R /6  m onths)
C erv ica l, axillary, 
m ediastina l, periaortic  
and para iliac  LN (6);
PD , 1 mo
H D S
au to B M T
C R , + 6 9  
m os
-3 CHO P-bleo/3 CVP
8 56/M
FL grade II, 
Stage IA
(R C /16 months); Periaortic, periiliac and 
inguinal LN (3.2)
CR +68
-H D S  (C R /24 months);
-8 Rituximab (C R /6  months)
PD, 1 mo AlloBMT mos
15 72 /M
LP, S tag e  
IA
-3  C H O P  (P R /8  m onths); 
-S p len ecto m y + R T  (P R /1 2  months); 
-1 2  m onths Leu keran (P R /7  m onths) 
-H D S  (C R /1 2  months);
-4 R ituxim ab (P D /n .a .)
C erv ica l, axillary, 
m ediastinal, periaortic  
and para iliac  LN (6 .5 );  
BM  and PB
PD , 1 mo D H A P D ied, 7 m os
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UPN: Unique Progressive Number; LP: lymphoplasmacytic lymphoma; Cheson criteria (Cheson, Pfistner et al. 
2007] have been used to define the response to vaccination: complete remission (CR), disappearance of all 
evidence of disease; partial response (PR), regression >50% of measurable disease and no new sites; stable 
disease (SD), failure to attain CR/PR or PD; progressive disease (PD), any new lesion or increase by >50% of 
previously involved sites from nadir; TTP: time to progression; CVP: cyclophosphamide, vincristine and 
prednisone; R-CVP: rituximab plus CVP; CHOP: cyclophosphamide, adryamicin, vincristine and prednisone; R- 
CHOP: rituximab plus CHOP; RT: Radiotherapy; CEOP: cyclophosphamide, epiadryamicin, vincristine and 
prednisone; R-CEOP: rituximab plus CEOP; HDS: high dose sequential chemotherapy; autoBMT: autologous 
bone marrow transplantation; alloBMT: allogeneic bone marrow transplantation; LN: lymph-nodes; BM: bone 
marrow; PB: peripheral blood; DHAP: desametasone, cis-platinum, aracytin; tx: therapy. *maximum diameter 
of the largest lesion.
2.3.2 Preparation and injection of vaccine
All procedures for the preparation of the vaccine were carried out under GMP 
conditions.
Tumour cells were isolated from malignant LNs and, in case of circulating tumour 
cells, from PB of indolent NHL patients. In 16 patients, LNs were processed by mechanical 
dissociation (BD™ Medimachine, BD Biosciences, Franklin Lakes, NJ) to yield single-cell 
suspensions. In the remaining 2 patients, circulating tumour cells were harvested by 
leukapheresis. CD19+ NHL cells were purified from PB and/ or LN by using a high-gradient 
immunomagnetic technique according to the manufacturer's instructions (CD19 
microbeads, Miltenyi Biotech, Gladbach, Germany). Tumour cells were heat shocked and 
then induced to undergo apoptosis by exposure to y-irradiation and UVC rays as previously 
described (Di Nicola, Napoli et al. 2003). Briefly, 120xl06 CD19+ cells were resuspended in 
10% autologous human serum-supplemented Iscove's modified Dulbecco's medium 
(Cambrex, Milan, Italy) and incubated for 60 min in a water bath at 46°C to induce the 
expression of HSPs. The cells were irradiated (150 Gy) and finally exposed to a T-UV9 UVC 
Germicidal Lamp (Philips, Holland) calibrated to provide 0.5 J/m2/sec UVC, for 25 sec, at a 
lamp-to-cell culture distance of 39 cm.
Autologous circulating monocytes, selected by a high-gradient immunomagnetic 
technique (CliniMacs CD14 microbeads, Miltenyi Biotech), were cultured for five days with 
recombinant human (rh)GM-CSF (Leucomax, Novartis, Basel, Switzerland) and rhIL-4 
(kindly provided by Shering-Plough, USA) as described (Sallusto and Lanzavecchia 1994). 
Then, immature DCs were co-cultured for 48 hours with heat-shocked, y-irradiated, and 
UVC-irradiated neoplastic B cells at a 1:2 ratio. Further DC maturation was promoted by 
adding TNF-a (Knoll, Ludwigshafen, Germany) for the last 12 hours of culture. Tumour- 
loaded DCs were finally resuspended in 1 ml of 0.9% NaCl to be injected subcutaneously 
into patients. Four administrations of the vaccine in close vicinity to axillary and inguinal 
LNs were repeated at two-week intervals.
2.3.3 Flow cytometry analysis
Monocyte-derived DCs and tumour-loaded DCs were labelled with the following 
mouse anti-human mAbs: fluorescein isothiocyanate (FITC)-labelled anti-CD14, peridinin 
chlorophyll protein (PerCP)-labelled anti-HLA-DR, FITC-labelled anti-CD19 (BD 
Biosciences, San Jose, CA), phycoerythrin (PE)-labelled anti-CD80, PE-labelled anti-CD83, 
PE-labelled anti-CD86 (BD Pharmingen), PE-labelled anti-CDla (Coulter, Krefeld, Germany). 
Tumour loaded-DCs were co-stained with propidium iodide (PI, Bender Medsystem, Wien, 
Austria) and anti-CD19 mAb to verify that unloaded tumour B cells present in the culture 
were nonviable.
The maturation status of T cells at tumour site was assessed by labelling LN cell 
suspensions with the following mouse anti-human mAbs: PE-labelled anti-CD45RA (BD 
Pharmingen), FITC-labelled anti-CD4, PerCP-labelled anti-CD8 and allophycocyanin (APC) - 
labelled anti-CCR7 (BD Biosciences, San Jose, CA).
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NK cells were characterized by staining PB samples with FITC-labelled anti-CD56 
(BD Biosciences), PE-labelled anti-CD16 (Miltenyi Biotech), PerCP-labelled anti-CD3 (BD 
Biosciences) and APC-labelled anti-NKG2D or anti-NKp46 mAbs (BD Pharmingen).
The ability of PB myeloid DCs to acquire co-stimulatory properties in vivo were 
studied by staining PBMCs with mouse anti-human FITC-labelled OX40L (Ansell, Bayport, 
MN), PE-labelled anti-CDlc or anti-CD14, PerCP-labelled anti-CD45, and APC-labelled 0X40 
(eBioscience, San Diego, CA) mAbs.
The percentage of Tregs was evaluated by intracellular FOXP3 staining of PB and LN 
cell samples collected before and after vaccination, using the “FITC-labelled anti-human 
F0XP3 staining kit” (eBioscience) according to the manufacturer's instructions, after 
staining cells with PE-labelled anti-CD25 (Miltenyi Biotech), PerCP-labelled anti-CD3, and 
APC-labelled anti-CD4 (BD Bioscences) mAbs.
Samples were acquired by setting photomultiplier tubes on the autofluorescence of 
the related negative control. All plots were gated on high Forward Scatter (FSC) and low 
Side Scatter (SSC) to exclude cell debris. A minimum of 50.000-gated events was collected 
per sample. Data were acquired on a BD fluorescence-activated cell sorting (FACS)Calibur 
using BD CellQuest software version 3.3 (Becton Dickinson, Lincoln Park, NJ) and 
analyszed by Flowjo 8.7.1 software version for Macintosh (Tree Star, Inc. Ashland, OR).
2.3.4 Amplification and sequencing of tumour-specific IgH and Bcl2/IgH
rearrangements
Molecular monitoring of the MRD (7/18 patients) and sequencing of Ig genes 
expressed by neoplastic B cells (patient #14) were performed at the Molecular Diagnostic 
Unit of our Institute. Either nested PCR amplification of the Bcl-2/IgH or semi-nested PCR 
amplification of the clonal rearrangement of IgH genes when Bcl-2 was not amplified were 
used (Corradini, Astolfi et al. 1997). In the latter instances, DNA obtained from paraffin- 
embedded sections of diagnostic biopsies from each patient was PCR-amplified using VH 
and JH consensus primers for the framework region 2 of the IgH gene. In order to obtain a 
patient-specific primer, the DNA was sub-cloned into a suitable plasmid and the PCR 
products were sequenced. DNA extraction from BM and PB samples was performed using 
the QIAamp DNA blood extraction kit (Qiagen, Valencia, CA, U.S.A.). A patient-specific 
positive control was included in all PCR experiments. Negative controls contained water 
instead of DNA. All PCR reactions were performed in duplicate for a minimum of two 
independent experiments.
2.3.5 Peptide prediction and HLA stabilization assay
The identification and the production of HLA-A*0201-binding peptides in the HLA- 
A*0201+ patient (#14) was performed by PRIMM s.r.l (San Raffaele Biomedical Science 
Park, Milan, Italy). Briefly, potential binding peptides of 9-10 amino acids were selected 
using three different algorithms (http://bimas.dcrt.nih.gov/molbio/hla_bind; 
http://www.syfpeithi.de/; and http//hlaligand.ouhsc.edu/SBT.htm) within the tumour- 
specific IgH sequence from the HLA-A*0201+ patient (#14). Three peptides, showing high 
scores by all three algorithms were selected: peptide 1 (sequence: TLLRLLFNWV) at the 
boundary between complementarity determining region (CDR) 1 and framework region 
(FR) 2; peptide 2 (QLVQSGAEVK) from FR1, and peptide 3 (YCARVPAGV) from CDR3. 
Synthetic peptides corresponding to these sequences were then screened for binding to 
HLA-A2 by the HLA stabilization assay using TAP-deficient T2 cells, as described (Sensi, 
Nicolini et al. 2005), using the HLA-A2-specific Abs CR11.351 and BB7.2 (ATCC, Manassas, 
VA). HLA-A2 stabilization was expressed as the Fluorescence Index (F.I.) (Trojan, Schultze 
et al. 2000) based on the mean fluorescence intensity (MFI) for HLA-A2, as follows: 
[MFI(T2 loaded with peptide)/MFI(empty T2)]-l.
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2.3.6 ELISPOT assays
The IFN-y and the IL-4 ELISPOT assays were performed as described with minor 
modifications (Di Nicola, Carlo-Stella et al. 2004). Briefly, plates were coated at 4°C 
overnight with 10 \ig/m\ of anti-IFN-y mAh (clone 1-D1K) or 10 pg/ml of anti-IL-4 mAb 
(clone IL-4-I) (Mabtech, Stockholm, Sweden). PB-derived lymphocytes were stimulated 
with the synthetic peptides 1, 2 or 3 (30 pg/ml). Treatment with 1% phytohemagglutinin 
(PHA) (for IFN-y ELISPOT) or phorbol 12-myristate 13-acetate (PMA) plus ionomycin (for 
IL-4 ELISPOT) was used as positive controls. After incubation at 37°C for 48-72 hours, 
plates were labelled for 2 hours at room temperature (RT) with 1 pg/ml of biotin- 
conjugated secondary anti-human IFN-y (clone 7B6-1) or IL-4 (clone IL-4-II) mAbs 
(Mabtech). After the addition of alkaline phosphatase (ALP)-conjugated streptavidin 
(Mabtech), the plates were developed with an ALP-conjugate substrate kit (Bio-Rad 
Laboratories, Hercules, CA). The number of spots for each well was evaluated using the AID 
ELISPOT reader (Autoimmun Diagnostika GmbH, Strasburg, Germany). The number of 
spots produced by unstimulated PB lymphocytes was <20% of the number of spots 
obtained in response to peptides and was subtracted from the latter values.
In some experiments, CD3+ T cells were purified by immunomagnetic sorting (Pan 
T cell isolation kit, Miltenyi) from involved LNs that were surgically removed before and 
after vaccination from three patients that achieved a partial response. These cells were 
then cultured for one week in the presence of autologous neoplastic B cells in medium 
supplemented with IL-2, and then evaluated by IFN-y-ELISPOT in response to autologous 
or allogeneic tumour B-cell challenge.
2.3.7 Purification of human Ig, biotinylation, and immunohistochemistry
Ab purification from human sera was carried out using the MultiClear kit (Cabru, 
Lesmo, Milano, Italy) following the manufacturer's instruction. After purification, total 
human Igs were biotinylated as described (Bayer and Wilchek 1990). Biotinylated Abs 
were used for immunohistochemistry (IHC) analyses on formalin-fixed, paraffin-embedded 
tissue using heat-induced antigen retrieval with 10 mmol/L of citrate buffer (0.07M pH 6.0, 
Bioptica, Milan, Italy), as described with minor modifications (Anichini, Mortarini et al. 
2006b). Briefly, sections were incubated with biotinylated patients' Abs for 1 hour at RT, 
washed, and then incubated with peroxidase-conjugated streptavidin. Immune complexes 
were visualized by 3,3'-diaminobenzidine (Sigma FastTM Sigma Chemical Co.) and 
hematoxylin counterstaining.
2.3.8 Statistical analysis
Analyses of statistical significance were performed using the two-sided Student's t  
test. When the sample size was small, the Fisher exact test or the non-parametric Mann- 
Whitney test was used. Statistical analyses were performed on the Prism 5.0a software 
version for Macintosh (GraphPad Software, Inc.). The significance of the results was 
annotated as follows: *: p < 0.05;**: p < 0.01; *** : p< 0.001.
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2.4 Results
2.4.1 Quality control of vaccine preparations
The preparation of the vaccine was carried out when the percentage of the 
malignant B-cell clone (IgG k  or A) was > 75%. The mean number of CD 19 positively 
selected tumour cells was 430 ± 35 xlO6, with > 90% cell viability, as determined by the 
Trypan blue exclusion test. PB-derived monocytes were cultured and skewed toward 
CD14-CDla+CD83- immature DCs in the presence of rhGM-CSF and rhIL-4, as described 
(Sallusto and Lanzavecchia 1994). After five days of culture, the average number of DCs 
was 250 ± 50 xlO6, with > 90% cell viability, as determined by the Trypan blue exclusion 
test. After co-culture with killed and heat shocked tumour cells, the immature DCs 
differentiated towards a mature phenotype (CD80+, CD86+, CD83+, HLA-DR+, CDla+) 
(data not shown). At the end of co-culture, vaccine preparations did not contain live CD19+ 
tumour cells, since B cells that eventually appeared in the cultures stained positive for 
propidium iodide. The mean number of injected DCs was 45 ± 3xl06. No microbiological 
contaminations were observed in any stages of the vaccine preparation.
2.4.2 Safety and clinical efficacy
All of the 18 enrolled patients received 4 doses of autologous vaccine. The only 
observed adverse events were injection site reactions that occurred in 66% of treated 
patients. Injections site reactions were transient and none of the patients required 
medication. In particular, no significant reduction of B cells or Ig levels in the circulation 
was observed during or after injections (data not shown). No signs of autoimmunity were 
detected, as measured by the absence of C-reactive protein and anti-nuclear antibodies 
(data not shown).
All patients were monitored for immune responses to the vaccine with a median 
follow-up of 68 months (range 7-81 months). Objective responses were identified in 6 out 
of 18 patients (33.3%) (Table 2.1), these included 3 complete and 3 partial responses and 
are summarized in Table 2.1. Complete responder patients (CR) received the vaccine whilst 
in relapse after the last chemotherapy regimen (n. 12, 13, 14, Table 2.1). Their overall 
tumour mass gradually reduced after starting the vaccination programme and completely 
disappeared after a median of 6 months from the last injection, when clinical and molecular 
responses were attained (Figure 2.1A for a representative example). Noteworthy, all CR 
have experienced a longer-lasting remission compared to the previous one obtained with 
standard regimens.
Partial responders (PR) achieved the response after a median of 5 months following 
the last vaccine injection, which lasted for a median of 12 months (n. 1, 5, 6, Table 2.1). 
Unfortunately, in this case, the vaccine was not able to induce a longer response compared 
to that achieved after the last therapy prior to enrolment in the present study, and the 
patients experienced tumour progression (Figure 2.IB for a representative example).
All non-responding patients (NR) had conspicuous tumour burden or bulky disease at the 
time of enrolment. Disease stabilization was observed in 8 patients with a median duration 
of 61.5 months. Interestingly, in 2 patients, tumour underwent progressive shrinkage until 
the achievement of a complete remission after two years from the last vaccine injection (n. 
4 and 16, Table 2.1). The last 4 patients progressed 1 month after the last vaccination.
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Three out of 4 patients are alive after salvage high-dose sequencial chemotherapy 
supported by auto or allograft. One patient died follow ing disease progression.
A
1 Before vaccination 6 months after vaccination
Tumor 
specific IgH
Actin
Before vaccination 4 months after vaccination
_ Tumor 
specific IgH
Actin
Figure 0.1 Therapeutic effects of vaccination.
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(A) Example of a clinical CR. CT scan images of the chest of patient #12 revealed multiple small enlarged 
mediastinal and left axillary LNs (i, left, red arrows) that normalized six months after vaccination (i, right), 
(ii) Involvement of BM (lane 1 and 2, before vaccination and 6 month after vaccination, respectively) and PB 
(lane 3-7, before vaccination, 3, 6, 12 and 18 months after vaccination, respectively) was evaluated by PCR 
amplification of the clonal tumour-specific IgH gene rearrangement using IgH specific molecular probe. Actin 
amplification was performed as a control. Line 8, no DNA. M, marker. (B) Example of a clinical PR. CT scan 
images of the retro-peritoneum of patient #5 showed enlarged retroperitoneal LNs (i, left, red arrows) that 
shrunk four months after vaccination (i, right), (ii) Involvement of BM (lane 1-3, before vaccination, 4 and 12 
months after vaccination, respectively) was evaluated by PCR amplification for panel A. Actin amplification 
was performed as a control. Line 4, no DNA. M, marker.
2.4.3 Biological efficacy
2.4.3.1 Tregs
Recent findings demonstrated that the expansion and induction of suppressor cells 
with a “naturally occurring” CD25+CD4+FOXP3+ Treg phenotype in PB and in the tumour 
microenvironment of B-NHL patients is a crucial factor contributing to the tumour immune 
evasion (Mittal, Marshall et al. 2008). To verify whether DC-based vaccination could 
counteract this mechanism and restore the physiologic balance of Tregs in PB and/or 
tumour site, the frequency of CD4+CD25+FOXP3+ T cells was evaluated in enrolled 
patients before and after vaccination. At the time of the enrolment, NHL patients showed a 
higher frequency of Tregs in PB (p= 0.0096) and LNs (p<0.0001) in comparison to healthy 
donors (Figure 2.2A). Interestingly, PB Treg frequency significantly decreased within 6 
months following vaccination, but only in R (p= 0.0076; Figure 2.2A-Bi-ii). Treg absolute 
counts confirmed these data (data not shown). In addition, CD4+CD25+FOXP3+ Treg 
frequency at tumour sites was considerably reduced at the time of response in PR (Figure 
2.2Biii). Accordingly, when the disease progressed, the percentage of Tregs increased 
again to pre-therapy values at tumour site (Figure 2.2Biii).
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Figure 0.2 Evaluation of Treg frequency in PB and LN of NHL patients before and after vaccination.
(A) Schematic comparison of CD4+CD25+FOXP3+ T cells frequencies in donors' or patients' PB and LNs 
before vaccination and in Rs' and NRs' PB after vaccination. Statistically significant differences, by two-sided 
Student's t test, are reported (*: p< 0.05; **: p< 0.01; ***: p< 0.001). (B) Representative examples of Treg 
frequencies in pre- versus post-vaccine PB of complete R #14 (i), NR #7 (ii), and in LN specimens collected 
before vaccination, after 6 (at the time of partial remission) and 12 months (at disease progression) from the 
last vaccine administration in PR #5 (iii). All plots were gated on CD3+CD4+ cells.
2A.3.2 NK cell activity
As a possible explanation for the observed Treg reduction in Rs, the frequency and 
phenotype of circulating NK cells were analysed before and after vaccination. This was 
because upon activation NK cells would be expected to prevent Treg differentiation, 
promote T cell proliferation and effector functions (Zingoni, Sornasse et al. 2004; Brillard, 
Pallandre et al. 2007). By studying the ratio of post- versus pre-vaccination cytotoxic NK 
cell (CD3-CD56dimCD16+) frequencies in PB samples, it was found that after vaccination 
the NK cells of Rs expressed CD16 at a higher frequency (p=0.009; Figure 2.3A) and 
intensity (p=0.0084; Figure 2.3B) compared to NRs (Figure 2.3C).
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Figure 0.3 Evaluation of CD56dimCD16+ NK-cell frequency in NHL patient PB before and after 
vaccination.
(A) Ratios of CD56dimCD16+ NK frequencies in post- versus pre-vaccination PB samples of R and NR. (B) 
Ratios of post- versus pre-vaccination circulating NK cell CD16 MFI in R and NR. Statistically significant 
differences were calculated using the Fisher exact test (**: p< 0.01). (C) Representative examples of 
CD56dimCD16+ NK cell frequencies in pre- versus post-vaccine PB of a complete R (left panels, patient #14), 
and of a NR (right panels, patient #7). All plots were gated on CD3-CD56+ cells.
Moreover, NK cells from 4 out of 5 Rs analysed showed increased expression of the 
NKp46 activating NK cell receptor after vaccination. In contrast, NK cells from just 1 out of 
4 NRs displayed a similar fold change in NKp46 expression (p=0.0442; Figure 2.4).
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Figure 0.4 NKp46+ NK-cell frequency in NHL patient PB before and after vaccination.
Ratios of post- versus pre-vaccination NKp46+CD56dimCD16+CD3- NK cell frequencies in R and NR PB. 
Statistically significant differences were calculated using the two-sided Student's t test (*: p < 0.05).
2A.3.3 Immunophenotype of conventional CD4 and CD8 T-cell populations
The function and maturation phenotype of T cells from vaccinated patients were 
also studied. T cells producing IFN-y in response to autologous tumour challenge were 
found in pre-vaccine LNs and at higher frequency compared to that of T cells responding to 
an allogeneic HLA-mismatched B-cell tumour challenge, included as control (Figure 2.5A). 
The frequency of IFN-y-producing T cells stimulated by the autologous B cell tumour was 
significantly increased in LNs harvested 6 months after the last vaccine administration in 
PR (Figure 2.5A, patient #1 and 5). A similar assay carried out in NRs after vaccination did 
not provide evidence for an increase of IFN-y releasing T cells against the autologous 
tumour (Figure 2.5A, patient #10). Comparison of pre- versus post-vaccine maturation 
phenotype of tumour infiltrating CD4+ and CD8+ T cells from 2 of 3 PRs showed a shift 
towards the more differentiated CCR7-CD45RA- Tem and/or CCR7-CD45RA+ Ttd 
phenotypes after vaccination (Figure 2.5B, patients #1 and 5). The maturation of TILs cells 
was not modified in NRs after vaccination (Figure 2.5B, patient #10).
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Figure 0.5 Functional and phenotypic analysis of T cells at tumour site from PRs or NRs.
T cells, isolated from malignant LNs before and after vaccination, were evaluated by IFN-y-ELISPOT assay 
when cultured alone (white), with the autologous tumour (black) or an allogeneic tumour (grey). Results 
obtained with 2 of the 3 partial R and with one NR are reported. Error bars indicate standard deviation of the 
mean. Statistically significant differences, by two-sided Student's t test, are reported (*: p<0.05; **: p<0.01; 
***: p<0.001). (B) Maturation profile of T cells at tumour site before and after vaccination was assessed by 
flow cytometry analysis of CCR7 and CD45RA expression in CD3+CD8+ gated cells.
In contrast to the results obtained with TILs from PR, IFN-y ELISPOT with PB 
lymphocytes from both Rs and NRs failed to show evidence of an increase in T cells 
reacting against autologous tumour cells after vaccination (data not shown). However, 
vaccination seemed to provide some activation of the immune system even at the PB level, 
since the expression of co-stimulatory molecules, such as OX40L, increased in both CD141+ 
and CDlc+ circulating myeloid DCs of treated patients that achieved at least the 
stabilization of the disease (data not shown). In addition, the potential occurrence of a T- 
cell response against the tumour Ig-Id was evaluated in one CR that expressed the HLA- 
A*0201 antigen. Indeed, this provided the opportunity to evaluate the frequency of T cells 
specific for HLA-A2-binding peptides (Figure 2.6B) derived from the tumour-specific IgH 
sequence in pre- and post-vaccination PB samples (Figure 2.6A). Using the HLA 
stabilization assay, all 3 selected peptides were found to bind to HLA-A2 molecules as 
indicated by F.I. values after staining T2 cells with two different anti-HLA-A2 mAbs (Figure 
2.6B). By ELISPOT assay, an increased frequency of T cells releasing IL-4 or IFN-y (Figure 
2.6C) in response to all the three peptides was found in post-vaccine PB samples of this 
patient in comparison to pre-vaccine samples (p<0.05). Amongst the three tested peptides, 
the CDR1- and FRl-encoded peptides gave rise to the strongest and longest-lasting 
response, which was detectable up to 517 days (for IFN-y; Figure 2.6, right) or 291 days 
(IL-4; Figure 2.6, left) after the first vaccine administration. However, 291 days after
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vaccination, a significant increase in the frequency of circulating T cells releasing IL-4 was 
also found in response to the CDR3-encoded peptide stimulation (Figure 2.6C, left).
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Figure 0.6 Circulating T cells directed against tumour-specific IgH-encoded epitopes in one CR.
(A) PB samples were obtained from patient #14 at the indicated time points before (pre) and after (post) 
vaccination. (B) Synthetic peptides (indicated as peptides #1, #2 and #3) corresponding to CDR1, FR1 and 
CDR3 sequences of the tumour-specific IgH gene from patient #14 were used to assess cytokine release by 
circulating T cells. F.I. Fluorescence Index, as evaluated by the HLA-A2 stabilization assay after staining T2 
cells with mAb CR11.351 (a) or BB7.2 (b). (C) Frequencies of IL-4 or IFN-y-producing T cells against peptides 
#1, #2 and #3, as evaluated by ELISPOT in blood samples taken at the indicated time points before and after 
vaccination from patient #14. The HLA-A*0201-binding HIV peptide ILKEPVHGV was used as negative 
control in both the IL-4 and IFN-y assays. Response to this peptide was <10 spots/10A6 cells in all blood 
samples analysed. *: Frequency of cytokine-releasing T cells, in the indicated blood samples, was significantly 
higher compared to pre-vaccine values (Mann-Whitney test, p<0.05).
2A.3.4 AutoAb response
Initially, to determine whether Rs also developed a tumour-specific Ab response, Igs 
were purified from pre- and post-vaccine serum samples of two Rs and two NRs, and used 
to immunostain autologous tumour biopsies (Figure 2.7, for representative examples). An 
increased tumour-restricted reactivity was found only when post-vaccine Igs from R were 
compared to the matched pre-vaccine samples (Figure 2.7A-B and 2.7C-D). Normal cells in 
the tumour biopsies from these patients showed no immunostaining (Figure 2.7A-B and E, 
arrows). No tumour-restricted immunostaining was detected with pre- and post-vaccine 
biotinylated Igs of the two NR (Figure 2.7E-F, for a represenatative example). These results
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may suggest that vaccination promoted also the induction of a tumour-specific B-cell 
response in R.
Complete responder Serum
dilutionB . - ,
Partial responder
M M
Non responder
Figure 0.7 Immunohistochemical analysis of tumour biopsies with purified Igs of vaccinated patients.
IHC analysis using biotin-conjugated Igs purified from pre- (A, C and E) and post-vaccine (B, D and F) serum 
samples on autologous NHL specimens of one CR (A-B), one PR (C-D) and one NR (A-F). Biotin-conjugated Ig 
samples were used at the indicated dilutions. Arrows indicate non-neoplastic follicular DCs in the inset of 
panels A, B and E. Panel insets are shown at x40 original magnification, panels at xlO original magnification.
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2.5 Discussion
This pilot study tested the efficacy and the activity of a vaccination programme using 
autologous DCs loaded ex-vivo with autologous whole dying tumour cells for the treatment 
of indolent NHL patients with measurable disease. Vaccination resulted clinically 
efficacious in 6 out of 18 patients, achieving 3 objective radiographic complete and 3 
partial responses. In all 3 CR, the duration of the clinical response after vaccination was 
longer compared to the duration of the first and second complete remissions obtained with 
the previous treatments. In agreement with a recent study of a patient-specific Id 
vaccination (Inoges S, Rodriguez-Calvillo M, et al. 2006], second longer remissions indicate 
a therapeutic effect. Differently from the study of Bendandi and colleagues (Bendandi 
1999; Bendandi 2006], the clinical results obtained in this study were observed in patients 
that were not in chemotherapy-induced remission at the time of vaccination.
In several published trials in indolent NHL patients, immunological and clinical 
responses were observed after a vaccination against the tumour specific Id used alone or 
with DCs as a natural adjuvant (Hsu Blood 1997; Timmerman 2002; Inoges, Rodriguez- 
Calvillo 2006]. Unexpectedly, 3 randomized phase-III studies, which started to prove the 
clinical benefit of Id-vaccination, failed to demonstrate an improvement in the 
progression/disease free survival of treated patients (Schuster et al. 2009; Levy 2009; 
Freedman, Neelapu et al. 2009]. As pointed out by Bendandi (Bendandi 2006], the reasons 
of these failures may be related to the clinical features of FL disease and to the 
heterogeneous characteristics of patient-tailored Id-based immunotherapy. Nevertheless, 
in the Levy's study (Levy at al. 2009] the patients mounting Id-specific immune responses 
after vaccination showed a significant clinical benefit in term of time to progression. These 
results paved the way for identifying novel vaccination methods able to increase the 
probability to provide an anti-tumour immune activation associated with clinical benefit. 
For this purpose, in the present study, whole tumour cells were used as a source of antigen 
with the intent to elicit immune responses not only to tumour-specific IgH-encoded 
epitopes, but also to other potentially immunogenic known and unknown lymphoma- 
associated antigens (Brossart, Schneider et al. 2001; Bae, Martinson et al. 2005; Mikaelsson, 
Danesh-Manesh et al. 2005]. In agreement with this hypothesis, Neelapu and colleagues 
(Neelapu, Gause et al. 2007] recently reported the clinical and immunological efficacy 
achieved in FL patients by a novel autologous whole tumour-derived proteoliposome 
vaccine formulation in a pilot clinical trial. Similarly, in this study, the antigenic cargo was 
represented by the whole proteic content of neoplastic B cells, but it was obtained by 
killing them with y-irradiation and UVC rays after being heat-shocked in order to increase 
their immunogenicity (Zitvogel, Apetoh et al. 2008]. The vast majority of studies of active 
immunotherapy targeting the lymphoma-Id have been designed to verify the role of 
vaccination in avoiding disease recurrences after chemotherapy with a de-bulking intent 
(Bendandi, Gocke et al. 1999; Timmerman 2002]. The rationale of this strategy derived 
from the multiple observations that, in the presence of limited tumour burden, a vaccine- 
induced anti-tumour immune response could be more likely clinically effective. In the 
present study, instead, treated patients still presented clinically measurable disease. 
However, all the clinical responses were observed in patients with the smallest tumour 
burden, whereas, they were independent of the histological type, pre-vaccination 
chemotherapy (comprising HDS therapy], source of neoplastic cells for vaccine preparation 
(LN versus PB], DC maturation/activation profile and other clinical characteristics.
Immunological monitoring of the enrolled patients showed significant cellular and 
humoral immune activation in R as compared to NR. This indicates that the clinical 
responses observed after DC-based vaccination may be the result of a positive modulation 
of different components of the immune system. In particular, the reduction of Treg 
frequency after vaccination in both PB and LN of R might have favoured the occurrence of
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anti-tumour responses by down-modulating Treg-mediated cancer tolerance (Zou 2006]. 
Accordingly, tumour progression was found to be associated with the recurrence of 
increased Tregs in both in PB and involved LNs.
Although the mechanisms accounting for the observed down-modulation of Tregs in 
Rs after vaccination remain to be fully elucidated, recent findings reported that NHL cells 
can recruit Tregs by production of chemokine CCL22 (Yang, Novak et al. 2006]. In addition, 
conventional T cells can be converted to functionally competent Treg within the tumour 
microenvironment (Colombo and Piconese 2007](Mittal, Marshall et al. 2008]. In support 
of the latter hypothesis, it has been shown that B-NHLs may produce regulatory factors, 
such as TGF-p, which in turn could promote the generation/expansion of Tregs. Tumour 
shrinkage in R after vaccination may thus partially explain the rebalance of Treg frequency 
(Chen, Jin et al. 2003; Huber, Schramm et al. 2004]. Treg reduction may also result as a 
direct consequence of a successful immunisation. In agreement with this mechanism, the 
reduction of circulating Tregs was also recently described in breast cancer patients 
immunized with a HER-2 neu peptide vaccine that showed a concurrent anti-tumour CTL 
response (Hueman, Stojadinovic et al. 2006]. Lastly, the activation of NK cells in R after 
vaccination might have also contributed to Tregs down-modulation (Brillard et al. 2007] 
(Roy, Barnes et al. 2008]. These cells indeed can inhibit peripheral Treg conversion and 
lyse Tregs directly in a NKG2D- and NKp46-dependent manner (Brillard et al. 2007; Roy, 
Barnes et al. 2008]. Accordingly, in R, in whom the parallel activation of NK and reduction 
of Tregs occurred, NK cells expressed higher levels of the activating receptor NKp46 after 
vaccination. Recent findings have yielded promising insights regarding the involvement of 
NK cells in the establishment of adaptive immunity in response to immunisation with DC- 
based vaccines (Osada, Clay et al. 2006; Woo, Clay et al. 2006]. The interaction between 
mature DCs and NK cells was shown to stimulate NK cell proliferation, cytolytic activity and 
IFN-y production (Bigley, Spence et al. 2010]. In turn, activated NK cells can provide key 
signals for DC maturation, favouring the onset of an adaptive immune response against 
tumours that usually preclude the effective DC maturation through different immune 
escape mechanisms (Bigley, Spence et al. 2010]. Accordingly, following vaccination, 
circulating myeloid DCs expressed higher levels of the co-stimulatory molecule OX40L. The 
immune modulation observed in Rs may thus reflect precise coordination of different 
immunological arms by ex-vivo matured DCs to properly present tumour antigens in vivo. 
In fact, as shown by Martin-Fontecha and colleagues (Martin-Fontecha, Thomsen et al. 
2004], the injection of mature DCs can promote the activation of NK cells that, in turn 
provides a source of IFN-y that is needed for a Thl polarization. Therefore, it is possible 
that, activating NK cells, DC-based vaccines may lead to the reduction of 
FOXP3+CD25+CD4+ Tregs, thus favouring the onset of a tumour-specific immune response 
associated with clinical benefit.
The frequency of anti-tumour T cells was significantly higher after vaccination at the 
tumour site in PRs but not in NRs, suggesting that immune modulation promoted by the 
vaccine contributed to the observed specific immune responses. In addition, in these Rs, 
the immunological intervention induced the differentiation of CD4+ and CD8+ TILs 
towards an activation phenotype, consistent with the promotion of T cell effector functions 
at tumour sites (Oehen and Brduscha-Riem 1998]. Nevertheless, the IFN-y ELISPOT 
detected no increase of circulating tumour-specific T-cell frequency in Rs after vaccination. 
It is likely that in PB they were below the assay detection limit, probably due to their 
selective homing to tumour sites. Accordingly, when ELISPOT assays were carried out 
against tumour-specific IgH peptides instead of whole tumour cells, thus increasing the 
probability of specific T cells to become activated, post-vaccine PB frequency of IFN-y or IL- 
4-releasing lymphocytes against IgH-encoding HLA-A*0201 peptides resulted higher to 
that observed in pre-vaccine samples of the same R. The responses against these epitopes 
were observed up to 17 (for IFN-y] and 10 (for IL-4] months after vaccination, suggesting
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that immunisation with tumour-loaded DCs has long lasting effects on the immune 
response to tumour-specific IgH-encoded peptides, as reported with Id-specific vaccination 
[Timmerman, Czerwinski et al. 2002).
The identification of an increased frequency of IL-4 releasing T cells in response to 
IgH-encoded peptides also suggests that such a vaccine can promote a concurrent Th2 
immune response. Such a response would be expected to provide helper functions for 13- 
cell activation (Ellyard, Simson et al. 2007). Accordingly, post-vaccine sera from R, but not 
from NR, contained Abs that specifically recognized autologous neoplastic cells. Therefore, 
DC-based vaccination may have concurrently induced the production of therapeutic Abs 
that contributed to the observed clinical responses. The key role of humoral response in 
controlling the growth of indolent NHLs is also supported by previous results obtained in 
FL patients after Id-vaccination, which indicated a strong association between the clinical 
outcome and the induction of a tumour-specific Ab response [Weng, Czerwinski et al. 
2004). These data led to the following study on the characterization of the antigens 
targeted by the humoral responses induced by DC-vaccination in Rs, whose results are 
described in Chapter 4.
In conclusion, active immunisation with autologous DCs loaded with autologous heat 
shocked and irradiated tumour cells can provide clinical and immunological efficacy in 
previously treated indolent NHL patients with measurable disease. However, most of these 
patients did not respond to this immune intervention, suggesting that it is not always able 
to generate the required anti-tumour therapeutic Abs and/or the sufficient numbers of 
effector T cells with the appropriate specificity, functional status, homing properties and 
survival characteristics to overcome existing tumour escape mechanisms and to promote 
effective anti-tumour responses in the presence of a significant tumour load [Rosenberg 
2004; Park 2008). Therefore, the identification of predictors of the clinical outcome of a 
cancer vaccine and the development of new strategies to potentiate the immunological and 
clinical efficacy of DC-based vaccination are required for a better selection of the patients 
and for improving the clinical benefit associated to this therapeutic intervention. The 
results described above highlight differences in the immune responses between the Rs and 
NRs to the autologous anticancer vaccine, which may help identifying those patients who 
may benefit most from this intervention, indicating areas of further study in the 
mechanisms of the anti-tumour response. These observations formed the basis of the 
subsequent work that is described in the following Chapters. In addition, the present study 
also provided valuable information on the potential to improve vaccine regimens.
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3 IMPROVED CLINICAL OUTCOME IN INDOLENT B-CELL 
LYMPHOMA PATIENTS VACCINATED W ITH AUTOLOGOUS 
TUMOUR CELLS UNDERGOING IMMUNOGENIC DEATH
3.1 Introduction
Vaccination with cancer cells treated ex-vivo with anthracyclines, or oxaliplatin, or 
ionizing radiation protects mice against a subsequent challenge with live tumour cells 
(Obeid, Tesniere et al. 2007a; Obeid, Tesniere et al. 2007b; Tesniere, Schlemmer 2010). The 
immunizing properties of killed tumour cells depends on the ability of a cytotoxic agent to 
render their death immunogenic so that the immune system can be specifically alerted to 
the presence of a tumour (Zitvogel 2008). Pre-clinical studies of radio/chemotherapy- 
elicited immunogenic cell death in sarcoma, breast, and colon carcinoma mouse models 
(Obeid, Tesniere et al. 2007a; Obeid, Tesniere et al. 2007b; Tesniere, Schlemmer 2010; 
Apetoh 2007) have shown that the release of "eat-me" and danger signals by tumour cells 
is the main molecular mechanism thereby DC engulfment of dead cell particles and their 
activation promote the cross-priming of tumour antigens and induction of a specific 
adaptive immune response (Shi, Evans et al. 2003; Tesniere, Apetoh et al. 2008). 
Contributing factors to the augmentation of the immune response are described below. 
During the early phase of apoptosis, the surface translocation of the endoplasmic 
reticulum-resident chaperone CRT on dying cells is crucial for their recognition and 
engulfment by DCs and constitutes the first checkpoint of the immunogenic death process 
(Obeid, Panaretakis et al. 2007) (Obeid, Tesniere et al. 2007a; Obeid, Tesniere et al. 2007b). 
Anthracyclines, oxaliplatin and ionizing irradiation induce the rapid translocation of CRT 
complexed to its molecular partner ERp57 onto tumour cell-surface (Panaretakis, Joza et al. 
2008), an event that strongly correlates with effective anti-tumour immunisation in mouse 
models (Obeid, Tesniere 2007a; Obeid, Tesniere et al. 2007b). The failure to expose CRT 
after the proper stimulation, thus impairing the immunogenicity of dying tumour cells, has 
been recognized as an additional mechanism of tumour immune escape (Panaretakis, Joza
2008).
In the late phase of apoptosis and during necrosis, HSP70 and HSP90 can be exposed 
on the cell surface, where they promote the activation of an immune response by acting as 
vehicles for peptide antigens (Binder, Srivastava et al. 2005) and providing "eat-me" and 
danger signals for DCs (Spisek, Charalambous et al. 2007; Somersan, Larsson et al. 2001). 
In addition, the release from late-apoptotic cells of the non-histone chromatin binding 
nuclear factor HMGB1 was shown to be indispensable for optimal tumour antigen 
presentation by DCs (Apetoh, Ghiringhelli et al. 2007). Importantly, TLR4 A896G 
polymorphism, which weakens HMGB1-TLR4 interactions, affects antigen cross­
presentation by DCs and is associated with an unfavourable outcome after antracycline- or 
oxaliplatin-based regimens in breast and colorectal cancer patients respectively (Apetoh, 
Ghiringhelli et al. 2007) (Tesniere, Schlemmer et al. 2010). Lastly, the release by dying 
tumour cells of HMGB1 together with nucleotides, such as ATP and UTP, have shown to 
participate to the activation in DCs of the "inflammasome" and caspase-1 that lead to the 
proteolytic maturation and release of IL-lp (Ghiringhelli, Apetoh et al. 2009). These events 
have been demonstrated decisive for the stimulation of an immune response against dying 
tumour cells, providing a novel link between the innate and acquired immune systems 
(Ghiringhelli, Apetoh et al. 2009; Aymeric, Apetoh L, Ghiringhelli F, et al. 2010).
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3.2 Aims of the Chapter
Increasing evidence argues that the success of an anticancer treatment may rely upon 
immunoadjuvant side effects, including the induction of immunogenic tumour cell death. 
Similarly, the way in which neoplastic cells are killed to produce the antigenic content of a 
DC-based vaccine may be crucial for priming a clinically efficacious anti-tumour immune 
response. In the present Chapter, the assumption that the occurrence of immunogenic 
death was a prerequisite even for the efficacy of an active immunotherapy using 
autologous DCs loaded with autologous killed tumour cells has been examined. Since 
vaccination with DCs pulsed with autologous tumour cells dying after exposure to heat 
shock (HS], y-irradiation (y) and UVC-rays (UVC) elicited a clinical response associated 
with tumour-specific immune-activation in 6 out of 18 relapsed indolent NHL patients, the 
aim of this study was to determine whether R and NR could be distinguished in terms of 
immunogenic tumour cell killing at the time of vaccine preparation. Towards this aim, the 
ability of HS, y, and UVC to induce CRT and HSP translocation as well as HMGB1 and ATP 
release was firstly investigated in 3 cell lines, representing low-, intermediate-, and high- 
grade NHLs. The possibility that a defective exposure of immunogenic signals (Panaretakis, 
Kepp et al. 2009] by heat shocked, y-, and UVC-irradiated tumour cells used as antigenic 
cargo for DC-based vaccination might be associated with a reduced probability of response 
was investigated. The information obtained finally aimed at identifying predictors of the 
clinical outcome of a cancer vaccine.
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3.3 Materials and Methods
3.3.1 Cell lines, primary cells, and culture conditions
DOHH-2, SU-DHL-6, and SU-DHL-4 cell lines, representing follicular 
centroblastic/centrocytic, diffuse mixed small and large cell, and diffuse large cell cleaved 
cell NHL respectively, were purchased from DSMZ (Braunschweig, Germany] and cultured 
in RPMI 1640 (Lonza, Basel, Switzerland] supplemented with 10% [v/v] inactivated fetal 
bovine serum [Lonza], 1% [v/v] L-glutamine [Lonza] and 1% [v/v] Hepes buffer [Lonza] 
in a humidified chamber (95% air, 5% C02] at 37°C. All cell lines were regularly screened 
to ensure absence of mycoplasma contamination by MycoAlert® Mycoplasma Detection Kit 
[Lonza], according to the manufacturer's instructions. Primary lymphoma cells were 
isolated from LNs or PB as reported in Chapter 2. Written informed consent for the 
investigational use of lymphocytes, serum samples and tumour specimens was obtained 
from each patient. Apoptotic and necrotic cell bodies were generated by exposing primary 
lymphoma cells and cell lines to HS, y, and UVC in accordance with cell death induction 
protocol described in Chapter 2, called ALL when compared with the same agents used 
singly. Lymphoma cells were also treated with DXR (Pfizer Italia s.r.l.] at the indicated 
doses as the positive control for immunogenic death induction.
3.3.2 Flow cytometry analysis
Surface immunolabelling studies were performed after blocking nonspecific Ab 
binding to the Fc-receptors within B-cell samples (FcR blocking reagent, Miltenyi Biotec]. 
The following mouse anti-human Abs were used: monoclonal FITC-labelled anti-HLA-DQ, 
PerCP-labelled anti-HLA-DR (BD Biosciences], PE-labelled anti-HSP70, anti-HSP90, purified 
anti-CRT (Stressgen, Ann Arbor, MI], and polyclonal anti-HLA class I (clone W6/32, Sera- 
Lab, Sussex, UK]. FITC-labelled goat anti-mouse Igs (Jackson Immunoresearch, Suffolk, UK] 
was the secondary Ab. To avoid intracellular protein detection, dead cells were excluded by 
7-AAD (Invitrogen, Eugene, Oregon, USA] co-staining (lpg/ml for 20 min at 4°C]. The 
immunophenotypic analyses of Tregs and NK cells were determined as described in 
Chapter 2 in pre- and post-vaccination PB samples from the patients whose immunological 
monitoring was not part of the previous study. As negative controls, cells were incubated in 
parallel with the relevant isotype Igs (PE-labelled and purified mouse IgGl, Stressgen; 
FITC-labelled Rat IgG2a, eBiosciences]. The Apoptosis Detection kit (Bender MedSystem, 
Vienna, Austria] was used in accordance with the manufacturer's protocol.
3.3.3 ELISA
Cellular release of HMGB1 was measured in 24-hour culture supernatants using the 
appropriate ELISA kit according to the manufacturer's instructions (Shino Test 
Corporation, Kanagawa, Japan].
3.3.4 ATP release assay
Extracellular ATP was measured in 24-hour culture supernatants by means of the 
luciferin-based ENLITEN ATP Assay (Promega, Madison, WI]. Light emission was recorded 
with a Berthold luminometer (Berthold Detection systems Gmbh, Pfortzheim, Germany].
3.3.5 Purification and biotinylation of human Igs
Ab purification from human serum and immunoglobulin biotinylation were 
performed as described in Chapter 2.
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3.3.6 Western Blot
DOHH-2 cells or apoptotic and necrotic cell bodies were lysed for 1 hour on ice in 
lysis buffer (50 mM Tris-HCl pH 7.2,150 mM NaCl, lOOmM NaF, lOOmM sodium pyruvate, 
1% Triton X-100) containing protease inhibitors (Complete Mini, Roche Applied Science, IN, 
USA], 2 mM phenylmethylsulfonylfluoride, and 2mM Na3V04. Protein concentration was 
determined by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA). 
Protein extracts were separated by electrophoresis on precast polyacrylamide gels 
(Invitrogen, Carlsbad, CA), transferred to hydrophobic polyvinylidene difluoride (PVDF) 
membranes (Amersham, Pittsburgh, PA), probed with biotinylated human Igs, anti-CRT, - 
HSP90 and -HSP70 (Stressgen) mAbs or rabbit anti-human actin polyclonal Ab (Sigma, 
Milan, Italy), and visualized as previously described (Pupa, Argraves et al. 2004). Full-range 
Rainbow molecular marker (12-225 kDa, Amersham, GE Healthcare) and Sharp Protein 
Standard (3.5-260 kDa, Novex, Invitrogen) were run in parallel in each sodium dodecyl 
sulphate - polyAcrylamide gel electrophoresis (SDS-PAGE) analyses. Images were acquired 
on ArtixScan F I scanner (Microtek International Inc., Hsin-Chu, Taiwan) using SilverFast 
Launcher software (MicrotekSDK) and processed with Photoshop CS4 software (Adobe 
Systems Incorporated, San Jose, CA).
3.3.7 In-gel tryptic digestion, MALDI-TOF-MS analysis, and peptide mass
fingerprinting
Protein profiling of DOHH-2 apoptotic and necrotic cell bodies was performed by 
the Proteomics Unit at our Institution. Briefly, protein bands were excised from Coomassie- 
stained preparative gels and processed as described (Gorla, Mondellini et al. 2009). Matrix- 
assisted laser desorption/ionization, time-of-flight mass spectrometry (MALDI-TOF-MS) 
was carried out with a Voyager-DE STR (Applied Biosystems; Milan, Italy), equipped with a 
nitrogen laser (337 nm). Monoisotopic peptide masses were analysed using Aldente 
software (http://www.expasy.ch/tools/aldente/). Input was searched according to the 
following database: Aldente, UniProtKB/SwissProt; predefined taxon: Mammalia; 
Spectrometer internal error max: 25. Only proteins identified from 3 or more separate 
experiments were considered.
3.3.8 Gene Ontology analysis
The Database for Annotation, Visualization, and Integrated Discovery (DAVID; 
http://www.david.niaid.nih.gov) was used to discover the gene ontology biological 
processes, cellular components, molecular functions (GO terms), and Kyoto encyclopedia of 
genes and genomes (KEGG) pathways significantly represented by proteins from DOHH-2 
apoptotic and necrotic bodies.
3.3.9 Statistical analysis
Statistical significance was calculated using the 2-sided Student's t  test [p <0.05). 
Pearson and Spearman correlation coefficients were calculated to measure dependence 
between variables. Statistical analyses were performed on the Prism 5.0a software version 
for Macintosh (GraphPad Software, Inc.).
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3.4 Results
3.4.1 Immunogenic signals in heat shocked, y-, and UVC- irradiated NHL cell lines
The extent of CRT cell surface translocation, HMGB1, and ATP release were 
evaluated in DOHH-2, SU-DHL-6, and SU-DHL-4 cell lines treated with HS, y, UVC, or ALL. 
Cells were treated with DXR in parallel as a positive control. The extent of CRT cell surface 
translocation was directly proportional to the amount of DXR in a limited dose interval 
(0.1-20 pM), and peaked at 0.5, 2.5, and 15 pM for DOHH-2, SU-DHL-6, and SU-DHL-4, 
respectively (data not shown). DXR was therefore administered at 0.5, 2.5, and 15 pM in 
cultures of DOHH-2, SU-DHL-6, and SU-DHL-4 cells respectively, and approximately 50% 
cell growth inhibition was reached after 24 hours (Figure 3.1A). ALL was highly cytotoxic 
against the 3 NHL cell lines tested, as shown by the Trypan blue exclusion test and flow 
cytometry analysis of apoptosis (Figure 3.1A and B).
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Figure 3.1 Cytotoxic effects of DXR or UVC-rays, y-irradiation, heat shock or ALL in indolent NHL cell 
lines.
(A) Percentage of viable (white) and dead cells (grey) as determined by the Trypan blue exclusion test; (B) 
flow cytometry analyses of apoptosis (Annexin V; PI: propidium Iodide; ANN V-PI-: white columns; ANN 
V+PI-: light grey columns; ANN V+PI+: dark grey columns; ANN V-PI+: black columns) in DOHH-2, SU-DHL-6, 
and SU-DHL-4 cells after 24-hour incubation following exposure to UVC- (UVC), y-irradiation (y) and heat 
shock (HS] as single or combined agents (ALL) or let untreated (NT). Significant differences with respect to 
ALL were calculated using Student t test (*p < .05; **p < .001; ***p < .0001). The average values of results 
obtained in 3 independent experiments are reported.
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ALL-treated cells expressed surface-CRT at a higher frequency (Figure 3.2Ai, white 
columns) and intensity (Figure 3.2Ai, grey columns) compared to cells exposed to y, UVC or 
DXR alone. ALL provided a similar amount of CRT cell-surface translocation, regardless of 
lymphoma histological grade (Figure 3.2Ai, left vs. middle vs. right panel). As additional 
signals promoting the recognition and uptake of dying cells by DCs, the surface-expression 
of stress-inducible HSP90 and HSP70 was evaluated. ALL significantly enhanced that of 
HSP90 in DOHH-2, SU-DHL-6, or SU-DHL-4 compared to y or UVC alone (Figure 3.2Aii), but 
that of HSP70 only in SU-DHL-6 cells and to a lesser extent (Figure 3.2Aiii). The ability of 
DXR and ALL to stimulate cellular release of HMGB1 and ATP, two distinctive signals of 
immunogenic cell death, was also compared. For each cell line tested, ALL provided a 
significantly higher release of HMGB1 and ATP from each cell line than DXR administration 
as revealed by specific ELISA and luciferin-based assays in 24-hour conditioned culture 
media (Figure 3.2Bi, p=0.045, p=0.029, p=0.0002; Figure 3.2Bii, p=0.049, p=0.045, p=0.024). 
Interestingly, CRT and HSP90 exposure in heat-shocked NHL cell lines was comparable to 
that achieved in ALL-treated cells (Figure 3.2Ai-ii); however, HS alone was less efficient 
than ALL to boost ATP and HMGB1 release from all 3 cell lines (data not shown).
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Figure 3.2 Immunogenic signals in treated NHL cell lines.
[A) Flow cytometry analyses of CRT (i), HSP90 (ii) and HSP70 (iii) relative median fluorescence intensity 
(MFI, grey columns) and positive cell frequency (white columns). Relative MFI was calculated as the ratio 
between stained sample and negative control MFI. Analyses were performed on 7-AAD negative-gated events.
(B) Quantification of HMGB1 (i) and ATP (ii) in culture supernatant For each cell line, ATP release was 
normalized by the amount found in untreated cultures, giving relative ATP values. Statistically significant 
differences between ALL and the other culture conditions were calculated using the 2-sided Student t test 
The average values of results obtained in 3 independent experiments are reported.
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3.4.2 Analyses of protein changes occurring as a result of "ALL” treatment
The combination of y and UVC with HS (ALL) was thus an effective way of inducing 
all reported mediators of immunogenic cell death in 3 differently aggressive NHL cell lines. 
Coomassie staining revealed that ALL modified patterns of proteins present in lysates from 
the DOHH-2 cell [Figure 3.3A, B). These proteins were subjected to mass spectrometry 
[MS] and the results are shown in Table 3.1.
Figure 3.3 Coomassie staining of DOHH-2 cells and apoptotic bodies.
[A) SDS-PAGE of live and [B) ALL-treated DOHH-2 cell protein extracts revealed by Coomassie staining. N°: 
identification number of bands analysed by MS as reported in Table 3.1.
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Table 3.1 List of MS-identified proteins in bands indicated in Figure 3.3B.
N°. *,f Swiss-Prot/TrEMBL accession and description line; t,§theoretical protein mass and isoelectric point; 
| |peptide/protein amino acid numbers.
N° AC det Mw* Pi* Cov"
1 P35579 Myosin-9 226 5.5 32
Q00610 Clathrin heavy chain 1 191 5.5 32
2 Q9NYU2 UDP-glucose ceramide glucosyltransferase-like 1 173 5.4 17
P53675 Clathrin heavy chain 2 187 5.6 12
Q9Y4L1 Hypoxia up-regulated protein 1 108 5.1 26
3 Q96F07 Cytoplasmic FMR1-interacting protein 2 148 7 18
P35579 Myosin-9 226 5.5 13
4 P53396 ATP-citrate synthase 121 7 18
Q14697 Neutral alpha-glucosidase AB 104 5.6 28
5 Q02218 Alpha-ketoglutarate dehydrogenase 111 6.1 26
Q9NSE4 Isoleucyl-tRNA synthetase, mithocondrial 109 6.2 23
£ Q14697 Neutral alpha-glucosidase AB 104 5.6 39
043707 Alpha-actinin-4 105 5.3 26
P13639 Elongation factor 2 95 6.4 31
7 P14625 Endoplasmin 90 4.7 27
P05023 Sodium/potassium-tramsporting ATPase sub 112 5.3 20
8 P08238 Heat shock protein HSP90-beta 83 5 41P07900 Heat shock protein HSP90-alpha 85 5 39
9 P27824 Calnexin 65 4.5 26
Q12931 Heat shock protein 75 kDa, mitochondrial 74 6.1 42
10 P11021 78 kDa glucose-regulated protein 70 5 31
P52272 Heterogeneous nuclear ribonucleoprotein M 77 8.8 27
Q12931 Heat shock protein 75 kDa, mithocondrial 74 6.1 50
11 P11021 78 kDa glucose-regulated protein 70 5 39P38646 Stress-70 protein mithocondrial 69 5.5 31
P26038 Moesin 68 6.1 27
P04843 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 66 6 49
12 P13796 Plastin-2 70 5.2 42
P31040 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 68 6.2 40
13 P10809 60 kDa heat shock protein, mitochondrial 58 5.2 43P14618 Pyruvate kinase isozymes M1/M2 58 8 33
14 P00367 Glutamate dehydrogenase 1, mitochondrial 56 6.7 38P30101 ERp57 54 5.6 36
15 P25705 ATP synthase subunit alpha, mitochondrial 55 8.3 57P00367 Glutamate dehydrogenase 1, mitochondrial 56 6.7 31
16 P06576 ATP synthase subunit beta, mitochondrial 52 5 56P34897 Serine hydroxymethyltransferase, mitochondrial 53 8.1 47
17 P31930 Cytochrome b-c1 complex subunit 1, mitochondrial 49 5.4 50P06733 Alpha-enolase 47 7 43
18 P61158 Actin-related protein 3 47 5.6 38
P60709 Actin, cytoplasmic 1 42 5.3 46
19 P63261 Actin, cytoplasmic 2 42 5.3 42
P00505 Aspartate aminotransferase, mitochondrial 45 9 33
20 P04406 Glyceraldehyde-3-phosphate dehydrogenase 36 8.6 38
Q99623 Prohibitn-2 33 9.8 68
21 P40926 Malate dehydrogenase, mithocondrial 33 8.5 69
P63244 Guanine nucleotide-binding protein subunit beta-2- like 1 35 7.6 67
22 Q99623 Prohibitn-2 33 9.8 63
P05141 ADP/ATP translocase 2 33 9.8 56
P12236 ADP/ATP translocase 3 33 9.8 49
23 P12236 ADP/ATP translocase 1 33 9.8 47
Q00325 Phosphate carrier protein, mitochondrial 35 9.3 37
Q13011 Delta(3,5)-DeIta(2,4)-dienoyl-CoA isomerase, mitochondrial 32 6 52
24 P35232 Prohibitin 30 5.5 57
25 P18669 Phosphoglycerate mutase 1 29 6.8 46
26 P24539 ATP synthase subunit b, mithocondrial 25 9.1 36
9 7 P23284 Peptidyl-prolyl cis-trans isomerase B 20 9.2 50
P48047 ATP synthase subunit 0 , mithocondrial 21 9.8 58
P62937 Peptidyl-prolyl cis-trans isomerase A 18 7.8 62
P62269 40S ribosomal protein S18 18 11 36
29 Q04837 Single-stranded DNA-binding protein, mitochondrial 15 8.2 77
9 0 Q04837 Single-stranded DNA-binding protein, mitochondrial 15 8.2 69O u P07737 Profilin-1 15 8.5 48
31 P56134 ATP synthase subunit f, mithocondrial 11 9.7 31
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MS-based multiplexed profiling of apoptotic/necrotic DOHH-2 cell bodies 
highlighted an enrichment in proteins involved in mitochondrial and endoplasmic 
reticulum functions, ATP metabolism, intracellular organelle reorganization, and stress 
response [Table 3.1), which are represented in 15 gene ontology (GO) categories [Table 
3.2). Seven KEGG pathways, including oxidative phosphorylation, citrate cycle, and antigen 
processing and presentation were also significantly represented in ALL-treated DOHH-2 
cells [Table 3.3). Most of the functions and pathways detected were integrally involved in 
apoptosis and in biochemical events associated with the immunogenicity of dying cells, and 
thus emphasized the ability of HS associated with y and UVC to generate immunogenic 
apoptotic and necrotic bodies from NHL cell lines.
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Table 3.2 Gene Ontology (GO) of proteins significantly represented in DOHH-2 apoptotic and necrotic 
bodies.
GO Terms Fold Enrichment P
Endoplasmic reticulum 1.87 1.36E-002
Actin cytoskeleton organization 1.95 1.12E-002
Heat-shock proteins (HSP70) 2.8 1.47E-003
Intracellular transport 3 1.05E-003
ATP carrier protein 3 1.02E-003
ATP biosynthesis 3.4 3.95E-004
UPR/stress response 3.7 1.70E-004
Localization/transport 4 9.31E-005
Heat-shock proteins (HSP90) 4.1 7.38E-005
Catabolic processes 4.1 7.27E-005
ATP binding 4.6 2.20E-005
Monosaccharide metabolism 5 8.89E-006
Intracellular 5.9 1.24E-006
Vesicle 6.8 1.60E-008
Mitochondrion 12.6 2.61E-013
Table 3.3 KEGG pathways significantly represented by ALL-treated DOHH-2 cells.
Kegg Pathway % Fold Enrichment P
hsa04810: Regulation of actin cytoskeleton 10.53 2.9 4.99E-002
hsa00190: Oxidative phosphorylation 12.28 5.6 1.15E-003
hsa04612: Antigen processing and presentation 8.77 6.4 6.55E-003
hsaOOOl 0: Glycolysis/Gluconeogenesis 7.02 6.9 1.87E-002
hsa05040: Huntington's disease 5.26 10.6 3.04E-002
hsa00710: Carbon fixation 5.26 13.4 1.96E-002
hsa00020: Citrate cycle (TCA cycle) 7.02 13.7 2.69E-003
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3.4.3 Immunogenic cell-death in primary indolent NHL exposed to heat shock, y- 
and UVC- rays
The results obtained in long-term NHL cell lines led to investigate whether 
combined exposure to HS, y, and UVC was the best way to induce immunogenic cell death 
in primary B-NHLs. Because ALL constituted the cell death protocol adopted to kill indolent 
NHL primary cells and obtain tumour antigen cargo for patient-specific anti-lymphoma DC- 
based vaccines, as shown in Chapter 2, the surface exposure of CRT and HSPs and the 
release of HMGB1 were analysed in treated FL cells isolated from 4 patients (Table 3.4, 
patients #1, 10, 11, 14) before immunotherapy. After 24 hours, ALL killed over 90% of 
tumour cells as revealed by flow cytometry analysis of apoptosis and reached statistical 
significance when compared to UVC or HS alone (Figure 3.4A; p=0.049, p=0.047). However, 
for each treatment condition no significant differences were found between tumour cells 
from Rs and NRs in terms of amount of cell death (Figure 3.4B).
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Figure 3.4 Cytotoxic effects of UVC-rays, y-irradiation, heat shock or ALL in primary indolent NHL cells.
Flow cytometry analysis of apoptosis (ANN V: Annexin V; PI: propidium iodide) in differently treated primary 
FL cells (NT: untreated; UVC-rays: UVC; HS: Heat Shock; y: y-irradiation; ALL: HS, y and UVC) from 4 
vaccinated patients (panel A: average patients #1, 10, 11, 14; panel B: average R #1 and 14 vs. NR #10 and 
11). Significant differences with respect to ALL were calculated using Student t test (*p < .05; **p < .001).
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Because only a trend toward the increase of CRT and HSP90 surface expression was 
observed in ALL as compared with single agent-treated tumours (average of 4 FL samples, 
data not shown], the ability of dying FL cells to determine these parameters was assessed 
in samples from Rs (patients #1, 14] and from NRs (patients #10, 11], separated into 2 
groups. The extent of CRT exposure on ALL treated tumour cells from Rs was significantly 
higher compared to the same samples exposed to single agents, as revealed by flow 
cytometry analysis of the relative MFI (Figure 3.5A, white columns; p=0.022, p=0.037, 
p=0.024). ALL significantly increased CRT and HSP90 surface expression in tumour cells 
from Rs as compared with NRs (Figure 3.5A, B white vs. grey columns, p=0.006, p=0.045]. 
No statistically significant differences were found when HSP70 exposure or HMGB1 release 
were analysed (data not shown].
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Figure 3.5 CRT and HSP90 expression on treated tumour cells from vaccinated patients.
Flow cytometry analyses of CRT (A] and HSP90 (B] relative MFI in tumour cells from 2 R (average patients #1 
and 14, white columns] and 2 NR (average patients #10 and 11, grey columns], 24 hours after exposure to 
UVC-rays (UVC], heat shock (HS] and y-irradiation (y) as single or associated treatments (ALL). Relative MFI 
was calculated as the ratio between stained sample and negative control MFI of high FSC and low SSC-gated 
events. Significance was calculated using the 2-sided Student t test (*p < .05; **p < .001).
These results indicate that equally treated primary FL, with a similar clinical history, 
may differ in their ability to emit immunogenic signals.
3.4.4 Humoral response to immunogenic cell death markers
To determine whether the immunisation efficacy of a DC-based vaccine depends on 
the extent of immunogenic signal exposure by dying tumour cells loaded on DCs, the 
presence of anti-CRT and -HSP90 Abs was verified in pre- and post-vaccination serum 
samples. Apoptotic and necrotic DOHH-2 cells were used as target cells in western blot 
analyses, because upon exposure to ALL they displayed surface CRT and HSP90 (Figure 
3.2Ai, Aii) as well as a significant proteome enrichment of HSP90 and Erp57, the cognate 
functional partner of CRT (Panaretakis, Joza et al. 2008) (Table 3.1). Protein extracts were 
probed with biotin-conjugated Igs purified from pre- and post-vaccination serum samples 
of Rs (Figure 3.6Ai, ii, Figure 3.6Bi, ii) and NRs (Figure 3.6Aiii, iv, Figure 3.6Biii, iv) or 
commercial anti-CRT (Figure 3.6Av) and -HSP90 (Figure 3.6Bv) mAbs. Remarkably, Rs 
showed the presence of a greater amount of circulating Abs directed against proteins 
migrating at molecular weights compatible with CRT (Figure 3.6Ai, ii vs. 3Av) and HSP90 
(3.6Bi, ii vs. 3Bv) compared to NRs (Figure 3.6Aiii, iv vs. 3.6Av and Figure 3.6Biii, iv vs. 
3.6Bv). This provided evidence for a positive association between tumour cell ability to
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expose immunogenic signals and their immunizing properties when loaded into DCs and 
injected into these two patients.
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Figure 3.6 Vaccine-specific humoral response in clinical Rs.
Western blot analyses of patients' Igs on DOHH-2 apoptotic and necrotic body extracts. [A) Reactive bands 
obtained by probing with pre- (lane 1, upper) or post- (lane 2, upper) vaccine Igs from 2 Rs (i, patient #1; ii, 
patient #14) and 2 NRs (iii, patient #10; iv, patient #11) or with anti-CRT commercial mAb (v, upper). (B) 
Reactive bands obtained by probing with pre- (lane 1, upper) or post- (lane 2, upper) vaccine Igs from R (i, 
patient #1; ii, patient #14) and NR (iii, patient #10; iv, patient #11), or with anti-HSP90 commercial mAb (v, 
upper). Actin protein expression is reported at the bottom of each panel as loading control. Arrows indicate 
specific bands for CRT and HSP90.
3.4.5 Immunogenic tumour cell death and clinical efficacy of vaccination with killed
autologous NHL cell-pulsed DCs
To determine the involvement of immunogenic tumour cell death in the efficacy of 
DC-based active immunotherapy in indolent NHL patients, the ability of tumour cells to 
provide immunogenic signals on exposure to ALL was studied in all samples still available 
from vaccinated patients (Rs=6; NRs=8) according to their outcome after vaccination 
(Table 3.4). Whereas the extent of cell death did not differ between the two groups (Figure 
3.7A, p=0.127), CRT positive cell percentage and MFI were significantly higher in dying 
tumour cells from Rs compared to NRs, as revealed by flow cytometry (Figure 3.7B, top left 
p=0.023 and bottom left p=0.039). Furthermore, apoptotic and necrotic bodies from 
tumour cells of Rs expressed surface HSP90 at a higher frequency and intensity compared 
to those from NRs (Figure 3.7B, top middle, p=0.001 and bottom middle, p=0.002); no 
significant differences were found when HSP70 was analysed (Figure 3.7B, top right 
p=0.421 and bottom right p=0.481). Flow cytometry analyses of HLA class I and II 
expression on dying tumour cells from Rs and NRs revealed no significant differences (data 
not shown), suggesting that they shared similar antigen presentation properties. Similarly, 
HMGB1 release from dying tumour cells did not differ between Rs and NRs (Figure 3.7C, 
p=0.705).
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Figure 3.7 Lethal and immunogenic response in tumour cells from Rs and NRs.
Twenty-four hours following exposure to ALL, the ability of tumour cells from Rs and NRs to undergo 
immunogenic death was assessed. Flow cytometry analyses of (A) propidium iodide+ tumour cell frequency 
(% PI+ cells); (B) positive cell frequency (upper) and MFI (lower) for CRT (left), HSP90 (middle) and HSP70 
expression (right); and (C) quantification of HMGB1 release in culture supernatant from apoptotic and 
necrotic tumour cells. Significance was calculated using the 2-sided Student t test (ns= non significant 
difference; *p < .001; **p < .001; ***p < .0001).
The strength of the correlation between the extent of CRT and HSP90 exposure on 
killed autologous tumour cells used to load DCs for vaccine preparation and patient 
outcome after vaccination was then measured. The results are summarised in Table 3.4. 
HSP90 surface-expression in dying tumour cells was found to be significantly associated 
with the occurrence of clinical responses (HSP90 MFI, Spearman r=0.8631, 
p<0.0001; %HSP90+ cells, Spearman r=0.8235, p=0.0003). The frequency of tumour cells 
expressing surface-CRT also positively correlated with a favourable outcome after 
vaccination (Spearman r=0.6087; p=0.0209). As reported in Chapter 2, Rs showed tumour- 
specific T- and B-cell activation, the reduction of Treg frequency and NK cell maturation, 
indicating a potential association between the exposure of immunogenic signals and the 
ability of a DC-based vaccine to induce a clinically efficient immune activation. Accordingly, 
clinical responses were significantly associated with NK cell maturation (Spearman 
r=0.7835, p=0.0015) and Treg frequency reduction (Spearman r=-0.7835, p=0.0015), 
which, in turn, were found to directly correlate with the extent of CRT and HSP90 
expression in the vaccine antigenic cargo (CRT MFI vs. NK maturation: Pearson r=0.8321, 
p=0.0004; %CRT+ cells vs. NK maturation: Pearson r=0.7506, p=0.0031; CRT MFI vs. Treg 
frequency reduction: Pearson r=-0.6594, p=0.0142; HSP90 MFI vs. Treg frequency 
reduction: Pearson r=-0.6164, p=0.0249; %HSP90+ cells vs. Treg frequency reduction: 
Pearson r=-0.6716, p=0.0119).
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3.5 Discussion
This study confirms, in a human setting, recent findings obtained in mice concerning 
the possibility of inducing immunogenic death in cancer cells in order to provide a reliable 
source of antigens for anti-tumour vaccination (Obeid, Tesniere et al. 2007a; Obeid, 
Tesniere et al. 2007b). The exposure to HS, y, and UVC in 3 human NHL cell lines 
representing low-, intermediate- and high-grade lymphomas provided all of the key 
features required to trigger a DC-mediated anti-tumour immune response. These include 
the plasma membrane translocation of CRT and HSPs, and the release of HMGB1 and ATP 
(Tesniere, Apetoh et al. 2008; Aymeric, Apetoh et al. 2010). Because these events were 
enhanced when the three agents were co-administered, it is necessary to combine HS, y, 
and UVC to efficiently induce an immunogenic tumour cell death. This combination was 
also more effective than DXR at inducing surface translocation of “eat-me" signals coupled 
with the release of HMGB1 and ATP.
Apoptotic and necrotic tumour cell bodies generated through the exposure of 
primary indolent NHL cells to HS, y, and UVC were used to pulse autologous monocyte- 
derived DCs and thus produce a patient-tailored vaccine. Interestingly, although displaying 
the same level of apoptosis, necrosis, and HMGB1 release, primary lymphoma samples 
from Rs demonstrated an improved ability to translocate CRT and HSP90 to the cell surface 
upon exposure to the combined treatment when compared to NRs patients. Remarkably, 
vaccination with DCs pulsed with ALL-treated autologous tumours induced the production 
of circulating anti-CRT and -HSP90 Abs in Rs, but not in NRs, and elicited clinical responses 
strongly associated with multifaceted anti-tumour immune activation, as described in 
Chapter 2. These observations, in an admittedly small number of cases, point to a positive 
correlation between the surface-expression of CRT or HSP90 in dying tumour cells used as 
antigen cargo for a DC-based vaccine and immunological responses associated with clinical 
benefit.
These results are in line with those obtained by Zitvogel and colleagues showing that 
the failure of one early step towards immunogenic cancer cell death was sufficient to 
abrogate the process (Tesniere, Apetoh et al. 2008). The lack of the CRT exposure alone, for 
example, may explain the hampered ability of cisplatin to induce immunogenic death in 
mouse colon cancer cells as compared with oxaliplatin, and thus reflect its limited 
therapeutic efficacy in colon carcinoma patients (Tesniere, Schlemmer et al. 2010). In this 
study, instead, the same treatment resulted in a different exposure of "eat-me” signals in 
clinically comparable primary indolent NHLs, whilst reproducibly providing human NHL 
cell lines of different histological grades with these immunogenic molecules. Similarly, HS 
exposure alone was sufficient to kill most of the cells in the 3 NHL cell line cultures and 
boost their translocation of CRT and HSP90, whereas it was less capable of eliciting the 
same effects in primary tumours. Alterations in the molecular pathways for chaperone 
trafficking (Panaretakis, Kepp et al. 2009), which render tumour cell death 
immunogenically silent, may confer survival advantages to B-NHLs in vivo and may be 
selected as new immune-escape mechanisms. Therefore primary tumour cells may be less 
prone to undergo immunogenic cell death compared to in-vitro established cell lines. 
Accordingly, the ability to down-regulate CRT expression has been shown to be associated 
with a negative prognostic/predictive impact in colon cancer (Toquet, Jarry et al. 2007), 
neuroblastoma (Hsu, Hsieh et al. 2005), and cervical carcinoma (Mehta, Jordanova et al. 
2008), as well as in follicular thyroid carcinoma (Netea-Maier, Hunsucker et al. 2008). 
Nevertheless, treated NHL cell lines in the current study consistently showed CRT and 
HSP90 cell surface translocation to be distinctive features induced by the combined 
exposure to HS, y, and UVC. CRT involvement in immunogenic tumour cell death is also 
illustrated by the investigation of its immunostimulatoiy properties, including its ability to 
elicit a CTL response against chaperoned antigens (Nair, Wearsch et al. 1999) or its own
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antigenic epitopes (Lieu, Newkirk et al. 1988} as well as to induce specific auto-Abs in a 
variety of autoimmune diseases (Eggleton, Ward et al. 2000). HSP expression on the 
surface of dying tumour cells similarly improves their recognition by DCs (Saito, Dai et al.
2005), and increases the efficient cross-presentation of tumour-derived chaperoned 
antigenic peptides (Srivastava 2005) and DC maturation (Somersan, Larsson et al. 2001) 
(Spisek, Charalambous et al. 2007).
Chaperone rich tumour cell lysates activate NK cell effector functions in the presence 
of accessory cells such as DCs (Zeng, Chen et al. 2006). Chaperone proteins may thus be 
endowed with a key role in the cross-talk between DCs and NK cells (Zeng, Graner et al.
2006). By killing tumour cells, activated NK cells may render tumour antigens available for 
further DC cross-presentation in vivo (Osada, Clay et al. 2006; Woo, Clay et al. 2006; Bigley, 
Spence et al. 2010), whilst inhibiting peripheral Treg conversion and directly lysing Tregs 
(Brillard, Pallandre et al. 2007; Roy, Barnes et al. 2008). Regression of the tumour mass 
may therefore result in re-establishment of the balance between immunity and tolerance in 
favour of tumour immune surveillance (Yang, Novak et al. 2006). A favourable clinical 
outcome after vaccination was found indeed to be significantly associated with the extent 
of chaperone protein expression on apoptotic and necrotic tumour cell bodies loaded into 
DCs, and, in turn, with NK cell activation and Treg frequency reduction. In keeping with the 
extensively described property of immunogenic tumour cell death to elicit specific T cell 
responses (Obeid, Tesniere et al., 2007a; Obeid, Tesniere et al. 2007b; Tesniere, Apetoh et 
al. 2008), anti-tumour adaptive cellular immunity was detected at the tumour site in PRs, 
and in PB in one CR, for whom a tumour-specific idiotype T cell response was assessed.
All Rs showed an increased ability to translocate HSP90 as compared to NRs, whereas 3 Rs 
displayed comparable ability in CRT exposure with respect to NRs, meaning that at least 
one “eat-me" signal was sufficient to provide the proper stimuli for DC antigen uptake and 
activation. The considerable expression of HSP90 in vaccines administered in all Rs may 
have compensated for the limited release of CRT in 3 of them.
These results delineate new ways of optimizing anticancer vaccines for the stimulation 
of a therapeutic anti-neoplastic immune response. Pulsing of DCs ex vivo with killed tumour 
cells avoids their physiological clearance by neighbouring cells before entering the late 
stages of the apoptotic process (Savill, Dransfield et al. 2002), and thus ensures optimal DC 
antigen-uptake and activation. An explanation may thus be found for the advantages gained 
by using apoptotic and necrotic tumour cells to generate specific DC vaccines (Strome, Voss 
et al. 2002). In addition, characterization of the molecular mechanisms responsible for "cell 
death immunogenicity" may provide novel strategies to favour its occurrence during the 
preparation of killed tumour cell-based vaccines. The present results, indeed, showed that 
dying neoplastic cells, due to their impaired ability to expose CRT or HSP90, lose their 
immunogenic properties. Because BCL-2 can impair CRT surface translocation (Panaretakis, 
Kepp et al. 2009) and its up-regulation constitutes one of the hallmarks of indolent NHLs, 
in particular FL, the association between BCL-2 over-expression and the reduced tumour 
cell ability to expose CRT was investigated in 8 (4 Rs and 4 NRs) vaccinated patients. 
However, a precise correspondence between these two features was not found in these 
patients (data not shown) and the absence of available tumour cell samples for the 
remaining 10 patients hampered further investigations of the mechanisms that account for 
these deficiencies. As shown for murine colon carcinoma and sarcoma models (Obeid, 
Tesniere et al. 2007a; Obeid, Tesniere et al. 2007b), cytotoxic agents can be combined with 
adjuvant compounds such as recombinant CRT or PP1/GADD34 inhibitors to enhance CRT 
surface expression. Oligodeoxynucleotides (i.e., class A CpG), and cytokines (i.e., IL-lp) can 
also boost DC engulfing, cross-presentation, and maturation, and new ways of increasing 
the potency of DC-based vaccination may thus be devised (Zitvogel, Apetoh et al. 2008) 
(Locher, Rusakiewicz et al. 2009). This information combined with the results described
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above lays the basis for improving the strategy of active immunotherapy using tumour cell- 
based vaccines.
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4 Serological identification of NHL cell-surface antigen(s) 
using Ab repertoires of vaccinated patients
4.1 Introduction
Therapeutic mAbs alone or in combination with standard treatments have 
considerably improved the clinical management of several malignancies, including NHLs 
(Adams and Weiner 2005). In particular, the anti-CD20 mAb Rituximab in combination 
with conventional chemotherapy has significantly increased the survival of B-NHL patients 
and has become a standard choice for the treatment of these diseases (Cheson and Leonard 
2008). However, it does not produce an effective therapeutic response in all patients 
(McLaughlin, Grillo-Lopez 1998; Cheson and Leonard 2008), and the majority of those that 
initially respond become "resistant" to repeated therapy (Davis TA Grillo-Lopez 2000).
Novel therapeutics with enhanced target-binding affinity or alternative, possibly 
tumour-restricted, specificity are thus required to improve the prognosis of NHL patients. 
Lymphoma-specific antigens, whose expression is not restricted to an individual 
lymphoma, have not been defined to date and few attempts have been made towards their 
identification (Huang, Preuss et al. 2002; Krackhardt, Witzens et al. 2002). One promising 
approach at this purpose is the study of the humoral immune response to TAAs. It is now 
largely established that cancer patients produce auto Abs to new epitopes derived from 
coding DNA mutations or genetic translocations in tumour cells (e.g., p53, BCR-ABL), or 
against proteins that show altered post-translational modifications (e.g., under­
glycosylated MUC1) and expression in cancer, including over- (e.g., HER2/neu) and 
ectopic-expression (e.g., cancer testis antigens such as NY-ESO-1) (Sahin, Tiireci, et al. 
1995) (Houghton 1994). Thus, the identification of TAAs using cancer patients' circulating 
Abs appears a valuable strategy for the discovery of novel potential tumour biomarkers 
and targets for therapy (Huang, Preuss et al. 2002; Shoshan and Admon 2007).
The study of the humoral immune response to human tumours has been 
revolutionized since the introduction of the serological analysis of recombinant cDNA 
expression libraries (SEREX), exploiting patients' Abs to screen autoantigens encoded by 
tumour-extracted mRNA (Liggins, Guinn et al. 2005) (Sahin, Tiireci, et al. 1995) 
(Krackhardt, Witzens et al. 2002). However, this approach carries certain technical 
drawbacks, these include the complexity and time-consuming nature of the SEREX process, 
and the lack of information on the overall range of the serospecificities in the individual 
cases and occurrence of particular serospecificities in patient populations (Desmetz, 
Cortijo et al. 2009). In addition, patient- but not cancer-related humoral responses are 
often detected as false positives, and antigenicity related to post-translational 
modifications cannot be identified due to the use of a prokaryotic system for recombinant 
protein expression (Desmetz, Cortijo et al. 2009). Serological proteome-based approach 
(SERPA), which combines the electrophoretic separation of cancer proteome and western 
blot analyses of patients' seroreactivities with mass spectrometry (MS) protein 
identification, has become a valuable and straightforward alternative. So far, SERPA has 
successfully characterized patients' humoral response against several types of cancer, 
including kidney (Klade, Voss et al. 2001), breast (Desmetz, Bascoul-Mollevi et al. 2009), 
colorectal (De Monte, Sanvito et al. 2008), pancreatic (Tomaino, Cappello et al. 2007) and 
ovarian cancer (Philip, Murthy et al. 2007), hepatocellular (Looi, Nakayasu et al. 2008) and 
squamous cell carcinoma (Fujita, Nakanishi et al. 2006; Yang, Xiao et al. 2007), as well as 
leukaemia (Cui, Li et al. 2005) and melanoma (Forgber, Gellrich et al. 2009). However, the 
clinical impact of these potential biomarkers has been limited, probably due to the need of 
a better understanding of the biological and clinical relevance of humoral immune 
responses against tumour antigens found in cancer patients (Desmetz, Bascoul-Mollevi et 
al. 2009).
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The introduction of improved more sensitive MS devices and the development of 
high-throughput techniques based on synthetic protein microarrays and Ab chips has been 
generating a renewed enthusiasm about the possibility to successfully exploit the Ab 
repertoire of cancer patients for the identification of novel tumour-restricted 
diagnostic/prognostic biomarkers and/or biotargets for therapy [Caron, Choquet- 
Kastylevsky et al. 2007; Kijanka and Murphy 2009].
4.2 Aims of the Chapter
The major aim of this study was to identify novel potential therapeutic biotarget[s] of 
B-NHLs, exploiting the Ab repertoires of patients vaccinated with autologous DCs loaded 
with killed autologous tumour cells, as described in Chapter 2. In that pilot study, 6 out of 
18 indolent B-cell lymphoma patients achieved objective clinical responses that positively 
correlated with anti-tumour immune-activation and with the occurrence of an 
immunogenic death in killed tumour cells used to prepare the patient-specific vaccines, as 
described in Chapter 3. Interestingly, only R showed the increase of circulating tumour- 
specific Abs after vaccination. These results led to the investigation as to whether the 
observed humoral responses were directed against common indolent NHL antigens, which 
could be exploited as novel targets for therapy. Towards this aim, tumour-specific cross­
reactivity of Rs' post-vaccine Abs was initially verified. Then, allogeneic NHL antigens 
differentially recognized by vaccine-induced Abs in R were identified by SERPA, and their 
biological relevance was assessed studying their expression and functional role in normal 
and neoplastic cells.
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4.3 Materials and Methods
4.3.1 Cell lines, primary cells, and culture conditions
The following human tumour cell lines were used: DOHH-2 and SC-1 (FL); RL-19, 
SU-DHL-6, KARPAS-422 and SU-DHL-4 (transformed DLBCL); GRANTA-519 (MCL); RAJI 
and NAMALWA (BL); HDMYZ and L-540 (HL); KMS-11 (multiple myeloma (MM)), MOLT-4 
(Acute T Lymphocytic Leukaemia (ALL)) and SU-DHL-1 (Anaplastic Large T Cell 
Lymphoma (ALCL)). All cell lines were purchased from DSMZ (Braunschweig) and were 
routinely maintained in RPMI 1640 medium (Lonza) supplemented with 10% (v/v) fetal 
calf serum (Lonza) and L-glutamine (Lonza) in a humidified chamber (95% air, 5% C02) at 
37°C. Primary lymphoma cells were isolated from LN or PB as reported in Chapter 2. 
Written informed consent for the investigational use of lymphocytes, serum samples and 
tumour specimens was obtained from each patient in accordance with the Declaration of 
Helsinki.
4.3.2 IHC analysis
IHC was performed on tissue sections of indolent (n=54), aggressive NHLs (n=43) 
or non-malignant LNs (n=26) obtained from the Tissue Bank of "Fondazione IRCCS Istituto 
Nazionale dei Tumori di Milano". Ab purification from human sera and their biotinylation 
were carried out as described in Chapter 2. Formalin-fixed and paraffin-embedded tissue 
sections, following epitope retrieval with 10 mmol/L of citrate buffer 0.07M pH 6.0 
(Bioptica, Milan, Italy), were incubated with human biotinylated Igs (100 p.g/ml) for 1 hour 
at RT and the immune reaction was developed using peroxidase-conjugated streptavidin. 
For Ki-67 and HSP105 staining, epitope retrieval was performed on formalin-fixed and 
paraffin-embedded tissue sections respectively treated with 6 mM citrate buffer for 6 min 
at 96°C or with 2 mM EDTA in distillated water pH 8 for 15 min at 98°C. Endogenous 
peroxidase activity was blocked by treatment with 30% hydrogen peroxide in PBS for 40 
min and followed by treatment with normal goat serum (1:50) (Dako, Glostrup, Denmark) 
for 40 min at RT. Mouse anti-human Ki-67 mAb (1:100) (Ki-67 Antigen, Clone MIB-1, Dako) 
was incubated for 1 hour followed by biotin-conjugated anti-mouse IgG (1:100, Dako) for 1 
hour at RT, whereas rabbit anti-human HSP105 polyclonal Ab (1:1500) (N-187, Santa Cruz 
Biotecnology, CA, USA) was incubated overnight at 4°C followed by biotin-conjugated anti­
rabbit IgG (1:200, Dako) for 1 hour at RT. The immunoreactivity was then revealed by 
HRP-conjugated streptavidin (1:300, Dako). The presence of immune-conjugated was 
visualized using the chromogenic substrate 3,3'-diaminobenzidine (Sigma) and 
counterstaining with hematoxylin. Ki-67 expression was scored as weak (5-10%), 
moderate (10-30%) and strong (>30%) based on the number of positive nuclei in tumour 
cells. HSP105 combining score (CS) was evaluated as low (0-2), moderate (3-5) and high 
(6-7) based on the % of positive neoplastic cells (0-4; 0= <1%, 1= >1% and <20%, 2= >20% 
and <50%, 3= >50% and <80%, 4= >80%) and staining intensity (1-3; 1= weak, 2= 
moderate, 3= strong). Sections were analysed by acquiring digital images of each tissue 
section (X10, X20 and X40) using Leica DMD108 (Heidelberg, Germany) equipped with HI 
Plan 10X/0.25 and 40X/0.65 objectives and processed using Adobe Photoshop CS4 
software (San Jose, CA).
4.3.3 Flow cytometry
Surface staining was performed on live tumour cells, as described in the previous 
Chapters, after blocking nonspecific Ab binding to the Fc-receptors (FcR blocking reagent, 
Miltenyi Biotec). Cytoplasmic staining was carried out after fixation and permeabilization 
with BD Cytofix/CytopermTM (BD Pharmingen, San Diego, CA), according to the 
manufacturer's instructions. Immunoreactivity of biotin-conjugated human serum-derived
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polyclonal Igs (100 ng/ml) and rabbit anti-human HSP105 polyclonal Ab (4 gg/ml, Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) were revealed respectively by FITC-labelled 
streptavidin (1:80) (BD Pharmingen) and FITC-labelled goat anti-rabbit Igs (Jackson 
Imunoresearch). As negative controls, cells were incubated in parallel with the matched Ig 
isotype (Santa Cruz Biotechnology, Inc.). Samples were acquired by setting photomultiplier 
tubes on the autofluorescence of the related negative control.
4.3.4 MTT assay
NHL cell lines were seeded in round-bottomed 96-well plates (10.000 cells/200 gl 
/well) in the presence of patients' post-vaccine Igs (1:50), Igs purified from donors' serum 
(1:50), rabbit anti-human HSP105 polyclonal Ab (two-fold dilution, range 8-0.125 gg/ml, 
Santa Cruz), or the matched Ig isotype (Santa Cruz) at the same concentrations as control. 
After 72-hour culture, 20pl of 5mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT, Sigma) was added directly to the wells. Following 4- 
hour incubation in a humidified chamber (95% air, 5% C02) at 37°C, plates were 
centrifuged for 10' at 2000 rpm and the supernatant was removed from each well. The 
converted formazan dye was then solubilised in DMSO (100gL/well). Absorbance was read 
at a wavelength of 550 nm with an automated ELISA microplate reader (Bio-Rad).
4.3.5 OFFGEL fractionation
Protein isoelectro-focusing was performed by the Proteomics Unit at our Institute. 
To this aim, the 3100 OFFGEL Fractionator and the OFFGEL Kit 3-10 (Agilent Technologies, 
Milan, Italy) were used following manufacturer's instructions. The device was set up for the 
24 fractions separation by using 24-cm-long immobilized pH gradient (IPG) gel strips with 
a linear pH gradient (range 3-10). DOHH-2 cell proteins were separated in a two-phase 
system: liquid upper phase separated in wells, and lower IPG gel strip phase. The sample 
was focused using the recommended method for OFFGEL proteins 24 wells fractionation 
with a maximum current of 50 pA. Separation method consisted in cooling platform 
temperature at 15°C; with electrical setting parameters: 8000V/h, 100000 V, 200W and 
50pA/strip. The focusing was stopped after total voltage reached 64 kVh. After focusing, 
samples were recovered from each well and transferred in individual micro tubes. 
Corresponding protein fractions were purified with 2-D Clean Up Kit and protein pellet 
dissolved in running sample buffer compatible with 1-D SDS-PAGE.
4.3.6 Western blotting and Immunoprecipitation
Lymphoma cell lines were solubilised for 40 min at 0°C with lysis buffer as 
described in Chapter 3. Glycoproteins were purified from total cell lysates as described 
(Pathak et al.) using the Qproteome Total Glycoprotein Kit (Qiagen). Briefly, the cleared 
lysates were applied to equilibrated affinity columns containing concanavalin A, which 
binds mannose, and wheat germ agglutinin, which binds sialic acid, and bound 
glycoproteins were eluted 3 times with elution buffer containing mannose, followed by 
elution 3 times with elution buffer containing sialic acid, each buffer supplemented with 
protease inhibitor solution (lOOx) and the detergent solution (lOx) according to the the kit 
instructions. After pooling the eluates, glycoprotein sample concentration were determined 
with Bradford reagent (Biorad).
For immunoprecipitation, lysates were precleared for 30 min at 4°C with immunopure 
immobilized protein A/G sepharose (Pierce) previously equilibrated in lysis buffer. 
Precleared lysates (3 mg DOHH-2 protein lysate/sample) were incubated for 2 h at 4°C 
with 3pg anti-HSP105 Ab or rabbit normal serum as negative control. They were 
subsequently incubated with aliquots of protein A/G-Sepharose (60 pl/sample, previously
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equilibrated in lysis buffer) overnight at 4°C on a rocker. Sepharose bound-immune 
complexes were washed three times with lysis buffer, eluted in loading buffer and divided 
in three aliquots to be successively separated in 1-D SDS-PAGE.
Eluted immunoprecipitated proteins, or OFFGEL protein fractions or lymphoma cell 
lysates, mixed with loading buffer and denatured upon heating for 5 min at 95 °C, were 
subjected to electrophoresis on 4-12% or 3-8% NuPAGE® Bis-Tris precast polyacrylamide 
gels [Invitrogen, Carlsbad, CA, USA). Separated proteins were transferred onto 
nitrocellulose membrane [Hybondl -C Super; Amersham Biosciences, GE Healthcare) in 
20% ethanol NuPAGE® transfer buffer [Invitrogen), stained with red ponceau solution, 
washed extensively with 0.5% Triton X-100 PBS and saturated overnight at 4°C in blocking 
solution [5% low-fat milk, 0.1% Triton X-100 PBS) before incubation with primary Abs 
[biotin-conjugated Igs purified from patients' pre- and post-vaccine serum samples [100 
pg/ml), rabbit anti-human HSP105 polyclonal Ab [l|ig/ml, Santa Cruz), or rabbit anti­
human actin polyclonal Ab [1:1000, Sigma, Milan, Italy)) in blocking solution for 1 hour at 
RT. Immunoreactive proteins were visualized using appropriate secondary antibodies: 
HRP-conjugated donkey anti-rabbit Ig [1:10,000) [Amersham Biosciences, GE Healthcare) 
or HRP-conjugated streptavidin [1:10,000) [Amersham Biosciences, GE Healthcare), and 
signals were detected using an enhanced ECL system [ECL Western Blotting Detection 
Reagents; GE Healthcare) according to the manufacturer's protocol.
4.3.7 In-gel tryptic digestion, MALDI-TOF-MS analysis and peptide mass
fingerprinting
For protein identification, protein bands were excised from silver-stained 
preparative gel and processed as described in Chapter 3 [Paragraph 3.3.7).
4.3.8 In-vivo experiments
Severe combined immunodeficient [SCID) mice [6-8 weeks old) with body weight 
of 20 to 25 g were purchased from Charles River [Calco, Italy).
Mice were injected subcutaneously with lOxlO6 NAMALWA [N=54) and SU-DHL-4 
[N=36) cells. When tumours reached 0.05-0.07 cm3, mice were randomized in three groups 
[n=6/group, for a total of three and two different experiments with NAMALWA and SU- 
DHL-4 models, respectively) to receive 3 intraperitoneal injections of 1 mg/ml rabbit anti­
human HSP105 polyclonal Ab or matched rabbit Ig isotype [250 pg/250 pi mouse, azide- 
free preparation for in vivo use, Santa Cruz Biotechnology, Inc.) or NaCl solution 0.9% [250 
pl/mouse). Tumours were calibrated twice/three times a week and tumour volume was 
calculated as 0.5 x d l2 x d2, where d l and d2 are the smaller and larger diameters, 
respectively.
In-vivo tumour growth was also evaluated [n=3 mice/group) by magnetic nuclear 
resonance [MNR) 24 hours after the second treatment, when tumours reached the 
maximum growth inhibition. MNR imaging was performed at the Radiology Unit of our 
Institute with 1.5-T systems [Achieva; Philips, The Netherland) by using similar pulse 
sequences. In all cases, coronal short tau inversion recovery [STIR) sequences, axial turbo- 
spin-echo [TSE) T2-weighted sequences and axial and coronal unenhanced TSE T l-  
weighted sequences were followed by an axial and coronal contrast-enhanced TSE T l-  
weighted sequences [section thickness 2 mm).
After 24 hours from the last treatment, tumours were excised and processed for IHC. 
Paraffin-embedded biopsies from NAMALWA and SU-DHL-4 xenografts were analyzed for 
HSP105 and Ki-67 expression as described in Paragraph 4.3.2. CD45, CD56 and granzyme- 
B immunostainings were performed on tissue sections from tumour xenografts using the 
following primary Abs: mouse anti-human CD45 [clones RP2/18 and RP2/22, Novocastra, 
UK), rat anti-mouse CD56 [clone H28.123, Abeam, USA), rat anti-mouse granzyme-B [clone
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16g6, eBioscience]. Binding of primary Abs was revealed by using the streptavidin-biotin- 
peroxidase complex method and 3-3'-diaminobenzidine as chromogenic substrate.
In-vivo staining of tumour vasculature with sulfosuccinimidyl-6- [biotinamido] 
hexanoate-biotin [Thermo Fisher Scientific] was performed after 24 hours from the last 
treatment to evaluate tumour vasculature injury, as described [Lavazza, Carlo-Stella et al. 
2010]. Experimental protocols were approved by the Ethical Committee for Animal 
Experimentation of the Fondazione IRCCS Istituto Nazionale dei Tumoridi Milano, according 
to the Italian laws [D.L. 116/92 and after additions], which enforce the EU 86/109 
Directive.
4.3.9 Statistical analysis.
Two-sided Student's “t"  test {p <0.05] for paired or unpaired data was used to test 
statistically significant differences. The non-parametric test Spearman rank correlation 
was used to measure the degree of association between two variables. Tumour volume 
data from the in-vivo study were analysed with 2-way analysis of variance [ANOVA], and 
individual group comparisons were evaluated by Bonferroni posttest. Statistical analyses 
were performed on the Prism 5.0a software version for Macintosh Pro personal computer 
[GraphPad Software, Inc.].
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4.4 Results
4.4.1 DC-based vaccination induced the development of cross-reactive therapeutic
Abs
In Chapter 2, it  was already shown that DC-based vaccination was able to induce a 
humoral im m unity against the autologous tumours in clinical Rs. In order to analyse 
whether vaccine-induced anti-tum our Ab response was directed to shared lymphoma- 
restricted antigens, total Igs isolated from patients' serum samples collected before and 
after vaccination were biotinylated and tested on allogeneic tum our biopsies. IHC analysis 
revealed tum our-restricted cross-reactivity only when post-vaccine Igs from Rs, either CR 
or PR, were used (Figure 4.1Ai, A ii right); whereas pre-vaccine Igs from the same Rs or pre- 
and post-vaccine Igs from NRs showed no tum our-restricted immunostaining (Fig. 4.1Ai, 
A ii left and A iii le ft and right). To study the cellular localization of the target TAAs, b iotin- 
conjugated patients' Igs were tested by flow  cytometry on live NHL cells, either as cell lines 
or from prim ary tumours, and normal B and T cells (Figure 4.1B). Vaccine-induced Ab 
responses to cell-surface tumour-specific antigens, evaluated as the ratio between post- 
and pre-vaccination Ig reactivity, were significantly higher in Rs compared to NRs (Figure 
4.1B for representative examples). As shown in Figure 4.1B (top), the ab ility  of post­
vaccination Igs from CR to recognize live tum our cell lines and prim ary cells increased by 
an average of 18-fold and 8-fold respectively compared to normal B cells. By contrast, post­
vaccination Igs from NR did not react w ith  significantly enhanced efficiency on live tum our 
versus normal B cells (Figure 4.1B bottom).
•>» A
Figure 4.1 Tumour-restricted patients’ Igs cross-reactivity.
(A) Representative IHC analysis showing immunoreactivity of biotin-conjugated pre- (left) and post-vaccine 
(right) Igs of one CR (top), one PR (middle) and one NR (bottom) tested on allogeneic human NHL specimens
y;v
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using HRP-streptavidin revealing system. Panels and their insets are shown, respectively, at X10 and X40 
magnification. (B) Flow cytometry analysis of the same Ig samples used in A (CR top, PR middle, NR bottom) 
represented as the ratio between post- and pre-vaccine Ig MFI revealed by FITC-labelled streptavidin on 
normal B (CD19) and T (CD3) cells, NHL cell lines (DOHH-2 and RL-19) and 4 different primary FL cells (TM 
#1-4).
These findings suggested that the induction of Abs directed against lymphoma cell 
surface antigens was associated with a clinical response to vaccination.
To study the therapeutic potential of Abs induced in CRs after vaccination, DOHH-2 
cells were cultured in the presence of donors' Igs or post-vaccine Igs obtained from all the 
3 CRs of the study and 2 NRs, and their growth was measured after 72 hours in a standard 
MTT assay (Figure 4.2).
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Figure 4.2 In-vitro anti-tumour activity of purified post-vaccine Igs of CRs.
Igs purified from pooled healthy donor serum samples (HD, white) or from post-vaccine serum of 3 CRs 
(black columns) or 2 NRs (grey columns) were incubated with DOHH-2 cells for 72 hours in a standard MTT 
assay. Data are mean and standard deviation of 4 replicates. Significance was calculated using unpaired 
Student's t test (*=p<0.05; **=p<0.01; *** = p<0.001, black stars: black vs. white columns; grey stars: black vs. 
grey columns).
Interestingly, Abs contained in post-vaccine serum of all CRs significantly impaired 
DOHH-2 cell growth compared to donors' Igs and either of the NRs' samples (Figure 4.2; 
p=0.05, p=0.01, p=0.004 and p=0.01, p=0.001), suggesting that vaccination induced the 
production of tumour-specific Abs that might have contributed to the observed clinical 
efficacy.
The findings above provide evidence for the existence of NHL widespread 
immunodominant antigen(s) that could be exploited as biotargets for a novel successful 
therapy.
4.4.2 Serological identification of HSP105 as a novel B-cell lymphoma antigen
To identify the lymphoma-specific antigen(s) therapeutically targeted by Rs' post­
vaccine Igs, biotin-conjugated patients' pre- and post-vaccine Igs were tested on DOHH-2 
total cell lysate by western blot. This preliminary approach revealed a sharp protein band
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migrating at about 110 kDa w ith  Rs' post-vaccine sample (Figure 4.3 Ai, lanes 2], but not 
w ith  the ir pre-vaccine Igs (Figure 4.3 Ai, lanes 1) or w ith  NRs' pre- and post-vaccine Igs 
(Figure 4.3 Aii, lanes 1 and 2]. The same strategy, applied to DOHH-2-purified 
glycoproteins, identified a differential protein band migrating at a sim ilar molecular weight 
w ith  Rs' post-vaccine Igs amongst sialylated (Figure 4.3B, right, lane 2 vs. lane 1] but not 
mannosylated proteins (Figure 4.3B, left]. These findings indicated that vaccination 
induced the production of Abs directed against lymphoma-associated glycoproteins, which, 
being preferentially expressed on the cell-surface, m ight represent very attractive targets 
for mAb therapy.
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Figure 4.3 Western blot analyses of biotin-conjugated patients' Igs.
Western blot analyses of DOHH-2 cell extracts probed w ith  biotin-conjugated Igs isolated from pre- (lanes 1) 
and post- (lanes 2) vaccine serum samples of Rs (i) and NRs (ii); (B) western b lo t analyses of DOHH-2 
purified mannosylated (left] and sialylated (right] proteins probed w ith  pre- (lanes 1] and post-vaccine 
(lanes 2) Igs from the same R serum samples shown in left panel of Figure Ai.
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To identify the differentially recognized proteins migrating at about llOkDa, a 2- 
step SERPA was applied. Initially, DOHH-2 glycoproteins were divided into 24 fractions 
according to their isoelectric point (p.i.), and each fraction was analysed by standard 
western blot using the same Ig samples showed in left panel of Figure 4.3Ai. The 
comparison of pre- and post-vaccine Ig reactivity for all the 24 fractions revealed 2 
differential bands migrating at about HOkDa in the low pH fractions only when the post­
vaccine sample was used (Figure 4.4B, left panel, red arrows). In addition, new or more 
intense bands were detected with post- compared to pre-vaccine Igs, further indicating 
that vaccination boosted the production of Abs directed against other lymphoma- 
associated glycoproteins (Figure 4.4B, black arrows).
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Figure 4.4 Western blot analyses of OFFGEL fractionated DOHH-2 glycoproteins.
Western blot analyses of DOHH-2 glycoproteins separated according to their isoelettric point (p.i.) into 24 
fractions (Fl-24) and probed with R's pre- (A) and post-vaccine [B] serum-derived Igs used in the left panel 
of Figure 4.3Ai. Arrows indicate differentially reacting bands.
The same analysis conducted on the whole lysate of DOHH-2 cells revealed 
additional proteins compared to those illustrated in Figure 4.4, and consistently showed 
one differential band migrating at about HOkDa in fraction "F6" only when post-vaccine 
Igs obtained from this R were used (Figure 4.5A vs. B, red arrow).
105
p . i .  3 3.29 3.58 3.87 4.16 4.45 4.74 5.03 5.325.51 5.80 6.09 6.38 6.67 6.96 7.25 7.54 7.83 8.12 8.418.70 8.99 9.28 9.57
kDa —  ( -  — j
2 2 5 -  
150-
102 -
7 6 -
5 2 -  
3 8 -  
31 - 
2 4 -
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 F21 F22 F23 F24
B
p . | .  3 3.29 3.58 3.87 4.16 4.45 4.74 5.03 5.325.51 5.80 6.09 6.38 6.67 6.96 7.25 7.54 7.83 8.12 8.418.70 8.99 9.28 9.57
kDa 
225- 
150-
102- ^  «■» / \
76
5 2 -  
3 8 -  
31 -
2 4 -
11:
A
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 F18 F19 F20 F21 F22 F23 F24
Figure 4.5 Western blot analyses of OFFGEL-fractionated DOHH-2 total proteins.
Western blot analyses of 24 protein fractions (Fl-24) separated from DOHH-2 cell whole lysate according to 
their isoelettric point (p.i.) and probed with R's pre- (A) and post-vaccine (B) serum-derived Igs used also in 
Figure 4.4. Arrows indicate differentially reacting bands.
MALDI-TOF-MS analysis, performed in that molecular weight range of a silver- 
stained preparative gel, identified in F6, and not in the non-reactive adjacent F5 and F7, 
U5S1 (component of the U5 small nuclear ribonucleoprotein particle), puromycin-sensitive 
aminopeptidase (PSA), mini-chromosome maintenance proteins (MCM)-4 (a DNA helicase 
activity factor), all constitutively expressed in the nucleus or cytoplasm, and HSP105, as the 
potential proteins differentially recognized by post-vaccination Igs (Figure 4.6A). In light of 
the possibility that HSP105 could be expressed on cell surface and the widely described 
roles of HSP family members in a broad range of neoplastic processes (Whitesell and 
Lindquist 2005; Luo, Solimini et al. 2009) the study was focused on understanding 
HSP105's involvement in B-NHLs.
Western blot analysis of DOHH-2 glycoprotein (F6-8, Figure 4.6B) and whole cell 
lysate (F5-7, Figure 4.6C) fractions probed with a commercial anti-HSP105 Ab revealed the 
presence of HSP105 specific band in the same fractions (glycoprotein F7 and F8 fractions 
and the whole lysate F6 fraction) and at a comparable molecular weight to that recognized 
by the Rs' post-vaccine Igs, thus validating the results obtained by SERPA.
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Figure 4.6 MALDI-TOF-MS-based identification of HSP105 in B-NHL.
(A) Silver staining of F5, F6 and F7 preparative SDS-PAGE for MS analysis of the numbered protein bands. (B) 
Comparison of DOHH-2 glycoprotein F6-8 fractions probed with R's pre- (i), post- (ii) vaccine Igs or (iii) 
commercial anti-human HSP105 Ab. (C) Comparison of DOHH-2 total cell lysate protein F5-7 fractions 
probed with R's pre- (i), post- (ii) vaccine Igs or (iii) commercial anti-human HSP105. (D) 
Immunoprecipitation of HSP105 from total DOHH-2 cell lysate with a commercial anti-human HSP105 Ab, 
followed by western blotting analysis with R's pre- and post-vaccine Igs, or anti-HSP105 Ab, as positive 
control. IP: immunoprecipitation; WB: Western blot
In addition, HSP105 was immunoprecipitated from DOHH-2 total cell lysate with a 
commercial anti-HSP105 Ab, and then probed with R' Ig samples used in SERPA. HSP105 
was better revealed by post-vaccine Igs rather than by the matched pre-vaccine sample 
(Figure 4.6D), indicating the increase of circulating anti-HSP105 Abs in this R after 
vaccination.
4.4.3 Expression analysis of HSP105 in NHL cell lines and primary tumours
HSP105 expression was analysed by western blot in a panel of tumour cell lines of 
B-(Figure 4.7, lanes 2-13) and T-cell origin (Figure 4.7, lanes 15-16) and their normal cell 
counterparts (Figure 4.7, lanes 1 and 14, respectively). As shown in Figure 4.7, the a-
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isoform, which is the one migrating at the highest molecular weight, was found expressed 
in all cells analysed, even though to a lesser extent in normal B and T cells (lanes 1 and 14). 
By contrast, the inducible p-isoform was preferentially expressed by neoplastic cells, 
although at variable levels (Figure 4.7].
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Figure 4.7 Western blot analysis of HSP105 expression in normal and neoplastic B and T cells.
One-dimensional SDS-PAGE of proteins extracts from normal B cells (1), B-NHL cell lines DOHH-2 (2), SC-1 
(3), SU-DHL-6 (4), KARPAS-422 (5), RL-19 (6), SU-DHL-4 (7], RAJI (8), NAMALWA (9) and GRANTA-519 (10), 
Hodgkin lymphoma cell lines L-540 (11) and HDMYZ (12), multiple myeloma cell line KMS-11 (13), normal T 
cells (14), T cell leukaemia cell lines MOLT-4 (15) and T-cell lymphoma SU-DHL-1 (16) probed with 
commercial rabbit anti-human HSP105 polyclonal Ab (top) and rabbit anti-human Actin polyclonal Ab 
(bottom).
To analyse the subcellular localization of HSP105, its expression was studied by 
flow cytometry on the same cells, used either alive (Figure 4.8A), or upon being fixed and 
permeabilized (Figure 4.8B). Interestingly, B-NHL cell lines show a gradual increase of 
HSP105 surface-expression according to their aggressiveness, when both the MFI (Figure 
4.8A left) and positive cell percentage (Figure 4.8A right) were analysed. Donor T cells (HD 
CD3) or cell lines derived from T-cell leukaemia and lymphoma did not express surface- 
HSP105 (Figure 4.8A). HSP105 was expressed on the surface of about 50% of normal 
circulating B cells (Figure 4.8A right), suggesting that the exposure of HSP105 may have a 
role in B-cell physiology and lymphomagenesis. As expected, HSP105 was expressed within 
the cytoplasm of all the cell lines tested (Figure 4.8B). However, intracellular staining was 
heterogeneous in B-cell malignancies (Figure 4.8B, columns 2-13), whereas it was 
comparably high in normal and neoplastic T cells (Figure 4.8B, columns 14-16).
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Figure 4.8 FACS analysis of HSP105 expression in normal and neoplastic B and T cells.
Flow cytometry analyses of surface (A) and intracellular (B) staining of anti-HSP105 Ab in normal B cells (1), 
B-NHL cell lines DOHH-2 (2), SC-1 (3), SU-DHL-6 (4), KARPAS-422 (5], RL-19 (6), SU-DHL-4 (7], RAJI (8), 
NAMALWA (9) and GRANTA-519 (10), Hodgkin lymphoma cell lines L-540 (11) and HDMYZ (12), multiple 
myeloma cell line KMS-11 (13), normal T cells (14), T cell leukaemia cell lines MOLT-4 (15) and T-cell 
lymphoma. Relative MFI was calculated as ratio between stained sample and negative control MFI.
The expression of HSP105 was then evaluated in primary NHL biopsies and normal 
LNs by IHC. In order to achieve this, a CS, ranging from 0 to 7, was arbitrarly defined to 
quantify the levels of HSP105 expression based on both the positive cell percentage and 
staining intensity, as described in the Materials and Methods section of this Chapter. To 
ascertain whether the presence of the antigen was associated with the clinical response to 
vaccination, the extent of HSP105 expression in the tumours of Rs were initially compared 
with that detected in tumours of NRs. The analysis of the available tumour biopsies (10 out 
of 18) revealed no significant differences in HSP105 expression level according to the 
clinical outcome of the patients, indicating that the lack of response was not due to a 
reduced lymphoma expression of HSP105 (Figure 4.9).
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Figure 4.9 Immunohistochemical analysis of HSP105 expression in tumour biopsies from vaccinated 
patients.
Combining score for HSP105 expression in tumour biopsies from 4 Rs and 6 NRs. Analysis of statistical 
significance was performed with Student’s t test (ns: not significant).
The IHC analysis was thus widened to include additional cases of both indolent 
(n=54) and aggressive (n=43) NHLs, as well as non-malignant LNs (n=26) biopsies. In this 
case, HSP105 expression was analysed in relationship to disease aggressiveness and 
malignancy, evaluated on the basis of lymphoma histological grade and Ki-67 staining, 
respectively. A CS=4 was arbitrarily considered as a threshold value that mainly 
discriminated between the low- and the high-grade B-NHLs (Figure 4.10). HSP105 
expression was significantly higher in the aggressive compared to the indolent B-NHLs or 
normal LNs (Figure 4.10A, p<0.001) and was directly correlated with the lymphoma 
histological grade (Figure 4.10A, p<0.0001, Spearman r=0.6951). In addition, high- 
proliferating tumors, characterized by an intense and widespread Ki-67+ staining (>50% 
Ki-67+ nuclei), expressed HSP105 at significantly higher levels compared to the low- 
proliferating forms (<50% Ki-67+ nuclei) (Figure 4.10B, p<0.001). The lymphoma 
proliferation rate thus correlated with HSP105 expression levels (Figure 4.10B, p<0.0001, 
Spearman r=0.7473).
B
8-1
6-
C0
o
LO
O  4H
c l 
co x
2-
T T
▼ ▼▼
▲ A
AAA
o o o
Q S M ffl)
O O O
(W n-
"m?r A A
Non-malignant
LN
T T T AAAAAAAAMAAAAAAAAA
CO
o
LOo
A A
CL
CO
X
rwmwwwwrw
LG HG Ki-67+ <50% Ki-67+ >50%
B-NHL
Figure 4.10 Immunohistochemical analysis of HSP105 expression in normal and neoplastic LNs.
Combining score for HSP105 expression in NHLs and normal LNs plotted against tumour aggressiveness 
based on lymphoma histological grade (A) or Ki-67 expression level (B). Analysis of statistical significance 
was performed with Student's t test (*: p<0.05; **: p<0.01; ***: p<0.001).
Even in normal reactive LNs and indolent NHLs, where the structure of the follicles 
was preserved, HSP105 was preferentially expressed in the GC lymphocyte-enriched areas 
(Figure 4.11A right, for a representative example) that also stained strongly for Ki-67 
(Figure 4.11A middle, for a representative example), suggesting a potential involvement of 
HSP105 in cell-cycle regulation of normal or malignant B cells. Further support for this was 
provided by the study of a case of indolent NHL before and after its progression. Increased 
HSP105 expression coupled with a stronger Ki-67 staining was observed in the progressed 
DLBCL (Figure 4.11Bii) compared to the diagnostic low-grade lymphoplasmacytic 
lymphoma (LPL) (Figure 4.11Bi).
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Figure 4,11 Example of immunohistochemical analysis of HSP105 and Ki-67 in low- and high-grade B- 
NHLs.
Hematoxylin eosin (left), Hi-67 (middle) and HSP105 (right) staining in one FL (A) and one LPL specimen (B) 
before (i) and after progression (ii) towards DLBCL. Arrows indicate HSP105 expression on lymphoma cell 
surface. Panels in A and B are shown, respectively, atXIO and X20 original magnification. GC: germinal centre.
4.4.4 In-vitro and in-vivo anti-lymphoma effects of HSP105 targeting
The therapeutic potential of targeting HSP105 w ith  a specific Ab was then 
investigated by standard MTT assays using different B-NHL cell lines. The concentrations 
of anti-HSP105 Ab or matched control isotype Igs that achieved a 50% growth inh ib ition  
[IC50] in culture after 72 hours of incubation are showed in Figure 4.12. Amongst the cell 
lines tested, SU-DHL-4 and NAMALWA resulted the most sensitive to the specific treatm ent 
compared to the control isotype Igs (Figure 4.12, p=0.02, p=0.04).
112
o>
n .
o10O
25 n
20
15 ■
10
5 ■
0
HI Rabbit anti-human HSP105 Ab 
□  Rabbit IgG
DOHH-2 SU-DHL-4 GRANTA NAMALWA
Figure 4.12 In-vitro anti-tumour effects of anti-HSP105 Ab against lymphoma cell lines.
Rabbit polyclonal anti-HSP105 Ab (black column) or matched isotype Igs (white column) concentrations 
reaching 50% growth inhibition (IC50) of DOHH-2, SU-DHL-4, NAMALWA and GRANTA-519 cell line cultures 
after 72 hour-incubation, measured using standard MTT assays. The average values of 3 independent 
experiments are shown. Analysis of statistical significance was performed with Student's t test (*: p<0.05).
In the attempt to define the potential therapeutic role of HSP105 targeting in B-cell 
lymphomas, anti-HSP105 Ab was tested in SCID mice xenografted with these cell lines. As 
control groups, mice were treated in parallel with the matched isotype Igs or NaCl solution. 
The in-vivo targeting of HSP105 was associated with a significant reduction of tumour 
burden in both NAMALWA and SU-DHL-4 models with respect to the control treatments, as 
measured by calliper (Figure 4.13A and B, respectively) or MNR in a limited number of 
cases (Figure 4.13C and D, respectively). After only two administrations of anti-HSP105 Ab, 
the NAMALWA and SU-DHL-4 tumours exhibited an average growth inhibition of 70% and 
60%, respectively, compared to those present in the untreated animals (Figure 4.13A and 
B).
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Figure 4.13 In-vivo anti-lymphoma activity of anti-HSP105 Ab.
(A) SU-DHL-4 (i) and NAMALWA growth (ii) in SCID mice treated with 3 i.p. injections of NaCl solution (ctrl], 
250 pg anti-HSP105 Ab or matched isotype Igs (rabbit IgG] every 4 days (black arrows]. Average tumour 
volumes (measured with a caliper], and SEM of 2 (SU-DHL-4 model] and 3 (NAMALWA model] independent 
experiments, in which 6 mice per group were analyzed, are shown. Statistically significant differences were 
calculated by using the 2-way analysis of variance (ANOVA] method (**: p<0.01; ***: p<0.001; black stars: 
anti-HSP105 Ab versus rabbit IgG; grey stars: anti-HSP105 Ab versus ctrl]. (B] NMR coronal STIR images of 
SU-DHL-4 (i] and NAMALWA (ii] xenograft-bearing mice 24 h after the second injection of rabbit IgG (top] or 
anti-HSP105 Ab (bottom]. White arrows indicate the hyperintense subcutaneous lesion
The greater NAMALWA tumour shrinkage compared to that of SU-DHL-4 (Figure 
4.13A] was most likely due to the higher cell-surface expression level of HSP105 in
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NAMALWA cells (Figure 4.8A). Importantly, the autopsy examinations confirmed the lack 
of detectable toxic ity in the animals.
A B
Figure 4.14 Immunihistochemical analyses of NAMALWA xenografts.
IHC analysis of NAMALWA xenografts. Hematoxylin and eosin staining (A), and IHC analyses of CD45 (B), Ki- 
67 (C) and HSP105 (D) expression on NAMALWA tissue sections from tumour biopsies harvested after 2 
weeks of tumour engraftment in control mice. Original magnification x200 for all panels.
NAMALWA xenografts (Figure 4.14A), as defined by CD45 staining (Figure 4.14B), 
expressed Ki-67 (Figure 4.14C) and HSP105 (Figure 4.14D) at levels superimposable w ith  
respect to those observed in human high-grade prim ary B-NHL specimens (Figure 4.1 IB ii 
bottom). A marked increase of necrotic areas was detected in anti-HSP105 Ab-treated 
xenografts w ith  respect to the controls, as revealed by hematoxylin and eosin stainings 
(Figure 4.15Ai bottom vs. top, for representative examples).
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Figure 4.15 Anti-tumour effects of HSP105 targeting in the NAMALWA model.
(A) IHC analysis of NAMALWA xenografts from control rabbit Ig- (top) and anti-HSP105 Ab-treated (bottom) 
animals. Representative hematoxylin and eosin (i), granzyme-B (ii) and CD56 (iii) stainings are shown. 
Original magnification x200 (i) and x400 (ii- iii); original magnification x400 for insets. (B) Absolute number 
of granzyme B+ (i) and CD56+ (ii) cells in sections from control rabbit Ig- and anti-HSP105 Ab-treated 
xenografts. Immunoreactive cells (i.e. yellow/brown-stained cells) were counted in out of five high-power 
microscopic fields (x400 magnification) for each condition and the result was expressed as an average. The 
boxes extend from the 25th to the 75th percentiles, the lines indicate the median values, and the whiskers 
indicate the range of values. Results from 2 independent experiments are shown. Statistically significant 
differences between groups were assessed using unpaired 2-tailed Student “t" test (***: p< 0.001).
Under low power, untreated tumours displayed the typical "starry sky" pattern of 
BL, indicating the presence of apoptotic tum our cells (Figure 4.15Ai top). Upon HSP105 
targeting, the tum our xenografts showed signs of single-cell necrosis and extended necrotic 
foci, which involved both lymphoid neoplastic cells and the branching fibrovascular
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stromal network (Figure 4.15Ai bottom}. Necrotic changes characterizing anti-HSP105 Ab- 
treated lymphomas were associated w ith  a significant in filtra tion  of immunological NK 
cells, highlighted by granzyme-B (Figure 4.15Aii bottom vs. top} and CD56 immunostaining 
(Figure 4.15Aiii bottom vs. top}, suggesting the contribution of ADCC to the anti-tum our 
activity of this Ab-based immunotherapy, as already described fo r other Abs in different 
tum our models (Nagayama S, Fukukawa C et al. 2005}. The quantitative evaluation of 
tum our-in filtra ting granzyme-B+ (Figure 4.15Bi} and CD56+ cells (Figure 4.15Bii}, which 
were counted in out of five high-power microscopioc fields in sections from anti-HSP105 
Ab- and isotype Ig-treated xenografts, reproducibly confirmed this finding.
The possibility that the treatment w ith  anti-HSP105 Ab could mediate anti- 
angiogenic effects was investigated in NAMALWA xenografted mice. Tumour vasculature 
was subjected to in-vivo biotin-conjugation and then quantified by IHC using HRP- 
conjugated streptavidin on tissue sections of the harvested tum our nodules. A significant 
reduction of tum our endothelial area was found in the anti-HSP105 treated mice compared 
to that detected in mice administered w ith  the matched isotype Igs (Figure 4.16A, 
p<0.0001; Figure 4.16B for a representative IHC analysis}. Such results may partly  explain 
the observed anti-lymphoma activity of anti-HSP105 Ab.
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Figure 4.16 Anti-vascular effects of anti-HSP105 Ab at the tumour site.
Twenty-four hours after the second treatment, SCID mice were intravenously injected w ith  sulfo-NHS-LC- 
biotin to biotinylate the tumour vasculature in vivo. (A) The relative endothelial area was calculated on whole 
tissue sections as (HRL-conjugated streptavidin stained area/total tissue area) xlOO. Sections obtained at 10, 
20 and 30 pm in depth were analysed per tumour nodule. Nodules from 4 mice per groups were studied in 
two independent experiments. The boxes extend from the 25th to the 75th percentiles, the lines indicate the 
median values, and the whiskers indicate the range of values (***: p< 0.001). (B) Representative histological 
images of in-vivo biotinylated tumour vessels in mice receiving control treatment (top) or anti-HSP105 Ab 
(bottom). Hematoxylin and eosin (left) and HRP-conjugated streptavidin (right) staining results are shown.
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4.5 Discussion
The present study allowed the identification of HSP105 as a novel potential 
therapeutic biotarget for B-NHLs. Specifically, starting from the observation that DC-based 
vaccination in NHL patients enhanced the frequency of circulating Abs directed against 
shared lymphoma antigens only in Rs, an appropriately modified SERPA applied to NHL 
cell line proteome revealed HSP105 as one of the possible Rs' Ab-targeted proteins. The 
cell-surface expression of HSP105 correlated with B-NHL proliferation rate and 
aggressiveness, both when cell lines and primary tumour biopsies were analyzed. HSP105 
targeting through a specific Ab significantly delayed and impaired the growth of aggressive 
human B-NHL xenografts. In-vivo anti-lymphoma activity of HSP105 engagement was 
associated with a significant increase of CD56+ and granzyme-B+ NK cells at tumour site 
that very likely contributed to tumour-restricted necrosis, via ADCC, and vascular damage. 
Results from this study indicate the clinical relevance of anti-tumour humoral responses 
induced by active immunotherapy against indolent NHLs. Accordingly, previous Id- 
vaccination studies in FL patients reported a strong association between clinical outcome 
and Ab response [Timmerman 2002; Ai, Tibshirani et al. 2009). These observations are 
also supported by the considerable improvement in the management of B-NHLs by the 
addition of mAb therapy to conventional and high-dose chemotherapy protocols [Cheson 
and Leonard 2008). However, although the anti-CD20 mAb rituximab has significantly 
ameliorated the prognosis of indolent and aggressive B-NHLs [Cheson and Leonard 2008), 
the occurrence of resistance in about half of the patients still represents a major challenge 
towards the cure of these diseases [McLaughlin, Grillo-Lopez 1998; Davis, Grillo-Lopez 
2000). Therefore, different and more specific biotargets as well as more potent mAbs are 
continuously being sought.
Vaccine-induced therapeutic Abs in patients showing a clinical response may 
represent a valid tool for the discovery of key TAAs, which can be exploited as biotargets 
for a more specific and efficient therapy. Indeed, if Abs against TAAs are commonly found 
in the serum of cancer patients, then, the frequency of those therapeutically targeting 
relevant tumour antigens is expected to increase following anti-tumour vaccination. 
Therefore, the serological identification of novel biotargets and/or biomarkers is likely to 
be facilitated by the possibility to compare the reactivity of pre- versus post-vaccine serum 
samples of Rs. Classical SERPA, in which cellular proteins are resolved by 2-D 
electrophoresis, transferred into membranes, and immunodetected using cancer patients' 
serum samples [Klade 2002; Hamrita, Chahed et al. 2008), has the intrinsic drawback in 
that it may barely detect low molecular weight proteins and those with extreme p.I., as well 
as low-abundance and poorly soluble hydrophobic proteins, such as cell-surface proteins. 
To circumvent these limitations, a 2-step approach for protein separation, including the pH 
gradient fractionation of protein lysates followed by 1-D SDS-PAGE of each protein fraction, 
has been coupled with MS analysis in the current study. Using this modified SERPA, 
HSP105 was identified amongst the proteins differentially revealed by Rs’ post-vaccine Abs. 
The ability of HSP105 to elicit a humoral response has been already observed in pancreatic 
and colorectal carcinoma patients, whose serum samples served for its identification by 
SEREX [Nakatsura, Senju et al. 2001).
HSPs are ubiquitous, highly conserved proteins that function as molecular 
chaperones [Takayama, Reed et al. 2003). Their expression can be constitutive or regulated 
by multiple cellular stresses to prevent apoptosis and enhance survival. HSP105oc and its 
alternative splicing form HSP105(3 belong to the HSP105/110 family, a divergent subgroup 
of the HSP70 family. Under physiological conditions, HSP105a is constitutively expressed 
and induced by various forms of stress preferentially in the cytoplasm, whilst HSP1O50 is 
expressed specifically during mild heat shock in the nucleus [Saito, Yamagishi et al. 2007; 
Saito, Yamagishi et al. 2009). HSP105(3 has been found to up-regulate HSP70 expression
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trough signal transducer and activator of transcription-3 [STAT3] [Yamagishi, Fujii et al. 
2009], and, like HSP105a, cooperates with HSP70 to suppress the aggregation of denatured 
proteins [Yamagishi 2003]. Results from the present study indicate an intriguing role of 
HSP105 in B-cell lymphoma physiopathology, which encourage further investigation in 
prospective settings to evaluate whether it can truly represent a novel biomarker and/or 
biotarget for some categories of NHL. Interestingly, B-NHLs showed a previously 
undescribed surface expression of HSP105, but not HSP70 [data not shown], that increased 
with tumour aggressiveness and proliferation rate. As described in Chapter 3, extracellular 
or membrane-bound HSPs can mediate immunological functions due to their carrier 
function for immunogenic peptides [Suto and Srivastava 1995]. Vaccines based on tumour- 
derived HSP70- and Gp96-peptide complexes have demonstrated potential clinical efficacy 
and minimal toxicity for the treatment of solid tumours as well as lymphoma and 
leukaemia [Srivastava 2000; Belli, Testori et al. 2002; Mazzaferro, Coppa 2003] Qanetzki, 
Palla et al. 2000]. It is therefore possible that DC-vaccination may have provided HSP105- 
peptide complex to the host immune system and/or have activated it towards multiple 
TAAs, including HSP105, favouring the onset of a clinical response. The finding of a low 
cell-surface expression of HSP105 in indolent B-NHLs, however, indicates that it may not 
be the only relevant antigen targeted by therapeutic humoral responses induced in Rs by 
vaccination.
Remarkably, the administration of an anti-HSP105 Ab showed significant inhibition 
of the growth of human aggressive lymphoma cell lines both in vitro and in in-vivo models. 
The anti-tumour activity of the in-vivo treatment with anti-HSP105 Ab was found to be 
associated with significant anti-angiogenic effects. The anti-angiogenic properties of 
targeting the heat shock response have been already documented upon HSP90 inhibition, 
which leads to HIF-dependent and independent VEGF suppression and to the negative 
regulation of key modulators of VEGF pathway [Bohonowych, Gopal et al. 2010]. Although 
the mechanism of the action of HSP105 targeting may be more complex, potentially 
affecting multiple signalling pathways downstream its client proteins and/or in-vivo 
immune effector functions [and which await further investigations] the present findings 
represent the proof of principle for the design and the study of anti-HSP105 passive 
immunotherapy for B-NHL patients.
Accumulating reports of a deep and multifaceted involvement of HSPs in the 
oncogenic process indeed support that the heat shock response may represent a suitable 
target for anticancer therapy. Due to the extreme aneuploidy, copy-number variation, and 
transcriptional alterations that increase the amount of toxic, unfolded protein aggregates, 
tumour cells need the expression of chaperone proteins to maintain normal homeostasis of 
the proteome [Whitesell and Lindquist 2005]. Furthermore, HSPs are required for the 
correct maturation and function of several oncogenes, which are often chaperone client 
proteins. The differential expression of HSPs in tumours compared to normal cells is most 
likely consistent with the possibility of a sufficiently large therapeutic window for their 
targeting and the development of potentially efficacious rationale combination treatments 
[Luo, Solimini et al. 2009]. A leading example in this field is provided by the experience 
achieved during 20 years of the study of HSP90 in cancer and 10 years of HSP90 inhibitors 
in clinical trials [Trepel, Mollapour et al. 2010]. Its function as chaperone of oncogenes, 
including HER2/neu, mutant EGFR, c-KIT, BCR-ABL, BRAF, H IFl-a and, very recently, Bcl6 
in DLBCL [Bohonowych, Gopal et al. 2010; Trepel, Mollapour et al. 2010] [Cerchietti, Lopes 
et al. 2009], and the ensuing recognition of its role as a crucial facilitator of oncogene 
addiction and cancer cell survival [Whitesell and Lindquist 2005] have spurred the 
development of specific inhibitors as novel anticancer treatment [Workman, Burrows et al.
2007]. Early and more advanced clinical trials with about a number of different HSP 
inhibitors, representing multiple drug classes, are showing very promising results, in 
particular when they are combined with other targeted treatments, such as trastuzumab
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(Modi et al. 2008), EGFR inhibitors (Sequist et al. 2009), bortezomib (Richardson et al. 
2009), or chemotherapeutic agents (Hubbard, Erlichman et al. 2010), and/or radiotherapy 
(Hwang, Moretti et al. 2009).
Despite being studied to a lesser extent, the oncogenic potential of HSP105 has been 
already reported in solid, but not haematological, malignancies. HSP105 was indeed found 
to be overexpressed in thyroid, breast, gastric, esophageal, hepatocellular carcinomas and 
melanoma compared to normal tissues, and was thus proposed as a pertinent cancer 
antigen for diagnosis and immunotherapy (Nakatsura, Senju et al. 2001) (Park, Park et al. 
2009). In preclinical studies, specific DNA/protein vaccination was found to be highly 
effective in preventing the growth of colorectal carcinoma and melanoma growth in 
challenged immunocompetent mice, without any signs of autoimmune reaction (Wang, 
Chen et al. 2003; Miyazaki, Nakatsura et al. 2005). In addition to its property as a potential 
target for immunotherapy, HSP105 seems to have a direct involvement in tumorigenesis, 
through the protection of cancer cells against apoptosis (Yamagishi, Ishihara et al. 2006; 
Yamagishi, Saito et al. 2008). Indeed, HSP105 siRNA treatment was found able to induce 
caspase-dependent apoptosis in pancreatic, colorectal and gastric cancer cell lines both in 
vitro and in vivo (Hosaka, Nakatsura et al. 2006).
The increasing cell-surface expression of HSP105 according to B-NHL aggressiveness 
and the contribution of specific Abs to the clinical efficacy of DC-vaccination, even in the 
setting of indolent lymphoma, strongly highlight the potential therapeutic efficacy of anti- 
HSP105 mAbs. The preferential expression of HSP105 in normal GC lymphocytes is 
consistent with recent findings showing the localization of HSP90 in normal centroblasts, 
thus suggesting that a stress response may govern the physiological formation of GCs 
(Cerchietti, Lopes et al. 2009). Although HSP105 expression was detected on the surface of 
normal B cells, no significant toxicity was documented after targeting HSP105 in 
xenografted lymphoma mouse models. This is in line with results obtained using HSP90 
inhibitors that showed a good safety profile even in more extensive toxicity analyses using 
immunocompetent mice (Cerchietti, Lopes et al. 2009). On the other hand, the significant 
in-vivo anti-lymphoma activity of anti-HSP105 Ab treatment indicates that HSP105, or its 
client proteins, may represent crucial elements for tumour but not normal cell survival and 
supports the potential therapeutic efficacy of its selective inhibition by a specific mAb. 
Lymphoma have demonstrated a high sensitivity to mAb therapy, an approach that has the 
great advantages of a reduced off-target toxicity compared to standard chemotherapeutic 
regimens and also to stimulate important anti-tumour immune functions that can 
contribute to the long-lasting control of the disease (Hilchey, Hyrien et al. 2009). Therefore, 
the production of anti-HSP105 blocking mAbs may represent a good strategy to further 
study the therapeutic potential of targeting this molecule in B-NHL alone and in 
combination with conventional chemo/radiotherapy or targeted drugs to fine tune their 
cytotoxic effects on tumour cells and enhance their therapeutic anti-lymphoma activity.
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5 OPTIMIZATION OF ANTICANCER IMMUNOTHERAPY:
BOOSTING THE AFFERENT AND/OR THE EFFERENT PHASES 
OF VACCINE-INDUCED ANTI-TUMOUR IMMUNE RESPONSES
5.1 Introduction
Despite the promise of harnessing the immune system to target cancer cells, most 
phase-III trials of cancer vaccines have shown very limited clinical impact [Koos, Josephs et 
al. 2010) [Bendandi 2009). Importantly, the most significant clinical results have been 
observed only in patients treated whilst in complete response after conventional 
chemotherapy [Palucka, Ueno, et al. 2007; Inoges, Rodriguez-Calvillo et al. 2006). Indeed, 
although active immunotherapy has repeatedly proven to boost a tumour-specific 
immunity into cancer patients [Neelapu, Kwak et al. 2005), it does not seem able to 
generate sufficient amounts of effector cells with the required functional status, homing 
properties and survival characteristics to overcome existing tumour escape mechanisms, 
particularly in the presence of a significant tumour load, and provide a therapeutically 
efficacious anti-tumour immune response. The relatively high clinical response rate 
observed in the pilot study of DC-based vaccination described in Chapter 2 is in line with 
the clinical efficacy achieved by DC vaccine formulations [Timmerman, Czerwinski 2002), 
which have the advantage to enhance multiple immunostimulatoiy signals, whilst 
promoting the down-modulation of immunoregulatory mechanisms more efficiently 
compared to non-DC vaccine ones [Park and Neelapu 2008; Gilboa 2007). Nevertheless, 
even in this case, the clinical responses were primarily achieved in patients with low 
tumour burden, suggesting that there may be the opportunity for further improvement of 
vaccine strategies to allow for the complete disease eradication and control independently 
of the tumour size. Recent findings in basic immunology have highlighted several new ways 
to potentiate both the afferent [priming) and the efferent or [effector) phases of the 
immune response. For example, novel immune-adjuvant agents, such as TLR ligands, or the 
adoptive transfer of highly avid tumour specific T cells may enhance the afferent phase of a 
vaccine-induced anti-tumour immune response [Wrzesinski, Paulos et al. 2007). By 
contrast, the efferent phase may be favoured by inhibiting various immunosuppressive and 
tolerance mechanisms in the tumour microenvironment, such as inhibitory co-stimulation 
[Attia, Phan et al. 2005) and/or Treg activity [Dannull, Su et al. 2005), as well as by 
stimulating pathways able to prolong the immune response elicited after a productive 
afferent phase [Kober, Leitner et al. 2008). These agents may be used in combination with 
therapeutic cancer vaccines for optimal induction of anti-tumour immunity that, in turn, 
may lead to improved clinical outcome.
Manipulation of the immune system by adoptive transfer of tumour-specific 
lymphocytes, activated and expanded in vitro, has shown remarkable clinical results in 
cancer patients [Rosenberg, Yannelli et al. 1994; Haque, Wilkie et al. 2007; Bollard, Aguilar 
et al. 2004) [Dudley and Rosenberg 2003), and in combination with chemotherapy has 
been demonstrated to mediate significant tumour regression in heavily pre-treated 
metastatic melanoma patients with conspicuous tumour burden [Dudley, Wunderlich, et al. 
2005). However, this strategy is technically demanding; for example, it requires a lot of 
time for the generation of large amounts of anti-tumour T cells for every patient [Gattinoni, 
Klebanoff et al. 2005). Furthermore, on reaching the terminal stages of differentiation after 
long-term ex-vivo stimulation, most expanded T cells exhibit a limited capacity to further 
divide and persist in vivo [Yee, Thompson et al. 2002; Gattinoni, Klebanoff et al. 2005; 
Hinrichs, Borman et al. 2009; Robbins Dudley et al. 2004). Improvements to efficiently 
boost the rapid expansion of functional anti-tumour T cells possessing extensive replicative 
capacity and long-term in-vivo persistence are required to better exploit the therapeutic
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potential of adoptive immunotherapy as a tool to enhance the afferent phase of an anti­
tumour immune response into cancer patients.
The increased appreciation of the relevance of T cell co-stimulatory pathways in fine- 
tuning an efficient immune response and the concurrent development of the related 
agonist or antagonist agents have provided novel strategies to favour the establishment of 
anti-tumour immunity (Croft 2009). In particular, 0X40 (CD134) and its partner OX40L 
(CD252), both members of the tumour necrosis factor receptor (TNFR)/TNF superfamily, 
provide one of the most important and prominent interactions (Croft 2010; Ishii, 
Takahashi et al. 2010). OX40-OX40L co-stimulation has the ability to sustain an ongoing 
immune response by inducing cell division and survival signals to differentiating or already 
differentiated T cells, and by enhancing the production of differentiating cytokines to 
further polarize the immune responses (Croft 2010; Ishii, Takahashi et al. 2010). Thus, this 
interaction not only regulates the magnitude and the efficiency of the primary response, 
but also the generation of the T-cell memory pool. In addition, 0X40 stimulation has been 
recently found to inhibit existing Tregs and block their peripheral conversion in basic and 
tumour mouse models (Valzasina, Guiducci et al. 2005; Kroemer, Xiao et al. 2007; Piconese, 
Valzasina et al. 2008). These properties, together with the restricted expression of 0X40 on 
antigen activated T cells, make it an attractive and promising molecular target to be 
stimulated in combinatorial immunotherapeutic approaches, including DC vaccines, ACT, 
and treatment with cytokines (GM-CSF and IL-12).
5.2 Aim of the Chapter
The major aims of this Chapter were the following:
• To develop a new expansion system for the production of large amounts of anti­
tumour T cells with an extensive replicative capacity and long-term in-vivo 
persistence potential. Towards this goal, the liposome-based artificial APCs 
(aAPCs) described by Albani and colleagues (Prakken, Wauben et al. 2000; 
Giannoni, Barnett et al. 2005) for the identification of rare antigen-specific T 
cells in autoimmune disorders were properly modified for ex-vivo T-cell 
activation and expansion. Artificial liposome-based systems are expected to 
preserve the properties of a fluid cellular membrane that allows for efficient 
immunological synapse formation, whilst providing highly reproducible 
stimulation that can be tightly regulated by the addition of the desired type and 
amount of immunomodulatory molecules;
• To study OX40-OX40L interactions in the lymphoma microenvironment and 
verify the possibility of exploiting this pathway as a potential target for 
immunotherapy for NHLs. The expression of 0X40 was analysed in lymphoma 
cell lines and primary tumours, as well as in T cells and Tregs in PB and at the 
tumour site in NHL patients. The effects of blocking or stimulating 0X40 on 
human T cells and Treg were also investigated in vitro.
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5.3 Materials and Methods
5.3.1 Generation of aAPC
For the preparation of aAPCs, the approach used by Albani and colleagues (Prakken, 
Wauben et al. 2000; Giannoni, Barnett et al. 2005] was adopted with some modifications. 
Briefly, mouse anti-human CD3 (clone UCHT1, isotype IgGlk; BD Pharmingen), CD28 
(cloneCD28.2, isotype IgGlk; BD Pharmingen) and LFA1 (clone 38, isotype IgG2a; 
Biodesign, Saco, MN) triggering mAbs were pre-clustered in microdomains (MDs) on a 
scaffold made of GM1 ganglioside-enriched liposomes (Figure 5.1A). To this end, 
biotinylated anti-CD3, anti-CD28 and anti-LFAl mAbs were combined with biotinylated 
cholera toxin B (CTB; Sigma) in a 3:1 molar ratio. After 5 min incubation, neutravidin (NA; 
Pierce Biotechnology, Rockford, IL) was added at a ratio of 1 mol per 4 biotinylated 
moieties for an additional 15 min. These reagents were then mixed with GM1-liposomes 
(kindly provided by Dompe Biotec Spa, L'Aquila, Italy) after the removal of detergent by 
dialysis for 72 hours against PBS in a 10K Slide A Lyzer (Pierce Biotechnology, Rockford IL). 
After mixing for 90 min incubation, the aAPC solution was spun in PBS at 14,000 rpm for 
10 min. The pellet containing the aAPC was resuspended in culture medium and used for T 
cell expansion. As controls, T cells were cultured in parallel in the presence of the liposome 
formulation (liposome alone) or biotinylated mAbs bound on NA rafts (MD alone) alone. To 
validate the efficacy of the association of the three mAbs on aAPC, initial experiments were 
performed using aAPC whose MDs contained only one (anti-CD3, or anti-CD28, or anti- 
LFAl) or two (anti-CD3 and anti-CD28, anti-CD28 and anti-LFAl, anti-CD3 and anti-LFAl) 
biotinylated mAbs. CFSE- (Invitrogen) stained PBMCs from healthy donors were stimulated 
with aAPC containing one of the following combinations of mAbs: anti-CD3/-CD28/-LFAl 
(hereafter named standard aAPC), anti-CD3/-CD28, anti-CD3/LFAl, anti-CD28/-LFAl, anti- 
CD3 alone, anti-CD28 alone, anti-LFAl alone. For each combination of mAb, aAPC were 
produced with two-fold serial dilutions (range 1/1 to 1/64) of the standard mAb 
concentration. CFSE dilution was assayed after 4, 7 and 10 days using a FACSCalibur flow 
cytometer and results were analysed with CellQuest software (Becton Dickinson). In 
addition, the T-cell expansion efficiencies of complete aAPC and those lacking anti-LFA-1 
mAb were tested in long-term cultures (14 and 28 days).
5.3.2 Human cells and culture conditions
Written informed consent was obtained from healthy donors and patients whose 
materials were used in this study after Institutional Review Board approval. Two sources 
of T cells were tested for the expansion: (i) CD3+ lymphocytes, negatively isolated from 
healthy donors' PBMCs, obtained by Ficoll-Hypaque density gradient separation of 
heparinised blood, which were prepared using a Pan T cell isolation kit and a MiniMACS 
device (Miltenyi Biotech), according to the manufacturer's protocol; and (ii) lymphocytes 
from HLA-A*0201 melanoma patients isolated from LN metastasis, which were cultured for 
2 weeks with HLA-A*0201+ T2 cell line loaded with 10 ^ig/ml of Melan-A/MART-1 27-35 
(modified sequence 27-35: ELAGIGILTV; PRIMM s.r.l.) as described (Anichini, Molla et al. 
1999). Lymphocytes from the melanoma-associated LNs were analysed for the frequency 
of MART-l-tetramer+CD8+ T cells before and at the end of culture.
T cells were seeded at a concentration of 0.2 x 106 cells/ml in a 96 flat-bottomed 
well plate with 2050 pl/well of RPMI 1640 (Lonza) containing 10% human serum, 1% 
PenStrep (Lonza), 1% Glutamine (Lonza) and 1% Hepes buffer (Lonza). A single 
stimulation with aAPC, or mouse anti-human CD3/CD28 mAb-coated immunomagnetic 
microbeads (Figure 5.1B, Dynabeads® CD3/CD28 T Cell Expander or Dynabeads® 
ClinExVivo CD3/28, Dynal Biotech ASA, Oslo, Norway), or purified mouse anti-human CD3
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mAb (0KT3 clone, eBioscience]-coated well plate (Figure 5.1C] was used to assess T-cell 
expansion. Anti-CD3 mAb was cross-linked to the well bottom of 96-flat bottomed well 
plates by 45 min incubation at a concentration of 0.5 ^g/ml in RPMI1640 (50 pl/well] after 
pre-coating the plate for an overnight with 10 ng/ml anti-mouse IgG (whole molecule, 
Sigma]. Before seeding the T cells, the cross-linking reaction was stopped by adding 20% 
human serum-supplemented RPMI 1640 (50 pl/well]. After stimulation with one of these 
systems, cultures were grown in the presence of the following combination of y-chain 
cytokines according to previous results (Anichini, Mortarini et al. 2006a]: (i] low dose (LD] 
recombinant human rhIL-2 (300UI/ml, Proleukin, Chiron, Emeryville, CA]; (ii] rhIL-15 (10 
ng/ml, Peprotech Inc., Rocky Hill, NJ]; (iii] high dose (HD] rhIL-2 (3,000 Ul/ml] plus rhlL- 
15 10 ng/ml. Complete culture medium with cytokines was replaced every 2 days during 
expansion. For some experiments, aAPC were generated with 1 or 2 log reduced 
concentrations of biotinylated mAbs and tested for the expansion of CD3+ purified T cells 
in comparison to the standard ones in association with HD IL-2 and IL-15. In addition, 
standard aAPC were used for the expansion of 10- (0.5 x 106 T cells/aAPC dose] or 100-fold 
(5 x 106 T cells/aAPC dose] increased starting cell number, in 1 or 4 ml culture medium per 
48- or 12-well plate well, respectively, in the presence of HD IL-2 plus IL-15. Complete 
culture medium with cytokines was replaced every 2 days during expansion.
5.3.3 Flow cytometry analysis
T-cell maturation and activation phenotypes were evaluated by flow cytometry 
using the following mouse anti-human mAbs in different combinations: FITC-labelled anti- 
CD3, PE-labelled anti-CD25 (Miltenyi Biotech], FITC-labelled anti-CD62L, FITC-labelled 
CD27, PE-labelled anti-CD45RA, PE- or PerCP-labelled anti-CD4, anti-CD69 and anti-CD3, 
APC-labelled anti-CD8 and anti-CD4 (BD Biosciences], and APC labelled anti-CCR7 (R&D 
systems, Minneapolis, MN, USA]. To detect antigen-specific T cells directed to Melan- 
A/MART-1, lymphocytes were stained with PE-labelled tetramers of HLA-A 0201 
containing Melan-A/MART-127-35 peptide (Beckman Coulter Inc., Fullerton, CA, USA]. 
Surface staining was performed by incubating the cells with the mAbs at 4°C for 30 min. 
Tregs were characterized by the expression of intracellular FOXP3 in association with the 
following mouse anti-human mAbs in different combinations: PE-labelled anti-CD25, 
PerCP-labelled anti-CD8 or anti-CD4, APC-labelled anti-CD4 or anti-OX40 (eBioscience] 
mAbs, as described in Chapter 2. APC-labelled anti-OX40 (eBioscience] and FITC-labelled 
anti-OX40L (Ansell] mAb co-staining was performed on human NHL cell lines listed in the 
Material and Methods section of Chapter 4 (paragraph 4.3.1], and in donors' PBMCs or 
normal reactive and malignant LNs in combination with the following mAbs: PE-labelled 
anti-CD19, -CD20 or -CD4, PerCP-labelled anti-CD45, -CD3 or -CD8 mAbs (BD Biosciences]. 
Apoptosis was assayed by staining with FITC-labelled annexin V (ANN V] and propidium 
iodide (PI] (rh Annexin V/FITC Kit, Bender MedSystem, Vienna, Austria], according to the 
manufacturer's protocol. To detect intracellular perforin or Granzyme B in T cells after 14 
days of stimulation with aAPC, microbeads or immobilized anti-CD3 mAb, expanded T cells 
were permeabilized with Cytofix/Cytoperm (BD Biosciences] and then stained with FITC- 
labelled mouse anti-human perforin (BD Biosciences] or PE-labelled mouse anti-human 
Granzyme B (CLB, Amsterdam, The Netherlands] in the presence of Perm/Wash solution 
(BD Biosciences]. The binding of aAPC on T cells was detected by staining with FITC- 
labelled goat anti-mouse IgG mAb (Jackson ImmunoResearch] at days 7 and 14 after 
stimulation. To assess the sensitivity of this assay, a fixed amount (5*104] of human CD3+ 
T cells were incubated with the indicated dilution of the anti-CD3, anti-CD28, and anti-LFA- 
1 mAb standard concentration used to prepare as many aAPC as required for the 
stimulation of such an amount of cells. The MFI obtained from the staining with the 
secondary Ab were then plotted against the known concentrations of anti-CD3, anti-CD28 
and anti-LFA-1 mAbs to obtain a titration curve. The amount of mAbs, and indirectly of
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aAPC, still present on T cells at days 7 and 14 after stimulation, were thus extrapolated for 
the experimentally derived MFI.
All stained samples were acquired on a FACSCalibur using the CellQuest software 
(Becton Dickinson). Data were subsequently analysed using Flowjo software.
5.3.4 Cytotoxic assay
The cytotoxic activity of expanded MART-1 specific T cells was assessed through 
51Cr-release assay using as target an HLA-A*0201+ lymphoblastoid cell line (LCL 9742) 
loaded with Melan-A/MART-127-35 peptide. Negative controls were represented by 
unloaded LCL or LCL loaded with Influenza A (Flu) Matrix58-66 (GILGFVFTL) or HIV 
(ILKEPVHGV) produced by PRIMM s.r.l.. Synthetic peptides were >95% pure (Anichini, 
Molla et al. 1999). Results were expressed as follows:
% Lysis = (experimental release (cpmj - spontaneous release (cpm ))/ (maximum release 
(cpm)  - spontaneous release (cpm))x 100
where spontaneous release was assessed by incubating target cells in the absence of 
effectors and maximum release was determined in the presence of 1% Nonidet P40 
detergent (BDH Biochemical, Poole, UK).
5.3.5 Purification of the CD4+CD25+ and CD4+CD25- T-cell subsests and the CFSE-
based proliferation assay
PBMCs isolated by Ficoll-Hypaque density gradient from donors' or lymphoma 
patients' heparinised PB or cell suspensions obtained from mechanic dissociation of 
malignant or reactive LN were used as source of CD4+CD25+ Tregs and CD4+CD25- 
effector T cells (Teffs). These subpopulations were purified using CD4+CD25+ Treg 
isolation kit (Miltenyi Biotec), according to manufacturer's instruction. Flow cytometry 
showed that the separate fractions were > 90% pure. For in-vitro assays, purified 
CD4+CD25- Teffs were labelled by incubation with 5 pM CFSE (Invitrogen) in PBS 
containing 5% FBS for 15 min at 37°C. Cells were washed twice with PBS and set up in a 
proliferation assay. To test Treg immunosuppressive activity, 10 or 5*104 CFSE-labelled 
CD4+CD25- Teffs were seeded, respectively, alone or with 5*104 CD4+CD25+ Tregs in each 
well of a 96-well flat-bottom plate in complete medium supplemented with 1 pg/ml PHA 
(Sigma), to stimulate Teff proliferation through TCR engagement. In some experiments, an 
anti-OX40 neutralizing mAb (ACT35, eBioscience) or human recombinant OX40L fusion 
protein (FcIlzOX40L, kindly provided by Dr Weinberg) was added at the indicated doses. 
To verify the ability of OX40L recombinant protein to promote human T-cell survival and 
proliferation, its activity was tested in a soluble assay as described by Morris and 
colleagues (Morris, Peters et al. 2007), with minor modifications. Briefly, CFSE-labelled 
Teffs were initially stimulated for 48 hours in the presence of 1 pg/ml PHA and 10 UI rhlL- 
2 to boost their expression of 0X40, then they were seeded in 96-well flat bottom plate, 
pre-coated with two-fold serial dilution of anti-CD3 mAb (OKT3, range 0.3-40 pg/ml), in 
the presence of 10 pg/ml FcIlzOX40L. After 48- and 72-hour incubation, T-cell proliferation 
and survival was monitored by flow cytometry analyses of, respectively, CFSE dilution and 
7-aminoactinomycin D staining (7-AAD, Invitrogen) performed at a concentration of 
1 pg/ml in 2% fetal bovine serum PBS for 20 min-incubation at 4°C.
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5.3.6 Statistical analysis
Statistical significance was determined using the two-sided Student's “ t ” test. 
Regression analysis was conducted on GraphPad Prism version 5 for Mac software 
(GraphPad Software, La Jolla, CA].
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5.4 Results
5.4.1 aAPC with pre-clustered anti-CD28/-CD3/-LFA-1 mAbs are highly effective in 
inducing the ex-vivo expansion of functional human anti-tumour T cells
5.4.1.1 Generation of aAPC and expansion of human polyclonal T cells
As shown in Figure 5.1A, aAPC consist of a scaffold made of GMl-enriched 
liposomes, with anchor MDs containing the agonist biotinylated mAb (anti-CD3, anti-CD28, 
and anti-LFAl) through a biotinylated CTB subunit and NA.
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Figure 5.1 Structures of artificial systems tested for T cell expansion.
(A) Representation of the MD structure carried by aAPC (adapted from Giannoni 2005]. The lipid bilayer was 
enriched with GM1 ganglioside to form a bridge with biotinylated cholera toxin B (CTB). In each MD, one 
molecule of neutravidin (NA) anchored biotinylated anti-CD3 and anti-CD28 and anti-hLFA-1 agonist mAbs to 
the aAPC surface through one biotinylated CTB. (B) Schematic representation of Dynabeads® CD3/CD28 T 
cell Expander. Anti-CD3 and -CD28 triggering mAbs on immunomagnetic beads can interact with and activate 
the cognate molecules on T cells. (C) Schematic representation of mouse anti-human CD3 mAb (OKT3 clone) 
cross-linked through anti-mouse IgG to the plate well bottom. The exposed anti-CD3 mAb Fab domains 
interact with TCRs and activate T cells.
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Purified polyclonal CD3+ T cells (mean purity 90±3%), when stimulated with aAPC 
containing all the three agonist mAbs, displayed a higher proliferation rate compared to 
those cultured in the presence of aAPC lacking anti-LFA-1 mAb, after both 14- and 28-day 
incubation (Figure 5.2).
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Figure 5.2 Long-term expansion experiments.
Comparison of T-cell expansion after 7,14 and 28 days from a single stimulation with complete aAPC or anti- 
CD28/-CD3 aAPC (w/o anti-LFAl aAPC) in the presence of HD IL-2 and IL-15. Fold increase values were 
calculated on the basis of the percentage of ANN V -/P I- viable cells detected by flow cytometry (*: p < 0.05; 
**: p < 0.01) and the absolute cell count obtained by the Tripan blue exclusion test..
For this reason, aAPC containing the mixture of all three mAb were used in the 
subsequent experiments. They were tested in association with LD IL-2, or IL-15 or HD IL-2 
plus IL-15 for the in-vitro expansion of human polyclonal CD3+ T cells. In parallel, T cells 
were cultured with liposomes or with MDs alone as controls. After 7 days of stimulation, 
the greatest efficiency was observed when complete aAPC were associated with any 
cytokine combination. However, after 2 weeks, aAPC stimulation with HD IL-2 plus IL-15 
resulted in the greatest fold increase in T cell number, which was significantly higher with 
respect to the other conditions (Figure 5.3).
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Figure 5.3 Activity of complete aAPC compared to their single components.
Fold increase in viable T-cell number measured by the Tripan blue exclusion test after 7 and 14 days of 
culture of freshly purified donors’ polyclonal CD3+ T cells stimulated with aAPC, MDs or liposomes in the 
presence of LD IL-2, or IL-15, or the combination of HD IL-2 and IL-15. Results are representative of four 
independent experiments with different donors. Error bars indicate standard deviation of the mean. 
Statistically significant differences, calculated using two-tailed Student t test, are reported (*: p< 0.05; ***: p< 
0.001).
MDs alone provided a positive stimulus for T-cell proliferation, since they consisted 
of the biotinylated activating mAbs grouped on NA. However, placing them into a lipid 
membrane allowed their activity to be efficiently oriented, increasing the final stimulus for 
T-cell expansion. Liposomes alone did not provide any positive stimulations for T-cell 
expansion (Figure 5.3).
5.4.1.2 Survival of human polyclonal T cells after stimulation with aAPC
The activity of aAPC was then compared with that provided by the other 
commercially available artificial systems for T-cell expansion (anti-CD3 and -CD28 mAb- 
coated immunomagnetic microbeads, Dynabeads® CD3/CD28 T Cell Expander and 
immobilized anti-CD3 mAb, clone OKT3). Freshly purified donors' polyclonal CD3+ T cells 
were stimulated with one of these systems and expanded in the presence of IL-2 and/or IL- 
15. After 2 weeks of incubation, microbeads and aAPC in combination with HD IL-2 plus IL- 
15 provided the greatest T cell expansion efficacy (Figure 5.4A).
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Figure 5.4 Activity of aAPC compared to commercial artificial systems.
(A) Fold increase in donors' polyclonal CD3+ T-cell number after stimulation with aAPC, immobilized anti- 
CD3 mAb or anti-CD3/-CD28 microbeads in the presence of LD IL-2, or IL-15, or the combination of HD IL-2 
and IL-15. Viable cell counts were assessed using the Tripan blue exclusion test after 7 (d7) and 14 (dl4) 
days of culture. Results are representative of four experiments with different donors. Error bars indicate the 
standard deviation of the mean. (B) Representative flow cytometry analysis of apoptosis of the same cultures 
shown in A after 14-day expansion. FITC-labelled ANN-V [x-axis] and PI (y-axis). In each plot the frequency of 
total dead cells is reported (C) Fold increase in viable ANN-V-/PI- T-cell number after 14-day expansion with 
aAPC or anti-CD3/-CD28 microbeads in the presence of LD IL-2, or IL-15, or the combination of HD IL-2 and 
IL-15. Error bars indicate the standard deviation of the mean, p values were calculated using the two-tailed 
Student's ttest (*: p < 0.05;***: p < 0.001).
However, flow cytometry analysis of apoptosis revealed a significant increase of cell 
death in cultures stimulated for 14 days with microbeads or OKT3 in the presence of any 
cytokine combinations tested (Figure 5.4B). In the bead-stimulated culture, only 46% of T 
cells expanded with IL-2 and 11-15 were viable (ANN V-PI-), whereas 83% of T cells were 
still alive 14 days after the stimulation with aAPC. Accordingly, this system provided a 
significantly greater expansion of viable ANN V-PI- T cells compared to that afforded by the 
other artificial systems (Figure 5.4C). As a further control, anti-CD3/-CD28 microbeads 
were compared to aAPC lacking anti-LFA-1 mAb, to evaluate the T-cell expansion efficacy 
of the two systems, when the triggered molecules on T cells were the same. Even in these 
conditions, aAPC were able to expand a higher amount of T cells without affecting their 
viability (Figure 5.5).
130
standard aAPC
U5
■§ w/o anti-LFA1 aAPC 
—^ 
Beads
standard aAPC
to .......—.... —---   —
Jg w/o anti-LFA1 aAPC
Beads
100
Fold Increase
200
Figure 5.5 Anti-CD28/-CD3 aAPC vs. anti-CD28/-CD3 microbead T cell expansion.
Expansion efficiencies of the polyclonal CD3+ T cells of donors achieved by a single stimulation with complete 
aAPC, anti-CD28/-CD3 aAPC [w/o anti-LFAl aAPC) or anti-CD28/-CD3 microbeads in the presence of HD IL-2 
and IL-15 for 14 days of culture. Fold increase values were calculated on the basis of the percentage of viable 
ANN V -/P I- T cells, as detected by flow cytometry analysis of apoptosis, and the absolute cell count obtained 
with the Tripan blue exclusion test [*: p<0.05; **:p<0.01; *** p<0.001).
These results demonstrated the stimulation advantages provided by an artificial 
system based on a fluid membrane to carry triggering molecules for the activation of the 
cognate ligands on T cells. In addition, including anti-LFA-1 mAb amongst the stimulating 
moieties on the aAPC allowed for a further increase of T-cell expansion activity [Figure 5.5).
5.4.1.3 Immunophenotype of expanded polyclonal T cells
The immunophenotypic analysis, carried on after 14-day expansion, interestingly 
revealed an inverse ability of aAPC compared to microbeads to expand CD8+ and CD4+ T 
cells [Figure 5.6A), with aAPC preferentially increasing the frequency of the former in 
culture. In contrast to adherent anti-CD3 mAb stimulation, these systems provided 
comparable high levels of naive and effector cell enrichment in both T cell subpopulations, 
with beads favouring a significantly higher expansion of CD45RA and CD62L double­
positive T cells [Figure 5.6A-B).
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Figure 5.6 Phenotypic characteristics of polyclonal human T cells expanded with aAPC or other 
artificial systems.
After 14-day expansion in the presence of aAPC, microbeads or adherent anti-CD3 mAb plus HD IL-2 and IL- 
15, the maturation status of T cells was assessed by flow cytometry. (A) CD4+ and CD8+ T-cell frequencies 
are shown together with the frequencies of CD45RA+CD62L+, CD69+ and F0XP3+ cells in the two T-cell 
subsets. Results are representative of four independent experiments with different donors. Error bars 
indicate the standard deviation of the mean. Statistical analyses were performed using the two-tailed 
Student's t test (*: p < 0.05;**: p < 0.01; ***: p < 0.001). (B) A representative example of the T-cell 
immunophenotype after 14-day expansion with aAPC stimulation and HD IL-2 plus IL-15. Multiparametric 
FACS analysis was performed on CD4+ (CD4) and CD8+ (CD8) versus side scatter-gated cell populations. (C) 
Detailed analysis of maturation status of T cells expanded in the presence of aAPC or micreobeads. T cm and 
naive T cells were defined, respectively, as the CD62L+CD45RA- and CD62L+CD45RA+ cell subsets in the 
CCR7+ gated population. T em and effector T cells were defined, respectively, as the CD62L-CD45RA- and 
CD62L-CD45RA+ cell subsets in the CCR7- gated population. The average values of three independent 
experiments and their standard deviations are reported (**: p < 0.01).
However, when CCR7 and CD27 expression was included in the analysis, aAPC 
showed a trend towards the preservation of an even higher immature phenotype (CCR7+ 
and CD27+) in stimulated CD4+ and CD8+ T cells, compared to microbeads (Figure 5.6C). 
In all experimental conditions, a large fraction of T cells showed a phenotype compatible 
with a highly activated status due to TCR engagement, as demonstrated by the wide 
expression of CD69 (Figure 5.6A-B).
Furthermore, amongst the artificial systems tested, aAPC determined the lowest up- 
regulation of Granzyme B expression (Figure 5.7A, left) and induced the lowest level of 
perforin (Figure 5.7A, right) in expanded CD8+ or CD4+ T cells. The reduced differentiating 
properties of aAPC were confirmed even at the analysis of the expression of perforin and 
Granzyme B in the CCR7+ and CCR7- subpopulations in both CD4+ and CD8+ cell subsets 
(Figure 5.7B). These observations suggest that T cells expanded in the presence of aAPC 
might exert a cytolytic function, since they express Granzyme B, but they require further 
activation, due to the limited induction of perforin. This phenotype is consistent with the 
high expression of CD62L and with the increased survival of T cells expanded with artificial 
APC. The concurrent adoptive transfer of naive and activated cells, such as those derived by
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aAPC stimulation, might be advantageous, since the expression of the homing adhesion 
molecule CD62L on the former should make them capable of trafficking through LN and 
becoming activated, whilst CD69+ and Granzyme B+ T cells could exert immediate effector 
functions.
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Figure 5.7 Flow cytometry analysis of Granzyme B and perforin expression in expanded T cells.
After 14-day expansion in the presence of aAPC, microbeads or adherent anti-CD3 mAb, the expression of 
Granzyme B and perforin was assessed by flow cytometry. (A) Histogram plot representation of intracellular 
expression of Granzyme B (left) and perforin (right) in CD3+CD8+ - (top), and CD3+CD4+ -gated T cells 
(bottom) stimulated in the presence of the indicated cytokines. (B) Histogram representation of Granzyme B 
(right) and perforin (left) expression in CCR7+ (top) or CCR7- (bottom) T cells from cultures expanded in the 
presence of HD 11-2 and IL-15 gated as CD3+CD8+ (CD8) and CD3+CD4+ (CD4). The MFI values of Granzyme B 
and perforin expression are reported in each plot.
Immunopheenotypic analysis of T cells after long-term expansion with aAPC 
showed a decrease of CD62L+ cell frequency and the parallel increase of CD45RA+CD62L- 
CCR7- effector cells with respect to the more shortly stimulated cultures (Table 5.1). In 
agreement with these results, after 27-day expansion, T cells down-regulated also CD25 
expression, indicating the exhaustion of T cell activation (Table 5.1).
Similar results were obtained for microbead- or adherent anti-CD3 mAb-stimulated 
T cells (data not shown). Collectively, these observations suggested that 2 weeks of culture
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was the optimal time window to expand a large amount of T cells with suitable 
immunophenotypic characteristics for adoptive immunotherapy.
Table 5.1 Immunophenotypic analyses of T cells expanded with complete aAPC or aAPC lacking anti-
LFA-1 mAb._______________________________________________________________________
Freshly
FACS analyses 'cd? T *  aAPC stimulated CD3+ T cells
cells
+14 days +27 days
+ anti-LFA-1 - anti-LFA- + anti-LFA- - anti-LFA- 
mAb 1 mAh 1 mAh 1 mAb
CD4 CD4 43.57 26.42 25.89 9.18 6.99
CD62L+ 70.27 88.53 88.43 78.54 77.09
CCR7+ 60.09 31.37 15.89 28.71 18.01
CCR7+CD45RA+CD62L+ 72.38 24.90 13.30 23.17 16.03
CCR7-CD45RA+CD62L- 10.51 5.08 6.30 13.40 15.27
CD69+ 0.45 10.47 7.82 6.72 4.67
CD27+ 89.49 84.14 80.69 86.75 81.15
CD25+ 7.96 46.65 41.75 16.00 15.69
CD25-FOXP3+ 0.62 0.41 0.35 1.58 2.17
CD25+FOXP3+ 2.40 1.10 0.65 0.78 0.69
CD8 CD8 20.81 58.85 58.06 75.98 80.78
CD62L+ 51.99 77.82 74.22 53.87 47.44
CCR7+ 41.27 17.69 8.56 28.24 11.22
CCR7+CD45RA+CD62L+ 75.60 15.60 6.90 20.45 8.98
CCR7-CD45RA+CD62L- 50.13 18.65 22.57 37.35 48.34
CD69+ 1.14 7.99 24.68 29.66 31.23
CD27+ 77.14 85.04 71.11 79.31 70.41
CD25+ 0.66 23.15 13.67 2.52 1.96
CD25-FOXP3+ 0.13 1.97 1.42 1.49 3.40
CD25+FOXP3+ 0.21 1.04 0.52 0.26 0.48
Finally, the possibility to concurrently expand Tregs in culture after stimulation 
with the different artificial systems was evaluated. After 2-week expansion by aAPC, the 
frequencies of CD4+F0XP3+ and CD8+FOXP3+ T cell subsets were significantly lower 
compared to those induced by microbead- or adherent anti-CD3 mAb-stimulation (Figure 
5.6 A-B). When Tregs were analysed, both CD25+ and CD25- F0XP3+ T cells were 
considered, given the recent evidence that F0XP3 expression can be found independently 
of CD25 (Walker, Kasprowicz et al. 2003).
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5.4.1.4 Specific T-cell expansion with aAPC
Since aAPC were demonstrated to rapidly activate and expand polyclonal T 
lymphocytes, the possibility to efficiently also expand specific CTLs with this system was 
investigated. Lymphocytes from tumour-invaded LN of HLA-A*0201+ melanoma patients 
were activated in culture with the MART-1 peptide-loaded HLA-A*0201+ TAP-deficient T2 
cell line. After 2 weeks of specific stimulation, the resulting T cell lines were expanded for 2 
more weeks in the presence of the cognate antigen or standard aAPC, immobilized anti- 
CD3 mAb, or anti-CD3/-CD28 microbeads plus HD IL-2 and IL-15. The stimulation with the 
cognate antigen exhibited a limited expansion efficacy (Figure 5.8A] whilst maintaining a 
high percentage of MART-1 tetramer+ CD8+ T cells (73.5%]. The highest efficiency in T-cell 
expansion was obtained using aAPC (Figure 5.8A], which also preserved T-cell viability 
better than did either microbeads or anti-CD3 mAb (Figure 5.8B].
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Figure 5.8 Expansion of anti-MART-1 human T lymphocytes.
(A) After 7 and 14 days of stimulation with anti-CD3/-CD28 microbeads or immobilized anti-CD3 mAb or 
aAPC in the presence of HD IL-2 and IL-15, MART-1 specific CD8+ T-cell cultures were counted using the 
Tripan blue exclusion test to measure their proliferation rate. X-axis, days in culture; y-axis, fold increase in 
cell number. (B) Representative flow cytometry analyses of apoptosis after 14-day expansion with aAPC (left), 
adherent anti-CD3 mAb (middle) or microbeads (right). X-axis: FITC-labelled ANN V; y-axis: PI. (C) 
Cytotoxicity of anti-MART-1 T-cell cultures after 14-day stimulation with aAPC or anti-CD3/-CD28 
microbeads or immobilized anti-CD3 plus HD IL-2 and IL-15, or with MART-1 loaded T2 cell line (T2-MART- 
1) analysed by 51Cr release assay using as target cells LCL pulsed with the specific MART-1 peptide. Specific 
lysis is shown as percentage of the unrelated lysis when target cells were unloaded or loaded with the 
unrelated Flu or HIV peptides. Results are representative of three independent experiments. Error bars 
indicate the standard deviation of the mean. Statistical analyses were performed using Student t test (*: p < 
0.05). (D) Representative example of immunophenotype of anti-MART-1 T cell after 14-day expansion with 
aAPC. Flow cytometry analyses were performed on CD4+CD3+, CD4-CD3+ (CD8+ cells) and MART-1+CD4- 
CD3+ gated cell subpopulations. The expression of CD62L versus CD45RA, CD69 and of FOXP3 was evaluated 
to define, respectively, the maturation and activation level and Treg frequency in expanded cultures.
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In addition, anti-MART-1 CD8+ T-cell cultures stimulated with aAPC showed an 
enhanced specific cytotoxic activity compared to microbead- or anti-CD3 mAb-stimulated T 
cells (Figure 5.8C}. The greater ability of aAPC compared to microbeads to support CD8+ T- 
cell expansion in the polyclonal setting might partly explain the observed increased 
efficacy of aAPC to expand specific CD8+ T-cell cultures with high specific cytotoxicity 
(Figure 5.8C}.
Immunophenotypic analysis of MART-1 T cell cultures expanded with aAPC 
revealed that both CD8+ and CD4+ T cells still expressed a relatively high levels of the LN 
homing molecule CD62L, whilst displaying a broad CD69 positivity. These results indicate 
that the stimulation provided by aAPC is able to activate specific CTL as efficiently as 
polyclonal T cells (Figure 5.8D}. In agreement with previous findings, the frequency of 
FOXP3+ T cells did not increase either in total CD8+, anti-MART-1 CD8+, or in CD4+ T cell 
subsets after 14 days of culture with aAPC (Figure 5.8D}.
The comparison of the maturation status of MART-1 specific T-cell cultures before 
and after 2-week stimulation with aAPC or microbeads, showed the maintenance of an 
effector memory phenotype of T cells induced by the previous TCR stimulation with the 
cognate antigen (Figure 5.9, bottom vs. top}. Interestingly, aAPC-expanded T cell cultures 
showed a higher frequency of MART-1 specific CD8+ T cells as compared to the microbead- 
expanded cultures (Figure 5.9, bottom left vs. right}.
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Figure 5.9 Immunophenotype of aAPC-expanded MART-1-specific T cells.
T cells isolated from melanoma infiltrating LNs were cultured for 2 weeks in the presence of MART-l-loaded 
T2 cells (TALs). The frequency of MART-l-specific T cells was then detected using MART-1 tetramers (MART- 
1-tet} and revealed by flow cytometry in the CD3+CD4- gated T-cell subset (top left). The maturation status 
of these cells was evaluated by flow cytometry analysis of CCR7 and CD45RA expression in the CD3+CD4- 
MART-l-tet+-gated T cell subset (top right). The same parameters were assessed after additional 2 weeks of 
aAPC (bottom left) or microbead (bottom right) stimulation in the presence of HD IL-2 and IL-15.
5.4.1.5 Optimization ofaAPC-based system for T cell expansion
In order to verify the feasibility of the procedure in the light of large-scale clinical 
application, several experiments were performed. First, the results obtained by comparing 
aAPC with anti-CD3/-CD28 microbeads for research use were corroborated by a further 
comparison with the clinical grade ones (Dynabeads® ClinExVivo CD3/CD28}.
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Figure 5.10 T-cell expansion efficiency of anti-CD28/-CD3 microbeads developed for research and clinical use.
Fold increase in ANN V-/PI- viable T cell number calculated on the basis of the flow cytometry analysis of apoptosis and 
the Trian blu exclusion test performed on polyclonal T-cell cultures after 7 and 14 days from a single stimulation with the 
anti-CD28/-CD3 microbeads for research (Dynabeads® CD3/CD28 T Cell Expander] or clinical use (Dynabeads® 
ClinExVivo CD3/CD28], in the presence of HD IL-2 and IL-15.
The stimulation with the research and the clinical version of anti-CD3/CD28 
microbeads provided comparable T-cell expansion, definitely proving the advantages of 
aAPC over this system (Figure 5.10). In order to evaluate the possibility of using aAPC in 
compliance with GMP requirements, the persistence of aAPC components in expanded 
cultures was assessed by flow cytometry, after both 7 and 14 days from stimulation. To this 
aim, a regression line was derived to evaluate the sensitivity of mouse mAb detection on a 
fixed T-cell number (5xl04) on the basis of MFI values using a FITC-labelled anti-mouse IgG 
Ab (Figure 5.11A). Using this assay, the amount of mouse anti-human mAbs of aAPC MDs 
that still interact with T cells after 7 or 14 days of culture could be thus extrapolated 
(Figure 5.1 IB). Both these values (0.08 and 0.04 pmol found at days 7 and 14, respectively, 
Figure 5.11A) were at the lowest left end of the regression line, indicating a reduction of 
more than two logs in mouse mAb concentration on human T cells compared to the 
starting amount (represented by the highest value on the right of the titration curve).
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Figure 5.11 Persistence of aAPC in T-cell cultures.
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(A) Regression line obtained by plotting MFI values (y-axis) of T cells pre-incubated with decreasing 
concentrations (x-axis) of anti-CD3, anti-CD28, anti-LFA-1 mAb and stained with the proper secondary FITC- 
labelled Ab. Regression analysis of the data yielded a linear relationship between 0.1 and 10 pmol (described 
by the indicated equation). (B) Flow cytometry analysis of aAPC persistence after 7- (dotted line) and 14-day 
(black line) expansion. Unstimulated T cells stained with FITC-labelled anti-mouse IgG (grey filled histogram) 
were used as a control. MFI revealed at days 7 and 14 of culture are shown in A on the titration curve as grey 
dots.
Finally, two alternative strategies were investigated to reduce the cost of aAPC 
generation for large-scale application, whilst at the same time preserving their T-cell 
expansion efficiency. Initially the concentration of mAbs per aAPC was decreased by 1 or 2 
logs. However, these aAPC were less efficient than the standard ones in expanding T cells 
when the APC/T-cell ratio was unchanged (Figure 5.12). The observed activity loss might 
most likely be derived from the reduced probability to obtain MDs that were completely 
saturated with biotionylated mAb after this modification. Therefore, the possibility of 
decreasing the aAPC/T-cell ratio for T-cell expansion was investigated. Remarkably, an 
efficient T-cell expansion was achieved when the aAPC/T-cell ratio was reduced by 1 or 2 
logs (i.e. by keeping the amount of aAPC constant and increasing the starting T cell number 
by 10-100 fold, Figure 5.12A). Unexpectedly, an increase of 10 fold of the T-cell numbers 
per aAPC boosted T-cell proliferation even more than the standard condition (Figure 
5.12A). This suggested that the strength of T-cell stimulation is critical for the overall 
expansion yield and indicates the potential advantages of this system for the stimulation of 
large-scale cultures in which T cells may amplify the potent aAPC stimulation through 
direct interactions and/or the release of soluble mediators.
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Figure 5.12 Optimization of aAPC protocol for T-cell expansion.
(A) Fold increase in T-cell number after stimulation with standard aAPC, aAPC with 1- (1/10 mAbs on aAPC) 
or 2-log (1/100 mAbs on aAPC) lower mAb concentration, or with 1 (10X T cells/aAPC) or 2-log (100X T 
cells/aAPC) reduced aAPC/T-cell ratio in culture. Freshly isolated polyclonal CD3+ T cells were stimulated 
under these conditions in the presence of HD IL-2 plus IL-15. Cell counts were assessed using the Tripan blue 
exclusion test on days 7 and 14 after stimulation. Results are representative of three independent 
experiments with different donors. Error bars indicate the standard deviations of the mean (***: p <0.001).
(B) Representative example of CD45RA and CD62L expression after 14-day stimulation in the presence of 1 
or 2-log reduced aAPC/T-cell ratio in cultures. (C) Estimation of the amount of aAPC and the culture volumes 
required for the expansion of lxlO 10 cells (target T cell number) using different aAPC/ T cell ratios.
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In these expansion conditions, the potential capability of in-vivo persistence, based 
on CD62L expression, was preserved (Figure 5.12B}. In addition, using a 1- or 2-log 
decreased aAPC dose/ T cell ratio, 10 billion anti-tumour T cells could be generated in a 
reduced volume with a limited cost, making this procedure suitable for clinical application 
(Figure 5.12C}.
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5.4.2 Functional role of 0X40 expression in lymphoma microenvironment: towards 
0X40 agonist-based anticancer immunotherapy
5.4.2.1 0X40 expression and immunosuppressive function of Treg infiltrating indolent 
NHL
As shown in Chapters 2 and 3, the modulation of Treg frequency in the PB and at the 
tumour site of vaccinated patients with indolent NHL played a crucial role in dictating 
patients' outcome. Given the recent findings suggest an important involvement of 0X40 
signalling in the control of tolerance induced by Tregs in preclinical models [Valzasina, 
Guiducci et al. 2005; Piconese, Valzasina et al. 2008; Colombo and Piconese 2007), 0X40 
expression on human Tregs as well as its functional role in the indolent NHL 
microenvironment was investigated. Previous results described in Chapter 2 (Paragraph 
2.4.3.1) demonstrated a progressive increase in CD4+CD25+FOXP3+ Treg frequency from 
PB towards the tumour sites in NHL patients. Interestingly, 0X40 was more widely 
expressed on PB Tregs from lymphoma patients compared to healthy donors, and its 
expression was even more up-regulated on tumour-infiltrating Tregs (Figure 5.13 A-B).
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(A) Flow cytometry analysis of 0X40+ Treg frequency in healthy donor (HD) PB or in PB and malignant LN 
from patients with B-NHL. (B) Representative examples of 0X40 expression in CD4+CD25+FOXP3+ -gated 
cells in donors' (left), NHL patients' PB (middle) or malignant LN (right). *: p<0.05; **: ***: p<0.001.
To verify that the phenotypically identified CD4+CD25+FOXP3+ T cells were truly 
Tregs, their ability to suppress the proliferation of CD4+CD25- Teffs stimulated with PHA 
was tested in vitro using a standard proliferation assay. CD4+CD25+ Tregs and CD4+CD25- 
Teffs were purified from tumour cell suspensions obtained from pathologic LN. As shown 
in Figure 5.14, after a 5-day incubation with PHA, CFSE-labelled Teffs were highly 
proliferating, with five generations being observed (top left). Ninety-four percent of these 
cells expressed 0X40 (top right). When Tregs were added in culture, the Teffs failed to 
respond to PHA stimulation (Figure 5.14, bottom left), even though they could still up- 
regulate 0X40 expression (Figure 5.14, bottom right). Interestingly, the CFSE- Tregs 
became fully OX40-positive upon PHA stimulation (Figure 5.14, bottom right). These 
results indicate that a positive TCR stimulation might be responsible for the induction of 
0X40 expression in either of the T-cell subsets, which in turn can be associated with 
proliferation in case of Teffs or the immunesuppressive activity in case of Tregs.
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Figure 5.14 Immunosuppressive activity of Tregs infiltrating NHL lesions.
CFSE-labelled CD4+CD251ow/- Teffs were purified from primary NHL biopsies and cultured in the presence 
of PHA alone (top) or with CD4+CD25high Tregs (bottom) isolated from the same tumour at the indicated 
ratio. A representative flow cytometry analysis of CFSE dilution in Teffs (left) as well as 0X40 expression 
(right) in CFSE+ Teffs and CFSE- Tregs after 5-day stimulation with PHA is shown. MFI of 0X40 staining is 
reported in the dot plots.
0X40 expression was then studied in the Tregs of patients before and after 
vaccination. Interestingly, in Rs, the reduction of Treg frequency in both PB and LN was
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paralleled by their down-modulation of 0X40 expression (Figure 5.15 top left and bottom, 
for representative examples). In case of disease reactivation, Tregs that reappeared in the 
pathologic LN showed a concurrent up-regulation of 0X40 expression (Figure 5.15 bottom). 
In NRs no significant modulations of either 0X40+ Tregs or 0X40+ Teffs were detected 
after vaccination (Figure 5.15 top right, for a representative example). These observations 
suggest that a clinical response may be favoured by the reduction and/or inactivation of 
immunosuppressive cells after vaccination.
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Figure 5.15 0X40 expression in Tregs and Teffs before and after vaccination.
Flow cytometry analysis of CD25 vs. F0XP3 expression in CD4+ -gated T cells and of 0X40 vs. F0XP3 in 
CD4+CD25+ -gated T cells in pre- and post-vaccine PB samples of one CR and one NR and LN biopsies of one 
PR harvested before vaccination, at time of response (6 month post) and after disease progression (10 
months post).
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5A.2.2 0X40functional role in NHL microenvironment
The modulation of 0X40 expression on T cells according to their activation status 
and the reduction of Tregs together with their down-regulation of 0X40 in Rs after DC- 
vaccination led to the investigation concerning the functional role of 0X40 on these cells in 
the lymphoma microenvironment.
Given the recent finding that 0X40 triggering on murine Tregs by an agonist Ab can 
inhibit their immunosuppressive activity [Valzasina, Guiducci et al. 2005; Piconese, 
Valzasina et al. 2008; Colombo and Piconese 2007), the possibility that human Tregs could 
be inactivate through 0X40 stimulation was investigated as an alternative way to exploit 
OX40-OX40L pathway for anticancer purposes. If true, the resultant dual effects of 
inhibiting Treg and enhancing Teff functions upon 0X40 triggering would be expected to 
drive the re-balancing of tumour immune-surveillance towards a therapeutic effect. 
Unfortunately, the lack of commercially available agonist anti-OX40 Abs has greatly 
hampered this study. The use of a trimeric OX40L recombinant protein, whilst confirming 
to stimulate survival and proliferation of human Teffs [Figure 5.16 A), determined only a 
modest inhibition of Treg-mediated suppression of Teff proliferation in standard CFSE 
proliferation assays [Fig. 5.16 B).
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Figure 5.16 Effects of 0X40 triggering on Teffs and Tregs by recombinant human OX40L fusion 
protein.
CD4+CD251ow/- Teffs and CD4+CD25high Tregs were purified from PBMC or lymphoma biopsies and used in 
standard proliferation assay. (A) PHA pre-activated donors' Teffs were labelled with CFSE and cultured with 
escalating dose of immobilized anti-human CD3 mAb (0KT3 clone) in the presence (filled circles) or not 
(empty circles) of lOpg/ml soluble recombinant human OX40L fusion protein. After 4 days, flow cytometry 
analyses of CFSE dilution and 7-AAD staining were performed to evaluate, respectively, proliferation (left) 
and cell-death (right) in cultures. (B) CFSE-labelled Teffs purified from lymphoma cell suspension were 
cultured alone (i) or with autologous Tregs (ii) in the presence of PHA. After 24 hours, OX40L recombinant 
fusion protein was added at the indicated concentration. Teff proliferation was monitored by flow cytometry 
analysis of CFSE dilution in CFSE+-gated cells.
Therefore, the study was directed towards the analysis of the potential function of 
0X40 and OX40L expression in the lymphoma microenvironment. The modulation of these 
antigens was thus investigated in B- and T-cell subsets within the cell suspensions obtained 
from normal reactive and malignant LN, before and after stimulation with PHA. 
Remarkably, upon activation, not only T cells, but also CD19+ B cells, up-regulated both 
0X40 and OX40L expression (Figure 5.17 Ai and Bi). These effects were even stronger in 
the pathologic compared to the reactive LNs (Figure 5.17 Bi vs. Ai), suggesting that 0X40 
and OX40L up-regulation on lymphoma cells, as a consequence of TIL activation, may 
provide pro-survival signals through the co-stimulation of these molecules on tumour cells.
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Figure 5.17 OX40-OX40L co-stimulation in the lymphoma microenvironment.
Normal reactive (A) and malignant (B) LN cell suspension were labelled with CFSE and cultured in the 
presence of 1 pg/ml PHA. Before (i, top) and after 4-day (i, bottom) stimulation, 0X40 and OX40L expression 
was evaluated by flow cytometry in CD19+-, CD4+- and CD8+-gated cell subpopulations. Flow cytometry 
analysis of CFSE dilution (ii) was performed after 4-day culture in the presence (filled grey histogram) or not 
(black line histogram) of 5pg/ml soluble anti-OX40 neutralizing mAb.
Accordingly, the addition of an 0X40 neutralizing mAb impaired PHA-induced 
proliferation in all cell subsets analysed in both normal and malignant LN, including B cells 
(Figure 5.17 Aii and Bii, respectively). This finding led to the analysis of 0X40 and OX40L 
expression on B-lymphoma cells. A panel of human B-NHL cell lines was studied by flow
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cytometry. PBMCs pooled from 6 healthy donors were analysed in parallel as control. 
Whilst OX40L was not significantly detected in any samples analysed, 30 to 75% of cells in 
NHL cell line cultures expressed 0X40 [Figure 5.18A). Interestingly, compared to normal B 
cells, NHL cell lines showed higher level of 0X40 expression, as revealed by the comparison 
of the MFI values [Figure 5.18B).
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Figure 5.18 Analysis of 0X40 and OX40L expression in NHL cell lines and donors' PBMCs.
[A] Flow cytometry analysis of OX40L and 0X40 in CD20+ -gated cell subset of pooled PBMCs from 6 healthy 
donors [HD PBMCs), or the following NHL cell lines: DOHH-2, SC-1, KARPAS-422, SU-DHL-4, NAMALWA, RAJI, 
GRANTA-519. Cell frequency in the OX40L [x-axis) vs. 0X40 [y-axis) subsets are showed in each plot (B) 
Histogram plot of 0X40 expression in the same samples showed in A. Relative 0X40 MFI value obtained by 
the ratio between stained [black line) vs. isotype control [filled grey) MFI is indicated for each plot.
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5.5 Discussion
The Chapter describes the findings obtained from the study of a novel aAPC-based 
system for the polyclonal expansion of T cells for ACT and the functional role of 0X40 co­
stimulation in the lymphoma microenvironment. These represent two different ways to 
enhance, respectively, the afferent and the effector phases of an anti-tumour immune 
response in combinatorial immunotherapeutic approaches.
Results of T-cell stimulation through aAPC (produced by preclustering anti-CD3, - 
CD28 and -LFA-1 mAbs on liposome structures to resemble the physiological lip id rafts of 
APC plasma membranes) were as follows: (i) the generation of large amounts of T cells 
starting from polyclonal CD3+ T lymphocytes (ii) that displayed the highest cell viability in 
culture compared to the other commercial artificial systems, and (iii) a naive or effector 
phenotype, (iv) w ithout showing the increase of CD25highFOXP3+ Treg frequency; (v) the 
expansion of functionally competent anti-MART-1 CD8+ T cells; and (vi) the feasibility to 
apply this system large-scale settings.
Recent reports have indicated that pre-clustering MHC-peptide complexes in MDs on 
artificial lip id membrane positively affects the efficiency of immune synapse formation and 
the ensuing T-cell activation (Anderson, Hiltbold et al. 2000; Vogt, Spindeldreher et al. 
2002). Building upon these data, the liposome-based aAPC previously described by Albani 
and colleagues (Prakken, Wauben et al. 2000; Giannoni, Barnett et al. 2005), were modified 
by changing the MD constitution through the replacement of the HLA-peptide complex w ith 
an anti-CD3 mAb, combined w ith the addition of an anti-LFA-1 mAb, thus permitting a 
more efficient stabilization of aAPC-T cell interactions. These modifications allowed for the 
generation of novel aAPC capable to efficiently stimulate and expand T cells irrespective to 
their antigen specificity. Given the crucial role of CD4+ T-cell helper functions for 
adoptively transferred CTL activity and their in-vivo persistence, and the advantages of 
polyclonal, over tumour-antigen specific, CD8+ T cells for ACT (Antony, Piccirillo, et al. 
2005; Corthay, Skovseth et al. 2005; Perez-Diez, Joncker et al. 2007; Hunder, Wallen et al.
2008), most artificial systems have been developed to express only the relevant molecules 
for an aspecific T cell stimulation. Although several artificial system have been produced 
(Maus, Thomas, et al. 2002) (Oelke and Schneck 2004; Derdak, Kueng et al. 2006; Suhoski, 
Golovina et al. 2007), only anti-CD3/-CD28 mAb immunomagnetic microbeads (Laport, 
Levine et al. 2003; Thompson, Figlin et al. 2003) and the stimulation w ith anti-CD3 mAb 
immobilized on culture plates have been generated under GMP requirements for clinical 
use. Compared to the original methods, based on the use of natural APC (nAPC), such as 
DCs or virally infected B cells, these technologies have been shown to expand larger 
numbers of T cells in a reduced time w ith the advantage that they are produced following 
standard protocols, and thus display reproducible immunostimulatory functions. However, 
compared to these artificial systems, liposome-based aAPC have additional advantages of 
including, amongst T-cell triggering molecules, an anti-LFA-1 mAb, which provide signals 
that physiologically are mediated by one of the most relevant adhesion molecules (ICAM-1), 
and a fluid membrane rather than a rigid scaffold, which allows MDs to freely cluster and 
orient towards T cells for the immunological synapse formation. Remarkably, after 2 weeks 
of stimulation in the presence of IL-2 and IL-15, T cells expanded w ith  aAPC showed 
significantly lower levels of apoptosis and/or necrosis compared to those cultured w ith 
microbeads or an adherent anti-CD3 mAb. This result is of great relevance for the practical 
development of aAPC-based adoptive immunotherapy protocols. Furthermore, in contrast 
to microbeads and the adherent anti-CD3 mAb system, which boosted T-cell expansion 
towards exhaustion (as indicated by the high levels of cell-death in culture), T cells 
generated after aAPC stimulation were, in part, acutely activated (becoming CD69+) to 
exert immediate effector functions. They also, in part, expressed the specific homing 
molecules CD62L and CCR7, thus retaining the potential to traffic through the LNs, be re­
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stimulated in-vivo and thus persist in the memory compartment (Gattinoni, Klebanoff et al. 
2005]. Potential explanations for these results include the ability of aAPC-mediated TCR 
triggering to expand naive T cells, and to induce, in the presence of y-chain cytokines, 
central and effector memory T-cell differentiation (Geginat, Sallusto et al. 2001; Geginat, 
Lanzavecchia et al. 2003). These characteristics make aAPC-expanded T cells more suitable 
for ACT compared to those generated in the presence of the other clinical grade artificial 
expansion systems. Additional support for this arises from multiple studies showing the 
inverse correlation between the maturation level of in-vitro stimulated T lymphocytes and 
their in-vivo anti-tumour activity and persistence potential (Gattinoni, Klebanoff, et al. 
2005; Zhou, Shen et al. 2005; Yee, Thompson, et al. 2002). In addition, aAPC displayed the 
greatest capability to sustain CD8+ T-cell proliferation, whilst providing no increase in Treg 
frequency. This is in sharp contrast to the other artificial systems tested, further indicating 
the potential improvement of using aAPC to expand T cells for anticancer adoptive 
immunotherapy. Furthermore, when tested for the expansion of pre-enriched anti-MART-1 
CD8+ T cells, aAPC displayed similar properties, w ith the additional advantage of being 
able to efficiently re-stimulate these cells whilst preserving their antigen specificity. Finally, 
the possibility of stimulating higher amount of T cells per aAPC in a reduced culture 
volume compared to the standard condition, w ithout affecting T cell expansion efficiency, 
demonstrated the potential to scale up this approach for clinical purposes. In particular, 
aAPC may find an application for the aspecific ex-vivo expansion of the complete T-cell 
repertoire of cancer patients for ACT, w ith the aim to exogenously increase the frequency 
of TAA-specific lymphocytes that have often low antigen avidity and are usually under­
represented or not sufficiently amplified by active vaccination (Palucka, Ueno et al. 2007; 
Rosenberg, Yang et al. 2004). In addition, in the case of highly immunogenic tumours, for 
which TAAs are known and the related peptides available, aAPC can be exploited to boost 
the expansion of previously enriched antigen-specific CD8+ T cells w ithout any limitations 
due to HLA compatibility (Rosenberg, Restifo et al. 2008).
Experience from past clinical trials have shown that for the immunotherapy of 
human cancer it is unlikely that one strategy w ill be sufficient to reverse the tumour 
immune evasion phase towards the elimination of the tumour, mainly in those patients 
w ith conspicuous disease (Koos, Josephs et al. 2010). Of particular importance is the in-vivo 
generation, through active vaccination or ACT, of anti-tumour T cells w ith  appropriate 
antigen specificity, which are available in numbers compatible w ith the induction of an 
effective anti-tumour immune response. Such cells must persist over time in order to break 
tumour immune tolerance to achieve therapeutically relevant effects. The strong 
dependency of T-cell survival and memory development upon OX40-OX40L interactions, 
and their concurrent ability to augment NK and NKT cell function whilst reversing Treg- 
mediated tolerance (Croft 2010), make 0X40 an attractive target for adjuvant 
immunotherapy to enhance vaccine- and/or ACT-mediated anticancer protection. In 
addition, as the expression of 0X40 is mainly restricted to antigen-activated immune cells, 
its targeting may results in a relatively specific immune response being less likely to induce 
autoimmune side effects when compared to that of more-broadly expressed co-stimulatory 
molecules (Croft 2010; Ishii, Takahashi et al. 2010). Preclinical studies have already 
demonstrated that 0X40 agonists can augment protection against several solid tumours 
(Weinberg, Rivera et al. 2000) (Croft 2009). However, because the potential anti- 
tolerogenic effect of 0X40 triggering on mouse Tregs has only recently been recognized 
(Valzasina, Guiducci et al. 2005; Piconese, Valzasina et al. 2008; Colombo and Piconese 
2007), its contribution to these results remains unclear.
The observed significant increase of 0X40 expression on lymphoma-infiltrating versus 
PB-derived Tregs and its up-regulation upon TCR triggering on these cells in association 
w ith their suppressive activity may suggest a crucial role for 0X40+ Tregs in the tumour 
microenvironment. In this situation, indeed, the pro-inflammatory stimuli that could serve
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as feeder milieu for lymphoma need to be kept in check to avoid the initiation of an anti­
tumour immune response (Gribben 2010). Accordingly, the reduction of 0X40+ Tregs w ith 
the clinical remission of vaccinated patients and their reappearance w ith in  the tumour at 
relapse further highlight a potential symbiotic relationship between a growing lymphoma 
and this cell subset. Interestingly, although OX40L-negative, all 7 of the B-NHL cell lines of 
different histological grade tested in the current study were found to express 0X40 at 
higher levels compared to normal B cells. However, upon TCR stimulation in LN cell 
suspensions, primary malignant B cells up-regulated both 0X40 and OX40L, and their 
growth was impaired when a neutralizing anti-OX40 mAb was added in culture. Due to the 
intrinsic low ability of B cells to grow in vitro this effect was less evident in these cells, 
compared to that obtained in T lymphocytes. However, this suggests the possibility that 
OX40-OX40L co-stimulation might contribute to tumour cell survival in a similar way of the 
other well-known CD40- CD40L pro-lymphoma interactions w ithin the TNFR-TNF 
superfamily (Grdisa 2003; Kater, Evers et al. 2004). Whether the anti-proliferative effect on 
B cells is directly mediated by OX40L co-stimulation inhibition and/or depends upon the 
inhibition of bystander pro-survival signals remains to be ascertained. The concomitant 
observation that, under these conditions, FOXP3+ Treg proliferation was also impaired 
provides the indirect information that 0X40 stimulation may promote the survival and/or 
the growth of regulatory lymphocytes in lymphoma. This is in agreement w ith previous 
results obtained in normal human and mouse Tregs (Kroemer, Xiao et al. 2007; Hippen, 
Harker-Murray et al. 2008). A stimulatory action on Tregs and tumour B cells might impair 
the ability of 0X40 agonist reagents to effectively function as adjuvants. However, given the 
recognized strong activity of 0X40 stimulation in promoting expansion and survival of 
activated lymphocytes, including anti-tumour T cells, a positive effect on these cells may be 
a minor issue. Furthermore, since preclinical studies in mice have indicated that 0X40 
triggering may transiently block Treg suppressive activity (Piconese, Valzasina et al. 2008) 
and peripheral conversion (Vu, Xiao et al. 2007), an increased frequency of functionally 
inactive Tregs should not provide much constraint to the concurrent positive immune 
stimulation. To assess whether this could also be true in a human setting, the use of a 
trimeric human recombinant OX40L fusion protein, despite showing positive co­
stimulatory signals on human Teffs, revealed only a minimal capacity to counteract Treg- 
mediated suppression of Teff proliferation. Like other TNFR, 0X40 is constitutively 
expressed in mouse Tregs at high levels but is inducible in the human cell counterpart 
(Croft 2009), indicating a more complex regulation of 0X40 in human Tregs that could 
account for the difficulties to directly translate the findings obtained in mice to the human 
setting. The transient and variable expression of 0X40 in both human Teffs and Tregs and 
the need to study its functions in vitro makes it difficult to understand what actually 
happens in Tregs rather than Teffs after 0X40 stimulation in normal and pathological 
conditions. Ad hoc in-vitro assays able to accurately reproduce the in-vivo situation 
together w ith  more effective agonist reagents are required to definitely prove the 
therapeutic advantages to trigger 0X40 in B cell lymphoma as adjuvant treatment for 
anticancer immunotherapeutic approaches.
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6 SUMMARY AND FUTURE PLANS
Passive immunotherapy w ith mAbs has dramatically improved the overall survival of 
patients w ith indolent B-NHLs (Cheson and Leonard 2008). However, no treatments are 
curative at the present time and the pattern of continuing relapse and progressive decrease 
in response to therapy requires the development of more and more effective therapeutic 
strategies (Gribben 2007). The possibility of counteracting the peculiar clinical course of 
indolent NHLs through the effective recruitment of a continuing immune response attack 
on tumour cells is an attractive option.
In the present study, promising results have been achieved through vaccinating heavily 
pre-treated relapsed indolent NHL patients w ith autologous DCs loaded w ith autologous 
heat-shocked, y-irradiated, and UVC-treated tumour cells. Both T- and B-cell tumour- 
specific immune activation were associated w ith  clinical responses. In particular, 
vaccination skewed the maturation of T cells to effector memory and/or terminally 
differentiated phenotype, activated NK cells, and intriguingly, reduced the frequency of 
Tregs in the PB and/or at tumour site. The potential of this vaccine formulation in 
stimulating immune responses against multiple TAAs, avoiding the selection of tumour 
immune escape variants, resulted biologically and clinically effective. This effect, combined 
w ith the use of DCs as carriers for the antigenic “cargo" obtained through the induction of 
an immunogenic tumour cell death, may provide some of the reasons for the resulting 
enhancement of multiple immunostimulatory signals and down-modulation of the 
immunoregulatory elements associated w ith a high objective clinical response rate 
(33.3%) in the vaccinated patients. Importantly, such effects were prim arily induced in 
patients w ith low tumour burden, suggesting that there may be opportunities for the 
further optimization of vaccine strategies to eradicate disease in patients w ith  large 
tumour masses.
In this p ilot trial, NRs possessed lymphomas, which exhibited a decreased ability, 
compared to those present in Rs, to undergo to an immunogenic cell death in vitro. This 
suggests that the addition of compensatory immune stimuli w ithin killed tumour cell-based 
vaccines may provide effective formulations for boosting a therapeutic anti-tumour 
immunity in such patients. Prospective studies examining the added value of such immune 
parameters as new predictors for the clinical outcome, as well as randomized trials aimed 
at counteracting immunologic defects, w ill confirm this hypothesis. Alternatively, given the 
growing appreciation that some conventional treatments possess the immune stimulatory 
property of inducing immunogenic tumour cell death (Zitvogel 2008), then they, in 
association w ith DC activating agents, may be exploited to target TAAs to DCs in vivo. 
Recently, the proof of principle that this strategy, namely in-situ vaccination, can be feasible, 
safe and potentially clinically efficacious has been provided in a pilot study in which low- 
grade NHL patients were treated w ith low-dose radiotherapy w ith intra-tumour injection 
of a TLR9 agonist (Brody, Ai et al. 2010). If confirmed, and supported by a clear biologic 
mechanisms in a w ider series of patients, then these promising results may not only 
provide important information on underlying tumour immunity but, interestingly, may 
have the potential to pave the way for a future novel straightforward, non-customized 
active immunotherapy approach. Such an option w ill be widely applicable w ithout the need 
of following clinical grade procedures for the production of the vaccine.
At present, however, active anticancer immunotherapy by either ex-vivo or in-vivo DC 
therapy alone has not been demonstrated to generate consistent levels of immunity 
capable of eradicating established diseases (Koos, Josephs et al. 2010; Claesson 2009). The 
strategy to combine vaccination w ith the transfer of tumour-competent T cells to boost 
tumour-specific CTL responses induced by active immunisation may increase the 
probability of a clinical success. The recognition of the need for CD4+ T-cell help for in-vivo
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proliferation and activation of transferred T cells (Corthay, Skovseth et al. 2005; Perez-Diez, 
Joncker et al. 2007; Hunder, Wallen et al. 2008] has led to the development of expansion 
approaches that attempt to create a functional, endogenous, and polyclonal tumour- 
specific immune response of both CD8+ and CD4+ T cell subsets. The liposome-based 
aAPCs described in this study represent a reliable method for rapidly obtaining adequate 
amounts of functional and potentially long-lasting anti-tumour CTLs for anticancer ACT. 
The novelties of this system, which include the co-localization of T-cell ligands in artificial 
lipid rafts loaded on a fluid lipidic membrane and the targeting of an adhesion protein, both 
of which increase the efficiency of immunologic synapse formations, form the basis for its 
improvements over the two artificial approaches clinically available for polyclonal T-cell 
expansion. The use of aAPCs achieved a more efficient expansion of both polyclonal and 
MART-l-specific CD8+ T cells than the other systems. Stimulation w ith aAPCs permits for 
the generation of viable T cells displaying an immunophenotype consistent w ith the 
potential for their continued persistence in-vivo w ithout increasing the frequency of Tregs. 
After stimulation w ith aAPCs, the specificity of anti-MART-1 CD8+ T cells was preserved 
and their specific cytolitic activity was significantly higher when compared to CTLs 
expanded using the other systems. Remarkably, the aAPC-based approach used here 
proved to be suitable for large-scale application minimizing the volume and the costs of T- 
cell expansion. The ability of this system to provide the same results when used to 
stimulate circulating T cells obtained from NHL patients w ill be matter of further studies. If 
this is found to be the case, then it  w ill open up the possibility of using aAPCs for the 
expansion of in-vivo induced anti-tumour polyclonal T cells by whole tumour cell-based 
vaccination.
It is worth remembering that the major goal of cancer immunotherapy remains the 
development of a protective anti-tumour immunity that depends not only upon the amount 
of the induced tumour-specific effector T cells, but also, and more importantly, on their 
ability to persist and overcome tumour-induced immunosuppression (Koos, Josephs et al.
2010]. The study of the OX40-OX40L (two members of the TNFR/TNF superfamilies] 
pathway in indolent lymphomas to identify novel adjuvant agents for immunotherapy thus 
looks very promising. Indeed, in addition to the well-known ability to boost effector T-cell 
function in human (Morris, Peters, et al. 2007; Croft 2009], 0X40 triggering has recently 
been shown to abolish Treg immunosuppression in murine pre-clinical models (Valzasina, 
Guiducci et al. 2005; Piconese, Valzasina et al. 2008; Colombo and Piconese 2007; Vu, Xiao 
et al. 2007]. In the present study, not only Tregs, but also their expression of 0X40 was 
found to be increased in NHL biopsies compared to PB, thus indicating the concurrent 
presence of immune suppressive and inflammatory stimuli in the lymphoma 
microenvironment that may be crucial for the tumour growth. Accordingly, after DC- 
vaccination, 0X40+ Tregs decreased in the PB and at the tumour site of Rs, but reappeared 
upon relapse in the involved LNs. 0X40 stimulation by a trimeric recombinant human 
OX40L protein also demonstrated to boost the in-vitro expansion of lymphoma infiltrating 
Teffs in a human setting. However, this approach showed minimal effects in reversing Treg 
immunosuppressive functions, indicating the need of more effective agonist reagents for 
human 0X40 and/or the identification of more suitable culture conditions to assess this 
activity. If 0X40 stimulation demonstrates a role also in human Treg functions, then it  
should be possible to provide a double, apparently antithetic, activity that favours anti­
tumour immunity by the use of a single agent. In addition, very prelim inary results suggest 
that OX40-OX40L signalling may also influence malignant B cells. Indeed, under 
inflammatory conditions that led to 0X40 and OX40L up-regulation on the lymphoma B- 
cell surface, 0X40 neutralization by a specific Ab reduced the proliferation of prim ary 
malignant B cells in vitro. 0X40 triggering on B-NHLs has not as yet been studied in depth. 
Since the axis of CD40-CD40L interaction provides crucial signals for B-cell lymphoma 
survival (Grdisa 2003; Kater, Evers et al. 2004], it  remains important to investigate
152
whether OX40-OX40L co-stimulation may share similar properties. The demonstration of a 
direct involvement of 0X40 in lymphoma cell survival w ill come from an accurate analysis 
of 0X40 expression in different B-cell lymphoma histotypes coupled w ith the study of the 
functional inhibition or activation of 0X40 in malignant B cell lines to reveal, respectively, 
more significant anti- or pro-survival effects. If this is not the case, the possibility of 
indirect bystander effects on lymphoma cells of OX40-OX40L co-stimulation on accessory T 
cells cannot be ruled out. In-vitro co-cultivation of lymphoma cell lines w ith T cells in the 
presence of 0X40 agonist or antagonist compounds w ill assist in addressing this 
hypothesis. These studies w ill also be crucial to elucidate the most valuable modality of 
intervention through OX40-OX40L signalling in B-cell lymphoma for immune adjuvant 
purposes. Indeed, it  is important to take into account the potential drawback of an 0X40 
agonist-based therapy for B-NHLs to concurrently promote the growth and/or the survival 
of Tregs and malignant B cells. Therefore, the possibility that the exacerbation of Teff 
functions by 0X40 agonists at the tumour site (where inflammatory signals are 
precariously kept in balance for the malignant progression) may boost immunity to fight 
tolerance and favour cancer regression needs to be proven. Additional insights into the 
mechanisms whereby 0X40 triggering possesses immunostimulatoiy properties in the 
human w ill most likely come from next results of preclinical and clinical studies w ith novel 
human 0X40 agonist compounds.
The study of novel therapeutic ways for the improvement of the clinical efficacy of 
active immunotherapy in indolent NHL patients culminated in the extremely relevant work 
on the identification of HSP105 as a new potential immunotherapeutic biotarget of B-NHLs. 
Indeed, the induction of HSP105-specific Abs by DC-based vaccination was associated w ith 
a positive clinical outcome. The association between increasing expression levels of 
HSP105 and lymphoma aggressiveness and, importantly, also transformation suggests that 
a humoral immunity against HSP105 may keep the progression of indolent NHLs under 
control. This could allow the "equilibrium" phase of cancer immunoediting to be re­
established. Interestingly, the blocking of HSP105 w ith a specific Ab significantly reduced 
the lymphoma burden and caused anti-vascular effects in pre-clinical murine models. This 
finding represents the proof of principle to consider HSP105 as another attractive target 
for B-NHL passive immunotherapy. The activity of this molecular chaperone in normal, as 
well as malignant B cells, has been poorly investigated. Like other molecular chaperones, 
its pro-tumour activity may be related to its properties of stabilizing oncogenes and 
counteracting proteotoxic stress. Interestingly, in normal rat germ cells (Kumagai, Fukuda 
et al. 2000) and human colorectal carcinoma cells (Hosaka, Nakatsura, et al. 2006), HSP105 
has been found to stabilize and sequester p53 in the cytoplasm, a location far away from its 
functional nuclear site and avoiding its activation of pro-apoptotic pathway. The possibility 
that HSP105 chaperones p53 also in B-cell lymphoma represents an appealing hypothesis 
to be addressed in the near future. Loss of function of the tumour suppressor p53 is a 
common feature of NHLs, in particular transformed and aggressive subtypes, and leads to 
therapy resistance and disease recurrence (Moller, Nielsen et al. 2002; Koduru, Raju et al.
2011). Mutations of p53 have been also found to increase its protein half-life w ithout 
affecting its suppressive functions. In these cases, tumours activate alternative mechanisms 
that can impede the re-localization of p53 into the nucleus and the induction of pro- 
apoptotic genes. The ability of HSP105 to stabilize p53 showed in other tissues may thus 
represent one of such mechanism in lymphoma. A detailed biochemical analysis of the 
pathways that are affected upon HSP105 inhibition, including p53, is thus required to 
understand the possible molecular basis for anti-HSP105 mAb-based combination therapy. 
Aside from a direct inhibition of pro-survival/anti-apoptotic pathways on tumour cells, the 
involvement of immune-mediated and anti-angiogenic effects in the promotion of the 
observed in-vivo anti-lymphoma activity of anti-HSP105 Ab needs to be studied in more 
details. The contribution of anti-HSP105 Ab-mediated CDC and ADCC can be analysed both
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in vitro, demonstrating the dependency of the anti-tumour effects on the amounts of 
specie-specific serum or NK cells added in culture, and in vivo, by the comparison w ith the 
activity of the Ab lacking the Fc-mediated effector functions (the fragment antigen binding 
Fab). The "in-house” development of a specific mouse mAb, which is currently underway in 
collaboration w ith the Experimental Oncology Department of the Fondazione IRCCS Istituto 
Nazionaie dei Tumori di Milano, w ill greatly facilitate these analyses w ith respect to the use 
of the commercially available functional polyclonal rabbit anti-human HSP105 Ab. 
Collectively, these studies should lead to the generation of a novel mAb, which can be 
transferred from the pre-clinical animal models into the clinical settings as a new passive 
anti-lymphoma immunotherapeutic strategy for its validation in clinical trials.
In parallel, the possibility that more specific B-cell lymphoma antigens compared to 
HSP105 may have induced a humoral response associated w ith therapeutic effects in 
vaccinated patients w ill continue to be pursued. Indeed, results obtained in this study 
indicate a tumour-restricted enhancement of post- versus pre-vaccine Ab reactivity in Rs. 
Towards this aim, in order to facilitate and potentiate the serological analyses, Ab 
repertoires of vaccinated patients w ill be investigated using protein microarrays that w ill 
permit the direct testing of serum samples from a number of patients on a very wide range 
of targets in a single step. Although the use of recombinant proteins on the arrays may 
prevent the recognition of antigens that have undergone post-translational modification, 
this approach has been invaluable in other studies for the detection of disease-associated 
autoantigens. Furthermore, the risk of losing important Ab species during Ig processing for 
their purification and biotin-conjugation w ill be reduced.
In conclusion, the work presented in the current study has fulfilled the initia l aims of 
the project. These are as follows:
• demonstration of a correlation of a positive outcome after vaccination w ith  the 
induction of anti-tumour immunity;
• the identification of potential predictors of the clinical outcome following 
vaccination;
• the identification of NHL-associated antigens that have the potential to be 
exploited as targets of passive immunotherapy;
• the identification of approaches that can be used to optimize the immune 
response of patients w ith indolent NHL following active immunotherapy.
This thesis provides important data on mechanisms underlying tumour immunity that 
can be used to improve and also open up new treatment options for the therapy of indolent 
NHLs. This information also has potential relevance for the treatment of other 
haematological malignancies as well as solid tumours.
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